<SEC-DOCUMENT>0000950123-11-095255.txt : 20111104
<SEC-HEADER>0000950123-11-095255.hdr.sgml : 20111104
<ACCEPTANCE-DATETIME>20111104144238
ACCESSION NUMBER:		0000950123-11-095255
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20110930
FILED AS OF DATE:		20111104
DATE AS OF CHANGE:		20111104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GTX INC /DE/
		CENTRAL INDEX KEY:			0001260990
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				621715807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50549
		FILM NUMBER:		111180678

	BUSINESS ADDRESS:	
		STREET 1:		175 TOYOTA PLAZA
		STREET 2:		7TH FLOOR
		CITY:			MEMPHIS
		STATE:			TN
		ZIP:			38103
		BUSINESS PHONE:		901-523-9700

	MAIL ADDRESS:	
		STREET 1:		175 TOYOTA PLAZA
		STREET 2:		7TH FLOOR
		CITY:			MEMPHIS
		STATE:			TN
		ZIP:			38103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>c24070e10vq.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 10pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 10pt"><B>FORM 10-Q</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>(Mark One)</B>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<!-- xbrl,dc -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%"><B>For the quarterly period ended September&nbsp;30, 2011</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OR</B></DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>
Commission file number: 000-50549</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 10pt"><B>GTx, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>62-1715807</B><BR>
(I.R.S. Employer Identification No.)</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">incorporation or organization)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>175 Toyota Plaza</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>7</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>th</b></SUP> <b>Floor</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Memphis, Tennessee</B><BR>
(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>38103</B><BR>
(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(901)&nbsp;523-9700</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed
by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or
for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90&nbsp;days. Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period
that the registrant was required to submit and post such files). Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the
Exchange Act.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="center" valign="top">Large accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" valign="top">Accelerated filer <FONT style="font-family: Wingdings">&#254;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" valign="top">Non-accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" valign="top">Smaller reporting company <FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" valign="top">(Do not check if a smaller reporting company)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of
the Exchange Act). Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of November&nbsp;3, 2011, 62,790,223 shares of the registrant&#146;s Common Stock were outstanding.
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>






<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">





<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="C24070tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, INC.<BR>
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2011<BR>
INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>PAGE</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C24070101">PART I &#151; FINANCIAL INFORMATION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C24070102">Item&nbsp;1. Financial Statements (unaudited)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#C24070103">Condensed Balance Sheets as of September&nbsp;30, 2011 and December&nbsp;31, 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#C24070104">Condensed Statements of Operations for the Three Months and Nine Months Ended September&nbsp;30, 2011 and 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#C24070105">Condensed Statements of Cash Flows for the Nine Months Ended September&nbsp;30, 2011 and 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#C24070106">Notes to Condensed Financial Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C24070107">Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C24070108">Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C24070109">Item&nbsp;4. Controls and Procedures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C24070110">PART II &#151; OTHER INFORMATION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C24070111">Item&nbsp;1A. Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C24070112">Item&nbsp;6. Exhibits</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c24070exv31w1.htm">Exhibit 31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c24070exv31w2.htm">Exhibit 31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c24070exv32w1.htm">Exhibit 32.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c24070exv32w2.htm">Exhibit 32.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="gtxi-20110930.xml">EX-101 INSTANCE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="gtxi-20110930.xsd">EX-101 SCHEMA DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="gtxi-20110930_cal.xml">EX-101 CALCULATION LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="gtxi-20110930_lab.xml">EX-101 LABELS LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="gtxi-20110930_pre.xml">EX-101 PRESENTATION LINKBASE DOCUMENT</A></FONT></TD></TR>
</TABLE>
</DIV>
<DIV align="left">
<!-- /TOC -->
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C24070101"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>PART I: FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left">
<A name="C24070102"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 1.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>FINANCIAL STATEMENTS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.</B>
</DIV>

<DIV align="left">
<A name="C24070103"></A>
</DIV>
<!-- xbrl,bs -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED BALANCE SHEETS</B></DIV>
<!-- xbrl,body -->
<DIV align="center" style="font-size: 10pt"><B>(in thousands, except share data)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(unaudited)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>ASSETS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">73,296</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">58,181</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Short-term investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,715</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">450</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts receivable, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">830</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">683</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">171</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,351</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">875</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85,342</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60,360</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,302</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,040</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intangible and other assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">264</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,850</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">86,908</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">64,250</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">829</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">848</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued expenses and other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,367</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,112</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred revenue &#151; current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,345</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,196</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,305</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deferred revenue, less current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,721</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other long-term liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">497</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock, $0.001 par value: 120,000,000
and 60,000,000 shares authorized at September
30, 2011 and December&nbsp;31, 2010, respectively;
62,790,223 and 51,719,187 shares issued and
outstanding at September&nbsp;30, 2011 and
December&nbsp;31, 2010, respectively</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">456,901</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">404,555</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(375,492</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(352,880</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81,472</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51,727</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">86,908</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">64,250</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The accompanying notes are an integral part of these financial statements.
</DIV>
<!-- /xbrl,bs -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.</B>
</DIV>

<DIV align="left">
<A name="C24070104"></A>
</DIV>
<!-- xbrl,op -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED STATEMENTS OF OPERATIONS</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(in thousands, except share and per share data)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<tr>
<TD>&nbsp;</TD>
</TR>
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Product sales, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,029</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">960</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,903</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,358</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Collaboration revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">336</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56,450</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,029</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,296</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,969</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58,808</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Costs and expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cost of product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">311</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">216</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">780</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">501</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,593</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,075</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,720</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,904</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,058</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,900</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total costs and expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,875</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35,913</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,121</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">(Loss) income from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,367</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,579</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(22,944</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,687</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">332</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">136</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net (loss)&nbsp;income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,344</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(8,575</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(22,612</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">22,823</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net (loss)&nbsp;income per share:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.15</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.24</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.41</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average shares used in
computing net (loss)&nbsp;income per
share:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62,778,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,424,971</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55,529,320</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36,422,273</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The accompanying notes are an integral part of these financial statements.
</DIV>
<!-- /xbrl,op -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.</B>
</DIV>

<DIV align="left">
<A name="C24070105"></A>
</DIV>
<!-- xbrl,cf -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED STATEMENTS OF CASH FLOWS</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(in thousands)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash flows from operating activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net (loss)&nbsp;income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(22,612</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">22,823</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Adjustments to reconcile net (loss)&nbsp;income to net cash used in
operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">819</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,222</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Share-based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,178</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,771</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Directors&#146; deferred compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">141</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">141</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Deferred revenue amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,066</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(51,450</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Impairment of intangible assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,598</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,687</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Changes in assets and liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accounts receivable, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(147</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(103</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(27</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(103</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Prepaid expenses and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(476</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,301</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(19</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(115</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accrued expenses and other liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,062</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,746</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash used in operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(24,549</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(29,174</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash flows from investing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Purchase of property and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(45</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(88</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Purchase of short-term investments, held to maturity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(12,450</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8,119</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Proceeds from maturities of short-term investments, held to maturity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,185</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,779</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash (used in) provided by investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,310</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,572</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Cash flows from financing activities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Proceeds from issuance of common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Payments on capital lease and financed equipment obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(63</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(67</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Proceeds from exercise of employee stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash provided by (used in) financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48,974</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(67</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net increase (decrease)&nbsp;in cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,115</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(22,669</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents, beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58,181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,219</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents, end of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">73,296</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">17,550</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The accompanying notes are an integral part of these financial statements.
</DIV>
<!-- /xbrl,cf -->



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<!-- xbrl,ns -->

<DIV align="left">
<A name="C24070106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>NOTES TO THE CONDENSED FINANCIAL STATEMENTS</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(in thousands, except share and per share data)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(unaudited)</B></DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>1. Business and Basis of Presentation</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Business</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">GTx, Inc. (&#147;GTx&#148; or the &#147;Company&#148;), a Delaware corporation incorporated on September&nbsp;24, 1997
and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery,
development and commercialization of small molecules that selectively target hormone pathways for
the treatment of cancer, cancer supportive care, and other serious medical conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company is developing selective androgen receptor modulators (&#147;SARMs&#148;), including
Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM </SUP>(GTx-024). SARMs are a new class of drugs with the potential to prevent and
treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss
conditions, including chronic sarcopenia (age related muscle loss). The Company has commenced two
pivotal Phase III clinical trials evaluating Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for the prevention and treatment
of muscle wasting in patients with non-small cell lung cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additionally, the Company is developing Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> (GTx-758), an oral nonsteriodal
selective estrogen receptor alpha agonist. The Company is developing Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for
first line and second line hormonal treatment of advanced prostate cancer. With respect to first
line hormonal therapy, the Company has completed enrollment in a Phase II maintenance dose finding clinical trial and
has initiated a Phase II loading dose finding clinical trial evaluating Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> in
men with advanced prostate cancer. The Company will also initiate a second line hormonal therapy
Phase II clinical trial evaluating Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> in men with castration resistant prostate
cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company markets FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (toremifene citrate) 60 mg tablets, approved for the
treatment of advanced metastatic breast cancer in postmenopausal women, in the United States. The
Company previously determined to discontinue its toremifene 80 mg and toremifene 20 mg development
programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Basis of Presentation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The accompanying unaudited condensed financial statements reflect, in the opinion of
management, all adjustments (consisting of normal recurring adjustments) necessary for a fair
presentation of GTx&#146;s financial position, results of operations and cash flows for each period
presented in accordance with accounting principles generally accepted in the United States for
interim financial information and with the instructions to Form 10-Q and Article&nbsp;10 of Regulation
S-X. Accordingly, information and footnote disclosures normally included in financial statements
prepared in accordance with accounting principles generally accepted in the United States have been
condensed or omitted from the accompanying condensed financial statements. These interim condensed
financial statements should be read in conjunction with the audited financial statements and
related notes thereto, which are included in the Company&#146;s Annual Report on Form 10-K for the year
ended December&nbsp;31, 2010. Operating results for the three months and nine months ended September
30, 2011 are not necessarily indicative of the results that may be expected for the entire fiscal
year ending December&nbsp;31, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Use of Estimates</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The preparation of condensed financial statements in conformity with accounting principles
generally accepted in the United States requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and
liabilities at the date of the condensed financial statements, and the reported amounts of revenues
and expenses during the reporting period. Actual amounts and results could differ from those
estimates.
</DIV>
<!-- xbrl,ig -->

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.<BR>
NOTES TO THE CONDENSED FINANCIAL STATEMENTS<BR>
(in thousands, except share and per share data)<BR>
(unaudited)</B>
</DIV>
<!-- /xbrl,ig -->

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenue Recognition</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company recognizes revenue from product sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> less deductions for
estimated sales discounts and sales returns. Revenue from product sales is recognized when
persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and
collectability is reasonably assured. The Company accounts for rebates to certain governmental
agencies as a reduction of product sales. The Company allows customers to return product within a
specified time period prior to and subsequent to the product&#146;s labeled expiration date. The
Company estimates an accrual for product returns, which is recorded as a reduction of product
sales, based on factors which include historical product returns and estimated product in the
distribution channel which is expected to exceed its expiration date. At September&nbsp;30, 2011 and
December&nbsp;31, 2010, the Company&#146;s accrual for product returns was $978 and $802, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Collaboration revenue consisted of non-refundable upfront payments, license fees,
reimbursements for research and development activities, and milestone payments associated with the
Company&#146;s former collaboration and license agreements. Revenues from the Company&#146;s prior
collaboration and license agreements were recognized based on the performance requirements of the
specific agreements. The Company analyzed agreements with multiple element arrangements to
determine whether the deliverables under the agreement, including license and performance
obligations such as joint steering committee participation and research and development activities,
could have been separated or whether all of the deliverables must have been accounted for as a
single unit of accounting. Revenues from milestone payments for which the Company had no
continuing performance obligations were recognized upon achievement of the performance milestone,
as defined in the related agreement, provided the milestone was substantive and a culmination of
the earnings process had occurred. Due to the termination of the Company&#146;s license and
collaboration agreement with Ipsen Biopharm Limited (&#147;Ipsen&#148;) in March&nbsp;2011, the Company recognized
collaboration revenue of $8,066 in the first quarter of 2011 as the Company has no further
performance obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Research and Development Expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development expenses include, but are not limited to, the Company&#146;s expenses for
personnel, supplies, and facilities associated with research activities, screening and
identification of product candidates, formulation and synthesis activities, manufacturing,
preclinical studies, toxicology studies, clinical trials, regulatory affairs activities, quality
assurance activities and license fees. The Company expenses these costs in the period in which
they are incurred. The Company estimates its liabilities for research and development expenses in
order to match the recognition of expenses to the period in which the actual services are received.
As such, accrued liabilities related to third party research and development activities are
recognized based upon the Company&#146;s estimate of services received and degree of completion of the
services in accordance with the specific third party contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Cash, Cash Equivalents and Short-term Investments</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company considers highly liquid investments with initial maturities of three months or
less to be cash equivalents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At September&nbsp;30, 2011 and December&nbsp;31, 2010, short-term investments consisted of certificates
of deposit with original maturities of greater than three months and less than one year. As the
Company has the positive intent and ability to hold the certificates of deposit until maturity,
these investments have been classified as held to maturity investments and are stated at cost,
which approximates fair value.
</DIV>

<!-- xbrl,ig -->
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.<BR>
NOTES TO THE CONDENSED FINANCIAL STATEMENTS<BR>
(in thousands, except share and per share data)<BR>
(unaudited)</B>
</DIV>
<!-- /xbrl,ig -->

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Impairment of Long-Lived Assets</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company reviews long-lived assets for impairment whenever events or changes in facts and
circumstances are present, both internally and externally, that may indicate impairment of
long-lived assets held for use. An impairment loss is recognized when estimated future cash flows
are less than the carrying amount. The cash flow estimates are based on management&#146;s best
estimates, using appropriate and customary assumptions and projections at the time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Based upon the Company&#146;s decision to discontinue toremifene 80 mg development and after
analyzing future cash flows and estimates of fair market value from a market participant
perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and
recorded an impairment charge of $1,598 during the three months ended March&nbsp;31, 2011. The impaired
intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion
Corporation (&#147;Orion&#148;) related to the Company&#146;s toremifene 80 mg program. This license fee was paid
under the amended and restated license and supply agreement for the Company&#146;s exclusive license
from Orion to develop and commercialize toremifene-based products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The impairment charge was included in research and development expenses in the condensed
statement of operations for the nine months ended September&nbsp;30, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Income Taxes</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial
statements or tax returns. Under this method, deferred tax assets and liabilities are determined
based on the difference between the financial statement and tax basis of assets and liabilities
using enacted tax rates in effect for the year in which the differences are expected to reverse. A
valuation allowance is provided when it is more likely than not that some portion or all of the
deferred tax assets will not be realized. Accordingly, at September&nbsp;30, 2011 and December&nbsp;31,
2010, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income
taxes are described more fully in Note 9 to the Company&#146;s financial statements included in the
Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Other Income, net</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Other income, net consists of interest earned on the Company&#146;s cash, cash equivalents and
short-term investments, interest expense, foreign currency transaction gains and losses, and other
non-operating income or expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Subsequent Events</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has evaluated all events or transactions that occurred after September&nbsp;30, 2011 up
through the date the condensed financial statements were issued. There were no material
recognizable or nonrecognizable subsequent events during the period evaluated.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>2. Share-Based Compensation</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Share-based payments include stock option grants under the Company&#146;s stock option and equity
incentive plans and deferred compensation arrangements for the Company&#146;s non-employee directors.
The Company recognizes compensation expense for its share-based payments based on the fair value of
the awards over the period during which an employee or non-employee director is required to provide
service in exchange for the award. The Company&#146;s share-based compensation plans are described more
fully in Note 3 to the Company&#146;s financial statements included in the Company&#146;s Annual Report on
Form 10-K for the year ended December&nbsp;31, 2010.
</DIV>


<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.<BR>
NOTES TO THE CONDENSED FINANCIAL STATEMENTS<BR>
(in thousands, except share and per share data)<BR>
(unaudited)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes share-based compensation expense included within the condensed
statements of operations for the three and nine months ended September&nbsp;30, 2011 and 2010:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">503</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">442</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,410</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,742</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and administrative expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">623</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">677</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,909</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,170</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total share-based compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,126</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,319</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,912</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Share-based compensation expense recorded as general and administrative expense for both of
the three months ended September&nbsp;30, 2011 and 2010 included share-based compensation expense
related to deferred compensation arrangements for the Company&#146;s non-employee directors of $45.
Share-based compensation expense related to deferred compensation arrangements for the Company&#146;s
non-employee directors of $141 was included in share-based compensation expense recorded as general
and administrative expenses for both of the nine months ended September&nbsp;30, 2011 and 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The fair value of options granted was estimated using the following assumptions for the
periods presented:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected price volatility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">65.3</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">66.2</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">64.9</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">64.6</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk-free interest rate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2.3</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2.4</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2.5</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3.4</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average expected life in years</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="0" nowrap align="right">6.5 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="0" nowrap align="right">6.5 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="0" nowrap align="right">6.5 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="0" nowrap align="right">6.5 years</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following is a summary of stock option transactions for all of the Company&#146;s stock
option and equity incentive plans since the Company&#146;s most recent fiscal year end:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average Exercise</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Number of Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price Per Share</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options outstanding at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,430,495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10.91</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Options granted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,393,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.81</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Options forfeited or expired</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(843,662</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8.21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Options exercised</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options outstanding at September&nbsp;30, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,967,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9.12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>

<TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>3. Basic and Diluted Net (Loss) Income Per Share</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Basic and diluted net (loss)&nbsp;income per share attributable to common stockholders is
calculated based on the weighted average number of common shares outstanding during the period.
Diluted net (loss)&nbsp;income per share also gives effect to the dilutive potential of common stock
consisting of stock options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Weighted average options outstanding to purchase shares of common stock of 5,113,943 and
4,515,006 for the three months ended September&nbsp;30, 2011 and 2010, respectively, and 5,455,700 and
4,501,002 for the nine months ended September&nbsp;30, 2011 and 2010, respectively, were excluded from
the calculations of diluted net (loss)&nbsp;income per share as inclusion of the options would have had
an anti-dilutive effect on the net (loss)&nbsp;income per share for the periods.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.<BR>
NOTES TO THE CONDENSED FINANCIAL STATEMENTS<BR>
(in thousands, except share and per share data)<BR>
(unaudited)</B>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>4. Common Stock</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On May&nbsp;6, 2011, the Company filed a Certificate of Amendment to the Company&#146;s Restated
Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the
number of authorized shares of the Company&#146;s common stock, par value $0.001 per share, from
60,000,000 shares to 120,000,000 shares. The foregoing amendment was approved by the Company&#146;s
stockholders at the Company&#146;s 2011 Annual Meeting of Stockholders held on May&nbsp;5, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On June&nbsp;28, 2011, the Company completed an underwritten public offering of 10,000,000 shares
of its common stock at a price to the public of $4.75 per share. The Company also granted the
underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to
cover over-allotments, if any. The underwriters exercised this option and purchased an additional
1,023,000 shares of the Company&#146;s common stock on June&nbsp;28, 2011 at a price of $4.75 per share. Net
cash proceeds from the public offering were approximately $49,000 after deducting the underwriting
discount and offering expenses.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>5. Collaboration and License Agreements</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>University of Tennessee Research Foundation License Agreements</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company and the University of Tennessee Research Foundation (&#147;UTRF&#148;) are parties to a
consolidated, amended and restated license agreement (the &#147;SARM License Agreement&#148;) pursuant to
which the Company was granted exclusive worldwide rights in all existing SARM technologies owned or
controlled by UTRF, and certain improvements thereto, and exclusive rights to certain future SARM
technology that may be developed by certain scientists at the University of Tennessee or
subsequently licensed to UTRF under certain existing inter-institutional agreements with The Ohio
State University. Under the SARM License Agreement, the Company is obligated to pay UTRF annual
license maintenance fees, low single-digit royalties on net sales of products and mid single-digit
royalties on sublicense revenues.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additionally, the Company and UTRF previously entered into an amended and restated license
agreement (the &#147;SERM License Agreement&#148;) pursuant to which the Company was granted exclusive
worldwide rights to UTRF&#146;s method of use patents relating to SERMs, including toremifene for
chemoprevention of prostate cancer. In light of the Company&#146;s decision to discontinue further
clinical development of toremifene 20 mg, the Company exercised its right to terminate the SERM
License Agreement with UTRF during the first quarter of 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Ipsen Collaboration and License Agreement</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In September&nbsp;2006, the Company entered into a collaboration and license agreement with Ipsen
(the &#147;Ipsen Collaboration Agreement&#148;) pursuant to which the Company granted Ipsen exclusive rights
in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of
Independent States (the &#147;European Territory&#148;) to develop and commercialize toremifene in all
indications which the Company has licensed from Orion, which include all indications in humans
except the treatment and prevention of breast cancer outside of the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In accordance with the terms of the Ipsen Collaboration Agreement, Ipsen paid the Company
&#128;23,000 as a license fee and expense reimbursement. In February&nbsp;2008, the Company earned a
milestone of &#128;1,000 (approximately $1,482) with the achievement of the primary endpoint in the
Company&#146;s completed pivotal Phase III clinical trial evaluating toremifene 80 mg to reduce
fractures in men with prostate cancer on ADT. This amount was recognized as collaboration revenue
in the first quarter of 2008. Under the Ipsen Collaboration Agreement, the Company recorded
deferred revenue of $29,330 related to the Ipsen upfront license fee and expense reimbursement
which was being amortized into revenue on a straight-line basis over the estimated ten year
development period for toremifene in the European Territory.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GTx, Inc.<BR>
NOTES TO THE CONDENSED FINANCIAL STATEMENTS<BR>
(in thousands, except share and per share data)<BR>
(unaudited)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In March&nbsp;2011, the Company reacquired full rights to its toremifene program following the
termination by the Company and Ipsen of the collaboration and license agreement, as amended (the
&#147;Amended Ipsen Collaboration Agreement&#148;). During the first quarter of 2011, the Company recognized
as collaboration revenue all of the remaining $8,066 unamortized revenue that was deferred as of
December&nbsp;31, 2010. This amount is included in collaboration revenue in the condensed statement of
operations for the nine months ended September&nbsp;30, 2011. The Company recognized as collaboration
revenue $336 and $1,595 for the three months and nine months ended September&nbsp;30, 2010,
respectively, from the amortization of the Ipsen deferred revenue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Merck &#038; Co., Inc. Collaboration and License Agreement</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In December&nbsp;2007, GTx and Merck &#038; Co., Inc. (&#147;Merck&#148;) entered into a global exclusive license
and collaboration agreement (the &#147;Merck Collaboration Agreement&#148;) governing the Company&#146;s and
Merck&#146;s joint research, development and commercialization of SARM compounds and related SARM
products for all potential indications of interest. In March&nbsp;2010, the Company reacquired full
rights to its SARM program, including Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, following the termination by the
Company and Merck of the Merck Collaboration Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the Merck Collaboration Agreement, the Company granted Merck an exclusive worldwide
license under its SARM-related patents and know-how. The Company conducted preclinical research of
SARM compounds and products, and Merck was primarily responsible under the terms of the agreement
for conducting and funding development and commercialization of products developed under the Merck
Collaboration Agreement. Merck paid the Company an upfront licensing fee of $40,000 and purchased
approximately $30,000 of the Company&#146;s common stock. In addition, Merck paid the Company $15,000
in cost reimbursements for research and development activities in equal annual installments over a
three year period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company deferred the recognition of the upfront licensing fee of $40,000 and the $10,800
in equity premium received that represented the difference between the purchase price and the
closing price of the Company&#146;s common stock on the date the stock was purchased by Merck. These
payments were being recognized as collaboration revenue over the period of the Company&#146;s
performance obligation, which the Company estimated to be ten years. The $5,000 of cost
reimbursements received in both December&nbsp;2008 and December&nbsp;2009 were being recognized as
collaboration revenue over the remaining period of the Company&#146;s performance obligation. In March
2010, the Company reacquired full rights to the Company&#146;s SARM program following the termination by
the Company and Merck of the Merck Collaboration Agreement. In the first quarter of 2010, the
Company recognized as collaboration revenue all of the remaining $49,856 unamortized revenue that
was deferred as of December&nbsp;31, 2009, as well as the final $5,000 research and development
activities cost reimbursement due under the terms of the Merck Collaboration Agreement in December
2010 for which the Company had no further performance obligation. These amounts are included in
collaboration revenue in the condensed statement of operations for the nine months ended September
30, 2010.
</DIV>
<!-- /xbrl,ns -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left">
<A name="C24070107"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 2.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following discussion should be read in conjunction with the condensed financial statements
and the notes thereto included in Part&nbsp;1, Item&nbsp;1 of this Quarterly Report on Form 10-Q.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Forward-Looking Information</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This Quarterly Report on Form 10-Q contains forward-looking statements. The forward-looking
statements are contained principally in the sections entitled &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; and &#147;Risk Factors.&#148; These statements involve
known and unknown risks, uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements. Forward-looking statements
include statements about:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the anticipated progress of our research, development and clinical programs,
including whether our ongoing clinical trials will achieve similar results to clinical
trials that we have previously concluded;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing, scope and anticipated initiation, enrollment and completion of our
ongoing clinical trials and any other future clinical trials that we may conduct;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing of regulatory submissions and the timing, scope and anticipated
outcome of related regulatory actions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to establish and maintain potential new collaborative arrangements for the
development and commercialization of our product candidates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to obtain and maintain regulatory approvals of our product candidates and
any related restrictions, limitations, and/or warnings in the label of an approved product
candidate;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to market, commercialize and achieve market acceptance for our product
candidates or products that we may develop;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to generate additional product candidates for clinical testing;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to protect our intellectual property and operate our business without
infringing upon the intellectual property rights of others; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our estimates regarding the sufficiency of our cash resources, expenses, capital
requirements and needs for additional financing, and our ability to obtain additional
financing.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148;
&#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148;
&#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions intended to identify forward-looking
statements. Forward-looking statements reflect our current views with respect to future events,
are based on assumptions and are subject to risks, uncertainties and other important factors. We
discuss many of these risks in this Quarterly Report on Form 10-Q in greater detail in the section
entitled &#147;Risk Factors&#148; under Part&nbsp;II, Item&nbsp;1A below. Given these risks, uncertainties and other
important factors, you should not place undue reliance on these forward-looking statements. Also,
forward-looking statements represent our estimates and assumptions only as of the date of this
Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q and the
documents that we incorporate by reference in and have filed as exhibits to this Quarterly Report
on Form 10-Q, completely and with the understanding that our actual future results may be
materially different from what we expect. Except as required by law, we assume no obligation to
update any
forward-looking statements publicly, or to update the reasons actual results could differ
materially from those anticipated in any forward-looking statements, even if new information
becomes available in the future.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Business Overview</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are a biopharmaceutical company dedicated to the discovery, development and
commercialization of small molecules that selectively target hormone pathways for the treatment of
cancer, cancer supportive care, and other serious medical conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Business Highlights</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are developing selective androgen receptor modulators, or SARMs, a new class of drugs with
the potential to prevent and treat muscle wasting in patients with cancer, and other
musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle
loss). Our lead SARM product candidate, Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> (GTx-024), has to date been
evaluated in eight clinical trials enrolling approximately 600 subjects, including in a Phase Ib
and two Phase II efficacy studies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We held End of Phase II meetings with the U.S. Food and Drug Administration, or FDA, regarding
our planned Phase III clinical development of Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for the prevention and
treatment of muscle wasting in patients with non-small cell lung cancer, or NSCLC. Based upon
feedback from the FDA, we designed the POWER1 and POWER2 (Prevention and treatment Of muscle
Wasting in cancER) pivotal Phase III clinical trials evaluating Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for this
indication. We have commenced each of these trials, and they will be conducted at more than 125
clinical sites in the United States, Europe, and South America. In each of the placebo-controlled,
double-blind clinical trials, 300 patients with Stage III or IV non-small cell lung cancer
initiating first line chemotherapy are being randomized to placebo or
Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> 3 mg.
The trials are evaluating as co-primary endpoints the effect of Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> versus
placebo on total lean body mass (muscle)&nbsp;assessed by dual x-ray absorptiometry (DXA)&nbsp;and on
physical function assessed by the Stair Climb Test at three months. Durability of effect is being
assessed as a secondary endpoint at five months. We intend to continue our pursuit of a strategic
partnership or collaboration for the development and commercialization of SARMs, including
Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We are also developing Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> (GTx-758), an oral nonsteroidal selective estrogen
receptor, or ER, alpha agonist. We are developing Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for first and second line
hormonal treatment of advanced prostate cancer. In 2009, we completed two Phase I clinical trials,
a single ascending dose clinical trial and a multiple ascending dose clinical trial, evaluating
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM </SUP>in healthy<SUP style="FONT-size: 85%; vertical-align: text-top"> </SUP>male volunteers. Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM </SUP>was well
tolerated in both trials. In September&nbsp;2010, we announced that in a Phase II, open label,
pharmacokinetic and pharmacodynamic clinical trial in young healthy male volunteers,
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> suppressed serum total testosterone to medical castration levels, increased
serum sex hormone binding globulin, or SHBG, and reduced serum free testosterone, the form of
testosterone which is available to prostate cancer cells for growth. Medical castration (levels of
serum total testosterone less than 50ng/dL) was achieved in the 1000 mg and 1500 mg treatment
groups. Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> was well tolerated and no serious adverse events were reported in
the trial. In May&nbsp;2011, we completed a Phase I clinical trial of Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM </SUP>using a
tablet formulation in older healthy male volunteers. In this trial, reductions in testosterone to
medical castration levels, increases in SHBG and decreases in free testosterone were observed at
doses from 1000 mg to 2000 mg given orally each day. Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> was generally well
tolerated in this trial; however, one subject experienced a blood clot in his leg and was
discontinued from the trial. We have met with the FDA and confirmed that the primary endpoint for
approval of Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for first line hormonal treatment of advanced prostate cancer is
maintaining medical castration levels of serum testosterone (less than 50ng/dL) from day 28 to day
364. Based on this FDA feedback, we have designed two Phase II clinical trials to identify the
optimal dose to achieve and maintain medical castration. In June&nbsp;2011, we initiated our Phase II
maintenance dose finding clinical trial evaluating Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> 1000 mg and 2000 mg
once a day tablets compared to Lupron Depot<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (leuprolide acetate for depot suspension) in 156 men with
advanced prostate cancer. Enrollment of this clinical trial is
complete. We have also initiated this quarter a Phase II loading dose finding clinical trial evaluating the optimal dose to castrate
men by day 28. The two doses of Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> being tested are 1000 mg twice a day and
1500 mg twice a day in 102 men with advanced prostate cancer. After day 28, castrate patients will
continue treatment on one of three once a day doses of Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, 2000 mg, 1000 mg or
500 mg, until day 360. The Phase II loading dose finding clinical trial and the
Phase II maintenance dose finding clinical trial have a combined objective of assessing efficacy
and safety data necessary for the design of Phase III clinical trials, including the determination
of the optimal dose of Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> to achieve and maintain castration. Data from the
Phase II maintenance dose finding trial will also be used to assess differences in estrogen
deficiency side effects between Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and Lupron Depot<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. We plan to
release preliminary topline results of the two Phase II Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> clinical trials
together. The timing of the announcement is subject to patient enrollment in the Phase
II loading dose finding clinical trial and is expected by year end 2011 or in the first quarter of
2012. We are also initiating this quarter a second line hormonal therapy Phase II clinical trial
evaluating Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> 1000 mg and 2000 mg once a day tablets in 50 men with castration resistant
prostate cancer (CRPC). The objective of the trial is to determine the ability of
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> to reduce serum prostate specific antigen (PSA)&nbsp;and the duration of this PSA
reduction in men with CRPC who are currently receiving androgen deprivation therapy.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We market FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (toremifene citrate) 60 mg tablets, approved for the treatment
of advanced metastatic breast cancer in postmenopausal women, in the United States. We previously
determined to discontinue our toremifene 80 mg and toremifene 20 mg development programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Financial Highlights</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our net loss for the nine months ended September&nbsp;30, 2011 was $22.6&nbsp;million. Our net loss
included the recognition of the remaining $8.1&nbsp;million of deferred revenue following the
termination of our license and collaboration agreement with Ipsen and FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> net
product sales of $4.9&nbsp;million. We expect to incur significant net losses in 2011 and for the
foreseeable future as we continue our clinical development and research and development activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At September&nbsp;30, 2011, we had cash, cash equivalents and short-term investments of $83.0
million, compared to $58.6&nbsp;million at December&nbsp;31, 2010. On June&nbsp;28, 2011, we completed an
underwritten public offering of 11,023,000 shares of our common stock at a price to the public of
$4.75 per share. Net cash proceeds from the public offering were approximately $49.0&nbsp;million,
after deducting the underwriting discount and offering expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We estimate that our current cash, cash equivalents, and short-term investments, together with
interest income and product revenue from the sale of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, will be sufficient to
meet our projected operating requirements into the first half of 2013. We have based this estimate
on our current business plan and assumptions that may prove to be wrong. We could utilize our
available capital resources sooner than we currently expect, and we could need additional funding
sooner than currently anticipated. In any event, to complete the development of and seek
regulatory approval for Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, we will need to obtain
substantial additional funding.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Research and Development</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Since our inception in 1997, we have been focused on drug discovery and development programs.
Research and development expenses include, but are not limited to, our expenses for personnel
associated with our research activities, screening and identification of product candidates,
formulation and synthesis activities, manufacturing, preclinical studies, toxicology studies,
clinical trials, regulatory affairs activities, quality assurance activities and license fees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We expect our research and development expenses for fiscal year 2011 to increase from fiscal
year 2010 and to be primarily focused on the following:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the continued clinical development of Ostarine&#153;;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the continued clinical development of Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the continued preclinical development of other potential product candidates.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There is a risk that any drug discovery and development program may not produce revenue.
Moreover, because of uncertainties inherent in drug discovery and development, including those
factors described in Part&nbsp;II, Item&nbsp;1A &#147;Risk Factors&#148; of this Quarterly Report on Form 10-Q, we may
not be able to successfully develop and
commercialize any of our product candidates.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Product Candidates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table identifies the development phase and status for each of our clinical
product candidates:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Product</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Clinical</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Candidate/</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Development</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Proposed Indication</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Program</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Phase</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Status</B></TD>
</TR>

<!-- End Table Head -->
<tr>
<TD>&nbsp;</TD>
</TR>
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Ostarine</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>TM</B></SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Prevention and treatment of muscle wasting in patients with non-small cell lung cancer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SARM
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phase III
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Commenced the POWER1 and POWER2 pivotal Phase III clinical trials for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Capesaris</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>TM</B></SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">First line hormonal treatment of advanced prostate cancer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Selective ER<BR>
alpha agonist
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phase II
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Completed enrollment in a Phase IIb
maintenance dose clinical trial and initiated a Phase II loading dose clinical trial in men with
advanced prostate cancer.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Capesaris</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>TM</B></SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Second line hormonal treatment of advanced prostate cancer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Selective ER<BR>
alpha agonist
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phase II
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Will initiate a Phase II clinical trial in men on ADT with castration resistant prostate cancer in the fourth quarter of 2011.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Sales and Marketing</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We market and sell FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (toremifene citrate) 60 mg tablets, approved for the
treatment of advanced metastatic breast cancer in postmenopausal women, in the United States.
Effective June&nbsp;1, 2011, we no longer utilize a sales force for FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> promotional
efforts, which has the potential to result in a decline in sales volume in future periods. In
order to commercialize any future products, we will need to develop our sales and marketing
capabilities or establish and maintain agreements with third parties to market and sell our product
candidates.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>General and Administrative Expenses</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our general and administrative expenses consist primarily of salaries and other related costs
for personnel serving executive, finance, legal, human resources, information technology, investor
relations and marketing functions. General and administrative expenses also include facility
costs, insurance costs, professional fees for legal, accounting, public relations, and marketing
services, and FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> selling and distribution expenses. We expect our general and
administrative expenses for fiscal year 2011 to be less than fiscal year 2010 due primarily to the
June&nbsp;2011 reduction in our workforce.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Critical Accounting Policies and Significant Judgments and Estimates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our management&#146;s discussion and analysis of our financial condition and results of operations
is based on our condensed financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of America for interim financial
statements. The preparation of these financial statements requires us to make estimates and
assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the condensed financial statements as well as the
reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our
estimates and judgments related to revenue recognition, income taxes, intangible assets, long-term
service contracts and other contingencies. We base our estimates on historical experience and on
various other factors that we believe are reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">While our significant accounting policies are more fully described in Note 2 to our financial
statements appearing in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2010 filed
with the SEC, we believe that the following accounting policies are most critical to aid you in
fully understanding and evaluating our reported financial results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenue Recognition</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our revenues consist of product sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and revenues derived from our
collaboration and license agreements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Collaboration revenue consisted of non-refundable upfront payments, license fees,
reimbursements for research and development activities, and milestone payments associated with our
former collaboration and license agreements and was based on the performance requirements of the
specific agreements. We analyzed our agreements with multiple element arrangements to determine
whether the deliverables under the agreement, including license and performance obligations such as
joint steering committee participation and research and development activities, could have been
separated or whether all of the deliverables must have been accounted for as a single unit of
accounting. Cost reimbursements for research activities were recognized as collaboration revenue
if amounts were determinable and collection of the related receivable was reasonably assured.
Revenues from milestone payments for which we had no continuing performance obligations were
recognized upon achievement of the performance milestone, as defined in the related agreement,
provided the milestone was substantive and a culmination of the earnings process had occurred.
Performance obligations typically consisted of significant milestones in the development life cycle
of the related product candidates and technology, such as initiation of clinical trials,
achievement of specified clinical trial endpoints, filing for approval with regulatory agencies and
approvals by regulatory agencies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The factors that drive the actual development period of a pharmaceutical product are
inherently uncertain and include determining the timing and expected costs to complete the project,
projecting regulatory approvals and anticipating potential delays. We used all of these factors in
initially estimating the economic useful lives of our performance obligations, and we also
continually monitored these factors for indications of appropriate revisions. We estimated the
performance obligation period to be ten years for the development of toremifene under our former
collaboration agreement with Ipsen. However, due to the termination of our license and
collaboration with Ipsen in March&nbsp;2011, we recognized as collaboration revenue all of the remaining
$8.1&nbsp;million unamortized revenue that was deferred as of December&nbsp;31, 2010 in the first quarter of
2011. This amount is included in collaboration revenue in the condensed statement of operations
for the nine months ended September&nbsp;30, 2011. Additionally, we recognized as collaboration revenue
in the first quarter of 2010 all of the remaining $49.9&nbsp;million of unamortized revenue that was
deferred as of December&nbsp;31, 2009, as well as the final payment of $5.0&nbsp;million for cost
reimbursement for research and development activities that we received from Merck in December&nbsp;2010
due to the termination of our license and collaboration agreement with Merck. These amounts are
included in collaboration revenue in the condensed statement of operations for the nine months
ended September&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recognize revenue from product sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> less deductions for estimated
sales discounts and sales returns. We recognize revenue from product sales when persuasive
evidence of an arrangement exists, title
passes, the price is fixed or determinable, and collectability is reasonably assured. We account
for rebates to certain governmental agencies as a reduction of product sales. We allow customers
to return product within a specified time period prior to and subsequent to the product&#146;s labeled
expiration date. As a result, we estimate an accrual for product returns, which is recorded as a
reduction of product sales. We consider historical product return trend information that we
continue to update each period. We estimate the number of months of product on hand and the amount
of product which is expected to exceed its expiration date and be returned by the customer by
receiving information from our three largest wholesale customers about the levels of
FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> inventory held by these customers. These three largest wholesale customers
accounted for 94% of our product sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> for the nine months ended September
30, 2011. Based on this information and other factors, we estimate an accrual for product returns.
At September&nbsp;30, 2011 and December&nbsp;31, 2010, our accrual for product returns was $978,000 and
$802,000, respectively.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Research and Development Expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development expenses include, but are not limited to, our expenses for personnel,
supplies, and facilities associated with research activities, screening and identification of
product candidates, formulation and synthesis activities, manufacturing, preclinical studies,
toxicology studies, clinical trials, regulatory affairs activities, quality assurance activities
and license fees. We expense these costs in the period in which they are incurred. We estimate
our liabilities for research and development expenses in order to match the recognition of expenses
to the period in which the actual services are received. As such, accrued liabilities related to
third party research and development activities are recognized based upon our estimate of services
received and degree of completion of the services in accordance with the specific third party
contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development expenses for the nine months ended September&nbsp;30, 2011 included an
impairment charge of $1.6&nbsp;million related to the unamortized portion of capitalized license fees
paid to Orion Corporation related to our toremifene 80 mg program. Research and development
expenses for the nine months ended September&nbsp;30, 2010 also included an impairment charge of $1.7
million related to the unamortized portion of capitalized license fees paid to Orion Corporation
and the University of Tennessee Research Foundation related to our toremifene 20 mg program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Share-Based Compensation</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have stock option and equity incentive plans that provide for the purchase of our common
stock by certain of our employees and non-employee directors. We recognize compensation expense
for our share-based payments based on the fair value of the awards on the grant date and recognize
the expense over the period during which an employee or non-employee director is required to
provide service in exchange for the award.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The determination of the fair value of share-based payment awards on the date of grant include
the expected life of the award, the expected stock price volatility over the expected life of the
awards, expected dividend yield, and risk-free interest rate. We estimate the expected life of
options by calculating the average of the vesting term and contractual term of the options. We
estimate the expected stock price volatility based on the historical volatility of our common
stock. The risk-free interest rate is determined using U.S. Treasury rates where the term is
consistent with the expected life of the stock options. Expected dividend yield is not considered
as we have not made any dividend payments and have no plans of doing so in the foreseeable future.
The amount of share-based compensation expense recognized is reduced ratably over the vesting
period by an estimate of the percentage of options granted that are expected to be forfeited or
canceled before becoming fully vested. This estimate is adjusted periodically based on the extent
to which actual forfeitures differ, or are expected to differ, from the previous estimate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Total share-based compensation expense for the three months ended September&nbsp;30, 2011 was $1.1
million, of which $503,000 and $623,000 were recorded in the condensed statement of operations as
research and development expenses and general and administrative expenses, respectively. Total
share-based compensation expense for the three months ended September&nbsp;30, 2010 was $1.1&nbsp;million, of
which $442,000 and $677,000 were recorded in the condensed statement of operations as research and
development expenses and general and administrative expenses, respectively. Total share-based
compensation expense for the nine months ended September&nbsp;30, 2011 was $3.3&nbsp;million, of which $1.4
million and $1.9&nbsp;million were recorded in the condensed statement of operations as research and
development expenses and general and administrative expenses, respectively. Total share-based
compensation expense for the nine months ended September&nbsp;30, 2010 was $3.9&nbsp;million, of which $1.7
million and $2.2&nbsp;million were recorded in the condensed statement of operations as research and
development expenses and general and administrative expenses, respectively. Included in
share-based compensation expense for both of the three months ended September&nbsp;30, 2011 and 2010 was
share-based compensation expense related to deferred compensation arrangements for our non-employee
directors of $45,000 and $141,000 for both of the nine months ended September&nbsp;30, 2011 and 2010,
respectively. At September&nbsp;30, 2011, the total compensation cost related to non-vested awards not
yet recognized was approximately $7.3&nbsp;million with a weighted average expense recognition period of
3.0&nbsp;years.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Three Months Ended September&nbsp;30, 2011 and 2010</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenues. </I></B>Revenues for the three months ended September&nbsp;30, 2011 were $2.0&nbsp;million as compared to
$1.3&nbsp;million for the same period of 2010. Revenues for the three months ended September&nbsp;30, 2011
consisted of net product sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> marketed for the treatment of advanced
metastatic breast cancer in postmenopausal women while revenues for the same period of 2010
included net sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and collaboration revenue from our former collaboration
with Ipsen. During the three months ended September&nbsp;30, 2011 and 2010, FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> net
product sales were $2.0&nbsp;million and $960,000, respectively, while cost of product sales were
$311,000 and $216,000, respectively. FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> net product sales for the three months
ended September&nbsp;30, 2011 increased from the same period in the prior year due primarily to an
increase in sales volume and, to a lesser extent, an increase in the sales price of
FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. Collaboration revenue for the three months ended September&nbsp;30, 2010 was
$336,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Research and Development Expenses. </I></B>Research and development expenses increased 46% to $8.2&nbsp;million
for the three months ended September&nbsp;30, 2011 from $5.6&nbsp;million for the three months ended
September&nbsp;30, 2010. The decrease in &#147;Other research and development&#148; during the three months ended
September&nbsp;30, 2011 compared to the three months ended September&nbsp;30, 2010, as shown in the following
table, was due primarily to the discontinuance of our toremifene 80 mg and toremifene 20 mg
development programs during 2011. The following table identifies the research and development
expenses for each of our clinical product candidates, as well as research and development expenses
pertaining to our other research and development efforts, for both of the periods presented.
Research and development expenses for past periods may not be indicative of future periods.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Product Candidate/</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Increase/</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Proposed Indication</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Program</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(in thousands)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>




<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Ostarine</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>TM </B></SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prevention and treatment of muscle wasting in patients with non-small cell lung cancer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center"><B>SARM</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,702</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">563</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,139</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Capesaris</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>TM</B></SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><DIV style="margin-left:15px; text-indent:-15px">First and second line hormonal treatment of advanced prostate cancer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center"><B>Selective ER alpha agonist</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,815</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,886</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">929</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Other research and development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,664</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,144</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,480</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total research and
development expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8,181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,593</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,588</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>General and Administrative Expenses</I></B><B>. </B>General and administrative expenses decreased during the
three months ended September&nbsp;30, 2011 to $2.9&nbsp;million from $4.1&nbsp;million for the three months ended
September&nbsp;30, 2010. This decrease was primarily due to decreased personnel related expenses of
$225,000 resulting from the reduction in our workforce that occurred in June&nbsp;2011 and reduced
marketing and legal expenses of $539,000 and $150,000, respectively.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Nine Months Ended September&nbsp;30, 2011 and 2010</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Revenues</I></B><B>. </B>Revenues for the nine month periods ended September&nbsp;30, 2011 and 2010 were $13.0&nbsp;million
and $58.8&nbsp;million, respectively and included net product sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and
collaboration revenue. In the first nine months of 2011 and 2010, FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> net product
sales were $4.9&nbsp;million and $2.4&nbsp;million, respectively, while cost of product sales were $780,000
and $501,000, respectively. FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> net product sales for the nine months ended
September&nbsp;30, 2011 increased from the same period in the prior year due to an increase in the price
of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, and to a lesser extent, an increase in sales volume. Collaboration
revenue was $8.1&nbsp;million for the nine months ended September&nbsp;30, 2011, which resulted from
recognition of all of the remaining unamortized deferred revenue upon the termination of our
license and collaboration agreement with Ipsen in March&nbsp;2011. Collaboration revenue was $56.5
million for the nine months ended September&nbsp;30, 2010 and consisted of $1.6&nbsp;million from Ipsen and
$54.9&nbsp;million from Merck. As a result of the termination of our license and collaboration
agreement with Merck in March&nbsp;2010, we recognized as collaboration revenue the remaining $49.9
million of unamortized deferred revenue, as well as the final payment of $5.0&nbsp;million of cost
reimbursement that was received from Merck.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Research and Development Expenses. </I></B>Research and development expenses increased by 2% to $23.1
million for the nine months ended September&nbsp;30, 2011 from $22.7&nbsp;million for the nine months ended
September&nbsp;30, 2010. The decrease in &#147;Other research and development&#148; during the nine months ended
September&nbsp;30, 2011 compared to the nine months ended September&nbsp;30, 2010, as shown in the following
table, was due primarily to the discontinuance of our toremifene 80 mg and toremifene 20 mg
development programs during 2011. The following table identifies the research and development
expenses for each of our clinical product candidates, as well as research and development expenses
pertaining to our other research and development efforts, for both of the periods presented.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Product Candidate/</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Increase/</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Proposed Indication</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Program</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Decrease)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(in thousands)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>





<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Ostarine</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>TM </B></SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prevention and treatment of muscle wasting in patients with non-small cell lung cancer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center"><B>SARM</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,178</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,048</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,130</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Capesaris</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>TM</B></SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><DIV style="margin-left:15px; text-indent:-15px">First and second line hormonal treatment of advanced prostate cancer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center"><B>Selective ER alpha agonist</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,463</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,716</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,747</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Other research and development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,434</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,956</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,522</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total research and
development expenses</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">23,075</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">22,720</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">355</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>General and Administrative Expenses. </I></B>General and administrative expenses decreased during the
nine months ended September&nbsp;30, 2011 to $12.1&nbsp;million from $12.9&nbsp;million for the nine months ended
September&nbsp;30, 2010. This decrease was primarily due to decreased marketing, insurance and
occupancy expenses of $352,000, $260,000 and $193,000, respectively. These decreases were
partially offset by increased personnel related expenses due to the severance costs related to our
workforce reduction that occurred in June&nbsp;2011.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Liquidity and Capital Resources</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At September&nbsp;30, 2011, we had cash, cash equivalents and short-term investments of $83.0
million, compared to $58.6&nbsp;million at December&nbsp;31, 2010. On June&nbsp;28, 2011, we completed an
underwritten public offering of 11,023,000 shares of our common stock at a price to the public of
$4.75 per share. Net cash proceeds from the public offering were approximately $49.0&nbsp;million,
after deducting the underwriting discount and offering expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Net cash used in operating activities was $24.5&nbsp;million and $29.2&nbsp;million for the nine months
ended September&nbsp;30, 2011 and 2010, respectively, and resulted primarily from funding our operations
for the periods.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Net cash used in investing activities was $9.3&nbsp;million for the nine months ended September&nbsp;30,
2011 and was for the purchase of short-term investments of $12.5&nbsp;million and information technology
software and lab equipment of $45,000 offset by maturities of short-term investments of $3.2
million. Net cash provided by investing activities was $6.6&nbsp;million for the nine months ended
September&nbsp;30, 2010 and resulted from the maturities of short-term investments of $14.8&nbsp;million,
offset by the purchase of short-term investments of $8.1&nbsp;million and the purchase of information
technology equipment and research and development equipment of approximately $88,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Net cash provided by financing activities was $49.0&nbsp;million for the nine months ended
September&nbsp;30, 2011 and reflects proceeds from our underwritten public offering of common stock in
June&nbsp;2011 and proceeds from the exercise of employee stock options. These proceeds were reduced by
payments on our capital lease and financed equipment obligations. Net cash used in financing
activities of $67,000 for the nine months ended September&nbsp;30, 2010 was related to payments on
capital lease and financed equipment obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We estimate that our current cash, cash equivalents, and short-term investments, together with
interest income and product revenue from the sale of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, will be sufficient to
meet our projected operating requirements into the first half of 2013. We have based this estimate
on our current business plan and assumptions that may prove to be wrong. We could utilize our
available capital resources sooner than we currently expect, and we could need additional funding
sooner than currently anticipated. In any event, to complete the development of and seek
regulatory approval for Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM </SUP>and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, we will need to obtain
substantial additional funding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our estimate of the period of time through which our financial resources will be adequate to
support our projected operating requirements is a forward-looking statement and involves risks and
uncertainties, and actual results could vary as a result of a number of factors, including the
factors discussed under Part&nbsp;II, Item&nbsp;1A &#147;Risk Factors&#148; section of this Quarterly Report on Form
10-Q. Because of the numerous risks and uncertainties associated with the development and
commercialization of our product candidates and other research and development activities,
including risks and uncertainties that could impact the rate of progress of our development and
commercialization activities, we are unable to estimate with certainty the amounts of increased
capital outlays and operating expenditures associated with our anticipated future clinical trials,
other research and development activities, and potential commercialization activities. Our future
funding requirements will depend on many factors, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the scope, rate of progress and cost of our clinical trials and other research and development activities,
including our ongoing and any future clinical trials of Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the terms and timing of any potential future collaborative, licensing and other arrangements that we may
establish;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount and timing of any licensing fees, milestone payments and royalty payments from potential future
collaborators, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>future clinical trial results;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost and timing of regulatory filings and/or approvals to commercialize our product candidates and any
related restrictions, limitations, and/or warnings in the label of an approved product candidate;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost and timing of establishing medical education, sales, marketing and distribution capabilities;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of establishing clinical and commercial supplies of our product candidates and any products that
we and/or any potential future collaborators may develop;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the effect of competing technological and market developments;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property
rights, and the cost of defending any other litigation claims; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the extent to which we acquire or invest in businesses, products and technologies, although we currently
have no commitments or agreements relating to any of these types of transactions.</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not currently have any commitments for future external funding and until we can generate
a sufficient amount of product revenue, which we may never do, we expect to finance future cash
needs through public or private equity offerings, debt financings or collaboration and licensing
arrangements, or a combination of the above, as well as through interest income earned on the
investment of our cash balances and short-term investments and revenues from the sale of
FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. In June&nbsp;2011 and December&nbsp;2009, we announced workforce reductions of
approximately 15% and 26%, respectively, in order to reduce our operating expenses relating to our
discontinued toremifene development programs. If we are unable to raise additional funds when
needed, we may need to further reduce our expenditures, perhaps significantly, to preserve our
cash. Cost-cutting measures that we may take in the future may not be sufficient to enable us to
meet our cash requirements, and they may negatively affect our business and growth prospects.
To the extent we raise additional funds by issuing equity securities, our stockholders may
experience dilution, and debt financing, if available, may involve restrictive covenants. Any debt
financing or additional equity that we raise may contain terms that are not favorable to us or our
stockholders. To the extent we raise additional funds through potential future collaboration and
licensing arrangements, it may be necessary to relinquish rights to some of our technologies or
product candidates, or grant licenses on terms that are not favorable to us. Our ability to raise
additional funds and the terms upon which we are able to raise such funds may be adversely impacted
by the uncertainty regarding our financial condition, the outcomes of our ongoing clinical trials
of Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and/or current economic conditions, including
the effects of disruptions to and volatility in the credit and financial markets in the United
States and worldwide. As a result of these and other factors, we cannot be certain that additional
funding will be available on acceptable terms, or at all. If adequate funds are not available when
we need them, we may be required to delay, reduce the scope of or eliminate one or more of our
research or development programs, including our SARM and selective ER alpha agonist programs, or
conduct additional workforce or other expense reductions, any of which could have a material
adverse effect on our business.
</DIV>
<DIV align="left">
<A name="C24070108"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 3.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the nine months ended September&nbsp;30, 2011, there were no material changes to our market
risk disclosures as set forth in Part&nbsp;II, Item&nbsp;7A of our Annual Report on Form 10-K for the year
ended December&nbsp;31, 2010.
</DIV>
<DIV align="left">
<A name="C24070109"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 4.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>CONTROLS AND PROCEDURES</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We maintain disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e) of
the Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)) that are designed to
ensure that information required to be disclosed in the reports that we file or submit under the
Exchange Act is recorded, processed, summarized, and reported within the time periods specified in
the SEC&#146;s rules and forms and that such information is accumulated and communicated to our
management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to
allow for timely decisions regarding required disclosures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have carried out an evaluation, under the supervision and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness
of the design and operation of our disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report.
Based on the evaluation of these disclosure controls and procedures, our Chief Executive Officer
and Chief Financial Officer have concluded that our disclosure controls and procedures were
effective.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There were no changes in our internal control over financial reporting during the third
quarter of 2011 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.
</DIV>
<DIV align="left">
<A name="C24070110"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>PART II: OTHER INFORMATION</B>
</DIV>

<DIV align="left">
<A name="C24070111"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 1A.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>RISK FACTORS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have identified the following additional risks and uncertainties that may have a material
adverse effect on our business, financial condition or results of operations. Investors should
carefully consider the risks described below before making an investment decision. Our business
faces significant risks, and the risks described below may not be the only risks we face.
Additional risks not presently known to us or that we currently believe are immaterial may also
significantly impair our business operations. If any of these risks occur, our business, results
of operations or financial condition could suffer, the market price of our common stock could
decline and you could lose all or part of your investment in our common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have marked with an asterisk (*) those risks described below that reflect substantive
changes from the risks described under Part&nbsp;I, Item&nbsp;1A &#147;Risk Factors&#148; included in our Annual Report
on Form 10-K filed with the Securities and Exchange Commission on March&nbsp;8, 2011. In addition, the
risks described under, and the captions entitled, &#147;Off-label sale or use of third-party toremifene
products could decrease sales of any toremifene product candidates that we continue to develop and
that are approved for commercial sale, and could lead to pricing pressure if such products become
available at competitive prices and in dosages that are appropriate for the indications for which
we may continue to develop toremifene&#148; and &#147;Our license agreement with Orion excludes the use of
toremifene in humans to treat breast cancer outside of the United States and may limit our ability
to market toremifene for human uses outside the United States&#148; included under Part&nbsp;1, Item&nbsp;1A &#147;Risk
Factors&#148; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March&nbsp;8, 2011 have been removed.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Financial Condition and Need for Additional Financing</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>We have incurred losses since inception, and we anticipate that we will incur continued losses
for the foreseeable future.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of September&nbsp;30, 2011, we had an accumulated deficit of $375.5&nbsp;million. Due to the
recognition of the remaining $49.9&nbsp;million of unamortized revenue following the termination of an
exclusive license and collaboration agreement for our SARM program, we reported net income of $15.3
million for the year ended December&nbsp;31, 2010. However, we have incurred losses in each prior year
since our inception in 1997, including net losses of $46.3&nbsp;million and $51.8&nbsp;million in 2009 and
2008, respectively. Our net loss for the nine months ended September&nbsp;30, 2011 was $22.6&nbsp;million.
We expect to incur significant net losses in 2011 and for the foreseeable future as we continue our
clinical development and research and development activities. These losses, among other things,
have had and will continue to have an adverse effect on our stockholders&#146; equity and working
capital.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have discontinued our toremifene 80 mg and toremifene 20 mg development programs, and we do
not anticipate that we will receive any return on our investment in either of our toremifene 80 mg
or toremifene 20 mg product candidates. Our current product candidates, Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>
(GTx-024) and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> (GTx-758), are in various stages of clinical development, and
significant additional clinical development and financial resources will be required to obtain
necessary regulatory approvals for each of these product candidates and to develop these product
candidates into commercially viable products. Accordingly, we do not expect to obtain FDA or any
other
regulatory approvals to market any of our product candidates in the near future, and it is
possible these product candidates will never gain regulatory approval.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Because of the numerous risks and uncertainties associated with developing and commercializing
small molecule drugs, we are unable to predict the extent of any future losses or when we will
become profitable, if at all. We have financed our operations and internal growth primarily through
public offerings and private placement of our common stock, as well as payments from our former
collaborators. Currently, we have no ongoing collaborations for the development and
commercialization of our product candidates. FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> is currently our only commercial
product and, until such time that we receive regulatory approval to market any of our product
candidates, if ever, we expect that FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top"><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>will account for all of our product
revenue. For the nine months ended September&nbsp;30, 2011, we recognized $4.9&nbsp;million in net revenues
from the sale of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.<SUP style="FONT-size: 85%; vertical-align: text-top"> </SUP> If we and/or any potential future collaborators
are unable to develop and commercialize any of our product candidates, if development is further
delayed or eliminated, or if sales revenue from any product candidate that receives marketing
approval is insufficient, we may never become profitable and we will not be successful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>We will need to raise substantial additional capital and may be unable to raise capital when
needed, which would force us to further delay, reduce or eliminate our product development programs
or commercialization efforts.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We will need to raise substantial additional capital to:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fund our operations and conduct clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue our research and development;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>seek regulatory approval for our product candidates; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>commercialize our product candidates, if any such product candidates receive regulatory approval for commercial sale.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We estimate that our current cash, cash equivalents, and short-term investments, together with
interest income and product revenue from the sale of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, will be sufficient to
meet our projected operating requirements into the first half of 2013. We have based this
estimate on our current business plan and assumptions that may prove to be wrong. We could utilize
our available capital resources sooner than we currently expect, and we could need additional
funding sooner than currently anticipated. In any event, to complete the development of and seek
regulatory approval for Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, we will need to obtain
substantial additional funding. Our future funding requirements will depend on many factors,
including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the scope, rate of progress and cost of our clinical trials and other research and development
activities, including our ongoing and any future clinical trials of Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the terms and timing of any potential future collaborative, licensing and other arrangements that we may
establish;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount and timing of any licensing fees, milestone payments and royalty payments from potential
future collaborators, if any;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>future clinical trial results;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost and timing of regulatory filings and/or approvals to commercialize our product candidates and
any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost and timing of establishing medical education, sales, marketing and distribution capabilities;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of establishing clinical and commercial supplies of our product candidates and any products
that we and/or any potential future collaborators may develop;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the effect of competing technological and market developments;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual
property rights, and the cost of defending any other litigation claims; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the extent to which we acquire or invest in businesses, products and technologies, although we currently
have no commitments or agreements relating to any of these types of transactions.</TD>
</TR>



</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not currently have any commitments for future external funding and until we can generate
a sufficient amount of product revenue, which we may never do, we expect to finance future cash
needs through public or private equity offerings, debt financings or collaboration and licensing
arrangements, or a combination of the above, as well as through interest income earned on the
investment of our cash balances and short-term investments and revenues from the sale of
FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. In June&nbsp;2011 and December&nbsp;2009, we announced workforce reductions of
approximately 15% and 26%, respectively, in order to reduce our operating expenses relating to our
discontinued toremifene development programs. If we are unable to raise additional funds when
needed, we may need to further reduce our expenditures, perhaps significantly, to preserve our
cash. Cost-cutting measures that we may take in the future may not be sufficient to enable us to
meet our cash requirements, and they may negatively affect our business and growth prospects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To the extent we raise additional funds by issuing equity securities, our stockholders may
experience dilution, and debt financing, if available, may involve restrictive covenants. Any debt
financing or additional equity that we raise may contain terms that are not favorable to us or our
stockholders. To the extent we raise additional funds through potential future collaboration and
licensing arrangements, it may be necessary to relinquish rights to some of our technologies or
product candidates, or grant licenses on terms that are not favorable to us. Our ability to raise
additional funds and the terms upon which we are able to raise such funds may be adversely impacted
by the uncertainty regarding our financial condition, the outcomes of our ongoing clinical trials
of Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and/or current economic conditions, including
the effects of disruptions to and volatility in the credit and financial markets in the United
States and worldwide. As a result of these and other factors, we cannot be certain that additional
funding will be available on acceptable terms, or at all. If adequate funds are not available when
we need them, we may be required to delay, reduce the scope of or eliminate one or more of our
research or development programs, including our SARM and selective ER alpha agonist programs, or
conduct additional workforce or other expense reductions, any of which could have a material
adverse effect on our business.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Development of Product Candidates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>We and any potential future collaborators will not be able to commercialize our product
candidates if our preclinical studies do not produce successful results or if our clinical trials
do not adequately demonstrate safety and efficacy in humans.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Significant additional research and development and financial resources will be required to
obtain necessary regulatory approvals for our product candidates and to develop them into
commercially viable products. Preclinical and clinical testing is expensive, can take many years
to complete and has an uncertain outcome. Success in preclinical testing and early clinical trials
does not ensure that later clinical trials will be successful, and interim results of a clinical
trial do not necessarily predict final results. Typically, the failure rate for development
candidates is high. If a product candidate fails at any stage of development, we will not have the
anticipated revenues from that product candidate to fund our operations, and we will not receive
any return on our investment in that product candidate. For example, we announced in May&nbsp;2010 that
toremifene 20 mg failed to meet its primary efficacy endpoint in our Phase III clinical trial of
toremifene 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic
intraepithelial neoplasia, after we had incurred significant development costs. Even if the
results of a clinical trial are positive, the efficacy and/or safety results from the trial may be
insufficient to support the submission of a NDA to the FDA, or if submitted, the filing or approval
of the NDA by the FDA. For example, we received a Complete Response Letter in October&nbsp;2009 from the
FDA regarding our NDA for toremifene 80 mg to reduce fractures in men with prostate cancer on ADT,
notifying us that the FDA would not approve the NDA. We have since determined to discontinue our
toremifene development programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Significant delays in clinical testing could materially impact our product development costs.
We do not know whether future clinical trials will begin on time, or whether ongoing clinical
trials will need to be restructured or will be completed on schedule, if at all. We or any
potential future collaborators may experience numerous unforeseen
and/or adverse events during, or as a result of, preclinical testing and the clinical trial
process that could delay or prevent our or our potential future collaborators&#146; ability to
commercialize our product candidates, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulators or institutional review boards may not authorize us or any potential future
collaborators to commence a clinical trial or conduct a clinical trial at a prospective trial site, or we
may experience substantial delays in obtaining these authorizations;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preclinical or clinical trials may produce negative or inconclusive results, which may require us
or any potential future collaborators to conduct additional preclinical or clinical testing or to abandon
projects that we expect to be promising;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>even if preclinical or clinical trial results are positive, the FDA or foreign regulatory
authorities could nonetheless require us to conduct unanticipated additional clinical trials;</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>registration or enrollment in clinical trials may be slower than we anticipate, resulting in
significant delays or study terminations;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we or any potential future collaborators may suspend or terminate clinical trials if the
participating patients are being exposed to unacceptable health risks;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulators or institutional review boards may suspend or terminate clinical research for various
reasons, including noncompliance with regulatory requirements; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our product candidates may not have the desired effects or may include undesirable side effects.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If any of these events were to occur and, as a result, we or any potential future
collaborators have significant delays in or termination of clinical trials, our costs could
increase and our ability to generate revenue could be impaired, which would materially and
adversely impact our business, financial condition and growth prospects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we or any potential future collaborators observe serious or other adverse events during the
time our product candidates are in development or after our products are approved and on the
market, we or any potential future collaborators may be required to perform lengthy additional
clinical trials, may be denied regulatory approval of such products, may be forced to change the
labeling of such products or may be required to withdraw any such products from the market, any of
which would hinder or preclude our ability to generate revenues.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In our Phase II clinical trials for Ostarine&#153; for the treatment of muscle wasting in patients
with cancer and healthy older males and postmenopausal females, we observed mild elevations of
hepatic enzymes in a few patients in both the placebo and Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> treated groups.
Reductions in high-density lipoproteins have also been observed in subjects treated with
Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Capesaris&#153; is a new chemical entity that is selective for estrogen receptor alpha. Similar to
other estrogenic therapies, there may be an increased risk of venous thromboembolic events, or
blood clots, and increases in liver enzymes with Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> treatment. Although to
date Capesaris&#153; has been generally well tolerated in clinical trials that we have completed, one
subject receiving Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> in one of our completed studies experienced a blood clot
in his leg and was discontinued from the study. It is possible that blood clots, increases in
liver enzymes and other adverse effects may be observed in our ongoing and future
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> clinical studies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If the incidence of serious or other adverse events related to our product candidates
increases in number or severity, if a regulatory authority believes that these or other events
constitute an adverse effect caused by the drug, or if other effects are identified during clinical
trials that we or any potential future collaborators may conduct in the future or after any of our
product candidates are approved and marketed:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we or any potential future collaborators may be required to conduct
additional preclinical or clinical trials, make changes in the labeling of any such
approved products, reformulate any such products, or implement changes to or obtain
new approvals of our contractors&#146; manufacturing facilities;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulatory authorities may be unwilling to approve our product candidates or
may withdraw approval of our products;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may experience a significant drop in the sales of the affected products;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our reputation in the marketplace may suffer; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may become the target of lawsuits, including class action suits.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Any of these events could prevent approval or harm sales of the affected product candidates or
products, or could substantially increase the costs and expenses of commercializing and marketing
any such products.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Dependence on Third Parties</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we do not establish collaborations for our product candidates or otherwise raise
substantial additional capital, we will likely need to alter our development and any
commercialization plans.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our strategy includes selectively partnering or collaborating with leading pharmaceutical and
biotechnology companies to assist us in furthering development and potential commercialization of
our product candidates. We face significant competition in seeking appropriate collaborators, and
collaborations are complex and time consuming to negotiate and document. We may not be successful
in entering into new collaborations with third parties on acceptable terms, or at all, including as
a result of the collaboration discussions we are pursuing for Ostarine&#153; and Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>.
In addition, we are unable to predict when, if ever, we will enter into any additional
collaborative arrangements because of the numerous risks and uncertainties associated with
establishing such arrangements. If we are unable to negotiate new collaborations, we may have to
curtail the development of a particular product candidate, reduce, delay, or terminate its
development or one or more of our other development programs, delay its potential commercialization
or reduce the scope of our sales or marketing activities or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to increase our
expenditures to fund development or commercialization activities on our own, we will need to raise
substantial additional capital, which may not be available to us on acceptable terms, or at all. If
we do not have sufficient funds, we will not be able to bring our product candidates to market and
generate product revenues.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Any collaborative arrangements that we establish in the future may not be successful or we may
otherwise not realize the anticipated benefits from these collaborations. In addition, any future
collaboration arrangements may place the development and commercialization of our product
candidates outside our control, may require us to relinquish important rights or may otherwise be
on terms unfavorable to us.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have in the past established and intend to continue to establish collaborations with third
parties to develop and commercialize some of our current and future product candidates, and these
collaborations may not be successful or we may otherwise not realize the anticipated benefits from
these collaborations. For example, in March&nbsp;2011, we and Ipsen Biopharm Limited, or Ipsen, mutually
agreed to terminate our collaboration and, as a result, we will not receive any additional
milestone payments from Ipsen on account of our collaboration with Ipsen. As of the date of this
report, we have no ongoing collaborations for the development and commercialization of our product
candidates. In the future, we may not be able to locate third-party collaborators to develop and
market our product candidates, and we may lack the capital and resources necessary to develop our
product candidates alone.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Dependence on collaborative arrangements subjects us to a number of risks, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may not be able to control the amount and timing of resources that our potential
future collaborators may devote to our product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>potential future collaborations may experience financial difficulties or changes in
business focus;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we may be required to relinquish important rights such as marketing and distribution
rights;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>should a collaborator fail to develop or commercialize one of our compounds or
product candidates, we may not receive any future milestone payments and will not
receive any royalties for the compound or product candidate;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>business combinations or significant changes in a collaborator&#146;s business strategy
may also adversely affect a collaborator&#146;s willingness or ability to complete its
obligations under any arrangement;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>under certain circumstances, a collaborator could move forward with a competing
product candidate developed either independently or in collaboration with others,
including our competitors; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>collaborative arrangements are often terminated or allowed to expire, which could
delay the development and may increase the cost of developing our product candidates.</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If third parties do not manufacture our product candidates in sufficient quantities, in the
required timeframe, and at an acceptable cost, clinical development and commercialization of our
product candidates would be delayed.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not currently own or operate manufacturing facilities, and we rely, and expect to
continue to rely, on third parties for the production of clinical and commercial quantities of our
product candidates. Our current and anticipated future dependence upon others for the manufacture
of our product candidates may adversely affect our future profit margins, if any, and our ability
to develop product candidates and commercialize any product candidates on a timely and competitive
basis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We rely on third party vendors for the manufacture of Ostarine&#153; drug substance. If our supply
of Ostarine&#153; becomes unusable or if the contract manufacturers that we are currently utilizing to
meet our supply needs for Ostarine&#153; or any future SARM product candidates prove incapable or
unwilling to continue to meet our supply needs, we could experience a delay in conducting any
additional clinical trials of Ostarine&#153; or any future SARM product candidates. In addition, we rely
on third party contractors for the manufacture of Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> drug substance. We may not
be able to maintain or renew our existing or any other third-party manufacturing arrangements on
acceptable terms, if at all. If we are unable to continue our relationship with Orion for
toremifene, or to do so at an acceptable cost, or other suppliers fail to meet our requirements for
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, Ostarine&#153; or any future product candidates for any reason, we would be
required to obtain alternate suppliers. Any inability to obtain alternate suppliers, including an
inability to obtain approval from the FDA of an alternate supplier, would delay or prevent the
clinical development and commercialization of these product candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Use of third-party manufacturers may increase the risk that we will not have adequate supplies
of our product candidates or products.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Reliance on third-party manufacturers entails risks, to which we would not be subject if we
manufactured product candidates or products ourselves, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reliance on the third party for regulatory compliance and quality assurance;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the possible breach of the manufacturing agreement by the third party because of
factors beyond our control;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the possible termination or non-renewal of the agreement by the third party, based on
its own business priorities, at a time that is costly or inconvenient for us; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>drug product supplies not meeting the requisite requirements for clinical trial use.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If we are not able to obtain adequate supplies of our product candidates, it will be more
difficult for us to develop our product candidates and compete effectively. Our product candidates
and any products that we and/or our potential future collaborators may develop may compete with
other product candidates and products for access to manufacturing facilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have agreed to purchase exclusively from Orion our worldwide requirements of toremifene in
a finished tablet form at specified prices under a license and supply agreement. Orion may
terminate its supply obligations to us at its election at any time. If Orion elects to terminate
its obligation to manufacture and supply us with FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> tablets, any arrangements we
make for an alternative supply would have to be made with a qualified alternative supplier with
appropriate FDA approval in order for us to obtain our supply requirements for toremifene.
In addition, although Orion&#146;s composition of matter patents have expired, and as such, we
would not be prevented from manufacturing FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> tablets, there is no obligation on
the part of Orion to transfer its manufacturing technology to us or to assist us in developing
manufacturing capabilities to meet our supply needs. If our supply rights for FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
tablets are terminated by Orion for any reason, a disruption in the supply could impair our ability
to continue to commercialize FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our present or future manufacturing partners may not be able to comply with FDA-mandated
current Good Manufacturing Practice regulations, other FDA regulatory requirements or similar
regulatory requirements outside the United States. Failure of our third-party manufacturers or us
to comply with applicable regulations could result in sanctions being imposed on us, including
fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval
of our product candidates, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or products, operating restrictions and criminal
prosecutions, any of which could significantly and adversely affect supplies of our product
candidates.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If third parties on whom we rely do not perform as contractually required or expected, we may
not be able to obtain regulatory approval for or successfully commercialize our product candidates.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not have the ability to independently conduct clinical trials for our product
candidates, and we must rely on third parties, such as contract research organizations, medical
institutions, clinical investigators and contract laboratories to conduct our clinical trials. In
addition, we rely on third parties to assist with our preclinical development of product
candidates. If these third parties do not successfully carry out their contractual duties or
regulatory obligations or meet expected deadlines, if the third parties need to be replaced, or if
the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our
clinical protocols or regulatory requirements or for other reasons, our preclinical development
activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be
able to obtain regulatory approval for or successfully commercialize our product candidates.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Intellectual Property</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we lose our license from the University of Tennessee Research Foundation, or UTRF, we may
be unable to continue a substantial part of our business.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have licensed intellectual property rights and technology from UTRF used in a substantial
part of our business. This license agreement, under which we were granted rights to SARM compounds
and technologies, may be terminated by UTRF if we are in breach of our obligations under, or fail
to perform any terms of, the agreement and fail to cure that breach. If this agreement is
terminated, then we may lose our rights to utilize the SARM technology and intellectual property
covered by that agreement to market, distribute and sell licensed products, including
Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, which may prevent us from continuing a substantial part of our business and
may result in a serious adverse effect on our financial condition, results of operations and any
prospects for growth.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If some or all of our, or our licensors&#146;, patents expire or are invalidated or are found to be
unenforceable, or if some or all of our patent applications do not result in issued patents or
result in patents with narrow, overbroad, or unenforceable claims, or claims that are not supported
in regard to written description or enablement by the specification, or if we are prevented from
asserting that the claims of an issued patent cover a product of a third party, we may be subject
to competition from third parties with products in the same class of products as our product
candidates or products with the same active pharmaceutical ingredients as our product candidates.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our commercial success will depend in part on obtaining and maintaining patent and trade
secret protection for our product candidates, as well as the methods for treating patients in the
product indications using these product candidates. We will be able to protect our product
candidates and the methods for treating patients in the product indications using these product
candidates from unauthorized use by third parties only to the extent that we or our exclusive
licensors own or control such valid and enforceable patents or trade secrets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our rights to certain patents and patent applications relating to SARM compounds that we have
licensed from UTRF are subject to the terms of UTRF&#146;s inter-institutional agreements with The Ohio
State University, or OSU, and our rights to future related improvements in some instances are
subject to UTRF&#146;s exercise of exclusive options under its agreements with OSU for such
improvements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Even if our product candidates and the methods for treating patients for prescribed
indications using these product candidates are covered by valid and enforceable patents and have
claims with sufficient scope, disclosure and support in the specification, the patents will provide
protection only for a limited amount of time. Our and our licensors&#146; ability to obtain patents can
be highly uncertain and involve complex and in some cases unsettled legal issues and factual
questions. Furthermore, different countries have different procedures for obtaining patents, and
patents issued in different countries provide different degrees of protection against the use of a
patented invention by others. Therefore, if the issuance to us or our licensors, in a given
country, of a patent covering an invention is not followed by the issuance, in other countries, of
patents covering the same invention, or if any judicial interpretation of the validity,
enforceability, or scope of the claims in, or the written description or enablement in, a patent
issued in one country is not similar to the interpretation given to the corresponding patent issued
in another country, our ability to protect our intellectual property in those countries may be
limited. Changes in either patent laws or in interpretations of patent laws in the United States
and other countries may materially diminish the value of our intellectual property or narrow the
scope of our patent protection.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Even if patents are issued to us or our licensors regarding our product candidates or methods
of using them, those patents can be challenged by our competitors who can argue such patents are
invalid or unenforceable, lack sufficient written description or enablement, or that the claims of
the issued patents should be limited or narrowly construed. Patents also will not protect our
product candidates if competitors devise ways of making or using these product candidates without
legally infringing our patents. The Federal Food, Drug, and Cosmetic Act and FDA regulations and
policies create a regulatory environment that encourages companies to challenge branded drug
patents or to create non-infringing versions of a patented product in order to facilitate the
approval of abbreviated new drug applications for generic substitutes. These same types of
incentives encourage competitors to submit new drug applications that rely on literature and
clinical data not prepared for or by the drug sponsor, providing another less burdensome pathway to
approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We also rely on trade secrets to protect our technology, especially where we do not believe
that patent protection is appropriate or obtainable. However, trade secrets are difficult to
protect. Our employees, consultants, contractors, outside scientific collaborators and other
advisors may unintentionally or willfully disclose our confidential information to competitors, and
confidentiality agreements may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. Enforcing a claim that a third party illegally obtained and
is using our trade secrets is expensive and time-consuming, and the outcome is unpredictable.
Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.
Failure to obtain or maintain trade secret protection could adversely affect our competitive
business position.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we infringe intellectual property rights of third parties, it may increase our costs or
prevent us from being able to commercialize our product candidates.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There is a risk that we are infringing the proprietary rights of third parties because
numerous United States and foreign issued patents and pending patent applications, which are owned
by third parties, exist in the fields that are the focus of our drug discovery, development, and
manufacture and process synthesis efforts. Others might have been the first to make the inventions
covered by each of our or our licensors&#146; pending patent applications and issued patents and might
have been the first to file patent applications for these inventions. In addition, because patent
applications can take many years to issue, there may be currently pending applications, unknown to
us or our licensors, which may later result in issued patents that cover the production,
manufacture, synthesis, commercialization, formulation or use of our product candidates. In
addition, the production, manufacture, synthesis, commercialization, formulation or use of our
product candidates may infringe existing patents of which we are not aware. Defending ourselves
against third-party claims, including litigation in particular, would be costly and time consuming
and would divert management&#146;s attention from our business, which could lead to delays in our
development or commercialization efforts. If third parties are successful in their claims, we might
have to pay substantial damages or take other actions that are adverse to our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As a result of intellectual property infringement claims, or to avoid potential claims, we
might:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be prohibited from
selling or licensing any
product that we and/or any
potential future
collaborators may develop
unless the patent holder
licenses the patent to us,
which the patent holder is
not required to do;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be required to pay
substantial royalties or
other amounts, or grant a
cross license to our
patents to another patent
holder; or</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>be required to
redesign the formulation of
a product candidate so that
it does not infringe, which
may not be possible or
could require substantial
funds and time.</TD>
</TR>


</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Regulatory Approval of Our Product Candidates</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we or any potential future collaborators are not able to obtain required regulatory
approvals, we or such collaborators will not be able to commercialize our product candidates, and
our ability to generate revenue will be materially impaired.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our product candidates and the activities associated with their development and
commercialization are subject to comprehensive regulation by the FDA, other regulatory agencies in
the United States and by comparable authorities in other countries. Failure to obtain regulatory
approval for a product candidate will prevent us or any potential future collaborator from
commercializing the product candidate. We have not received regulatory approval to market any of
our product candidates in any jurisdiction, and we do not expect to obtain FDA or any other
regulatory approvals to market any of our product candidates in the near future, if at all. The
process of obtaining regulatory approvals is expensive, often takes many years, if approval is
obtained at all, and can vary substantially based upon the type, complexity and novelty of the
product candidates involved.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Changes in the regulatory approval policy during the development period, changes in or the
enactment of additional regulations or statutes, or changes in regulatory review for each submitted
product application, may cause delays in the approval or rejection of an application. For example,
the FDA announced in 2008 that, due to staffing and resource limitations, it has given its managers
discretion to miss certain timing goals for completing reviews of NDAs set forth under the
Prescription Drug User Fee Act, or PDUFA. Although the FDA has since publicly expressed a
recommitment to meeting PDUFA deadlines, it remains unclear whether and to what extent the FDA will
adhere to PDUFA deadlines in the future. If the FDA were to miss a PDUFA timing goal for one of our
product candidates, the development and commercialization of the product candidate could be
delayed. In addition, the Food and Drug Administration Amendments Act of 2007, or FDAAA, which was
enacted in September&nbsp;2007, expands the FDA&#146;s authority to regulate drugs throughout the product
life cycle, including enhanced authority to require post-approval studies and clinical trials.
Other proposals have been made to impose additional requirements on drug approvals, further expand
post-approval requirements and restrict sales and promotional activities. This new legislation, and
the additional proposals if enacted, may make it more difficult or burdensome for us or our
potential future collaborators to obtain approval of our product candidates. Even if the FDA
approves a product candidate, the approval may impose significant restrictions on the indicated
uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such
product, and may impose ongoing requirements for post-approval studies, including additional
research and development and clinical trials. The approval may also impose risk evaluation
mitigation strategies, or REMS, on a product if the FDA believes there is a reason to monitor the
safety of the drug in the market place. REMS may include requirements for additional training for
health care professionals, safety communication efforts and limits on channels of distribution,
among other things. The sponsor would be required to evaluate and monitor the various REMS
activities and adjust them if need be. The FDA also may impose various civil or criminal sanctions
for failure to comply with regulatory requirements, including withdrawal of product approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Furthermore, the approval procedure and the time required to obtain approval varies among
countries and can involve additional testing beyond that required by the FDA. Approval by one
regulatory authority does not ensure approval by regulatory authorities in other jurisdictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The FDA has substantial discretion in the approval process and may refuse to accept any
application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other studies. For example, in October&nbsp;2009, we received a Complete
Response Letter from the FDA regarding our NDA for toremifene 80 mg to reduce fractures in men with
prostate cancer on ADT notifying us that the FDA would not approve our NDA as a result of certain
clinical deficiencies identified in the Complete Response Letter. We have since determined to
discontinue our toremifene 80 mg development program. While we have met with the FDA to
discuss the development programs and endpoints for Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, there can be no assurance that the FDA will ultimately determine that data
from our current and potential future trials will be sufficient for approval of
either of these product candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, varying interpretations of the data obtained from preclinical and clinical
testing could delay, limit, or prevent regulatory approval of a product candidate. Even if we
submit an application to the FDA for marketing approval of a product candidate, it may not result
in marketing approval from the FDA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not expect to receive regulatory approval for the commercial sale of any of our product
candidates that are in development in the near future, if at all. The inability to obtain FDA
approval or approval from comparable authorities in other countries for our product candidates
would prevent us or any potential future collaborators from commercializing these product
candidates in the United States or other countries. See the section entitled &#147;Business &#151;
Government Regulation&#148; under Part&nbsp;1, Item&nbsp;1 of our Annual Report on Form 10-K, filed with the SEC
on March&nbsp;8, 2011, for additional information regarding risks associated with marketing approval, as
well as risks related to potential post-approval requirements.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Commercialization</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>The commercial success of any products that we and/or any potential future collaborators may
develop will depend upon the market and the degree of market acceptance among physicians, patients,
health care payors and the medical community.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Any products that we and/or any potential future collaborators may develop may not gain market
acceptance among physicians, patients, health care payors and the medical community. If these
products do not achieve an adequate level of acceptance, we may not generate material product
revenues or receive royalties to the extent we currently anticipate, and we may not become
profitable. The degree of market acceptance of our product candidates, if approved for commercial
sale, will depend on a number of factors, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>efficacy and safety results in clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the prevalence and severity of any side effects;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>potential advantages over alternative treatments;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether the products we commercialize remain a preferred course of treatment;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the ability to offer our product candidates for sale at competitive prices;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>relative convenience and ease of administration;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the strength of marketing and distribution support; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sufficient third-party coverage or reimbursement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Our only marketed product generating revenue is FARESTON</I></B><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP><B><I>, which is subject to a
number of risks. These risks may cause sales of FARESTON</I></B><SUP style="FONT-size: 85%; vertical-align: text-top"><B><I><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> </I></B></SUP><B><I>to decline.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top"><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>is currently our only marketed product. FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top"><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>is indicated
for the treatment of advanced metastatic breast cancer in postmenopausal women. FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top"><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
</SUP>competes against tamoxifen, fulvestrant, and several aromatase inhibitors, including
anastrozole, letrozole, and exemestane, for hormonal treatment of breast cancer. Sales of
pharmaceuticals for breast cancer in the SERM class have declined in recent years as competitors
have gained market share, and we believe this trend will continue. Further, the branded competitors
have greater resources and generic competitors are preferred by insurers. Although we continue to
market and sell FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, we no longer utilize a sales force for promotional efforts.
Additionally, continued sales may be impacted by many other factors, including the boxed warning
added to the label of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in March&nbsp;2011 to highlight that FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> has
been shown to prolong the QTc interval in a dose- and concentration-related manner and that
prolongation of the QTc interval can result in a type of ventricular tachycardia called Torsades de
pointes, which may result in syncope, or temporary loss of consciousness, seizure, and/or death. A
boxed warning is the strongest type of warning that the FDA can require for a drug product and
warns prescribers that the drug carries a significant
risk of serious or even life-threatening adverse effects. The occurrence of one or more of
the following risks may cause sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> to decline:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the loss of one or more of our three largest wholesale drug distributors, which together accounted
for approximately 94% of our product sales of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> for the nine months ended September&nbsp;30,
2011;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any further restrictions, limitations, and/or warnings added to the FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> label;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the continued success of competing products, including aromatase inhibitors;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the loss of coverage or reimbursement for FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> from Medicare and Medicaid, private
health insurers or other third-party payors;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exposure to product liability claims related to the commercial sale of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, which
may exceed our product liability insurance;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the failure of Orion to maintain regulatory filings or comply with applicable FDA requirements with
respect to FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the introduction of generic toremifene products that compete with FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> for the
treatment of breast cancer; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the loss of Orion, upon which we rely as a single source, as our supplier of FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.</TD>
</TR>


</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we are unable to expand our sales and marketing capabilities or establish and maintain
agreements with third parties to market and sell our product candidates, we may be unable to
generate product revenue from such candidates.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have limited experience as a company in the sales, marketing and distribution of
pharmaceutical products, and in any event have only limited company personnel to undertake such
activities, and we therefore need to expand our sales and marketing capabilities or establish and
maintain agreements with third parties to market and sell our product candidates. We may be unable
to build our own sales and marketing capabilities and there are risks involved with entering into
arrangements with third parties to perform these services, which could delay the commercialization
of any of our product candidates if approved for commercial sale. In addition, to the extent that
we enter into arrangements with third parties to perform sales, marketing and distribution
services, our product revenues are likely to be lower than if we market and sell any products that
we develop ourselves.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we and/or any potential future collaborators are unable to obtain reimbursement or
experience a reduction in reimbursement from third-party payors for products we sell, our revenues
and prospects for profitability will suffer.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Sales of products developed by us and/or any potential future collaborators are dependent on
the availability and extent of reimbursement from third-party payors. Changes in the reimbursement
policies of these third-party payors that reduce reimbursements for FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and any
other products that we and/or any potential future collaborators may develop and sell could
negatively impact our future operating and financial results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Medicare Prescription Drug, Improvement and Modernization Act of 2003 established
comprehensive Medicare coverage and reimbursement of prescription drugs under Medicare Part&nbsp;D. The
prescription drug program established by this legislation may have the effect of reducing the
prices that we or any potential future collaborators are able to charge for products we and/or any
potential future collaborators develop and sell through the program. This legislation may also
cause third-party payors other than the federal government, including the states under the Medicaid
program, to discontinue coverage for products that we and/or any potential future collaborators may
develop or to lower the amount that they pay.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In March&nbsp;2010, the United States Congress enacted the Patient Protection and Affordable Care
Act and the Health Care and Education Reconciliation Act. This health care reform legislation will
increase the number of individuals who receive health insurance coverage and will close a gap in
drug coverage under Medicare Part&nbsp;D as established in 2003. However, the legislation also
implements cost containment measures that could adversely affect our revenues. These measures
include increased drug rebates under Medicaid for brand name prescription drugs, such as
FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, and extension of these rebates to Medicaid managed care, each of which have
reduced the amount of net reimbursement received for FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and would reduce the
amount of net reimbursement for any
other products that we and/or any potential future collaborators may develop and sell. The
legislation also extended 340B discounted pricing on outpatient drugs to children&#146;s hospitals,
critical access hospitals, and rural health centers, which has reduced the amount of reimbursement
received for drugs purchased by these new 340B-covered entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additional provisions of the health care reform legislation may negatively affect our revenues
and prospects for profitability in the future. Along with other pharmaceutical manufacturers and
importers of brand name prescription drugs, starting in September&nbsp;2011, we will be assessed a fee
based on our proportionate share of sales of brand name prescription drugs to certain government
programs, including Medicare and Medicaid, made in the preceding year if such sales exceed a
defined threshold. As part of the health care reform legislation&#146;s provisions closing a funding
gap that currently exists in the Medicare Part&nbsp;D prescription drug program (commonly known as the
&#147;donut hole&#148;), as of January&nbsp;1, 2011, we are required to provide a 50% discount on brand name
prescription drugs, including FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, sold to beneficiaries who fall within the donut
hole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The health care reform legislation has been subject to judicial challenge. While some courts
have upheld the law, other courts have concluded that the individual mandate component of the law
is unconstitutional. One of those courts determined that the individual mandate component could
not be severed from the law and therefore concluded that the entire law was void. All of the
rulings on the merits are being appealed. There is no certainty regarding the final outcome of the
litigation or the impact of the outcome on the pricing and potential profitability of any products
that we and/or any potential future collaborators may develop.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Economic pressure on state budgets may result in states increasingly seeking to achieve budget
savings through mechanisms that limit coverage or payment for drugs. State Medicaid programs are
increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization
for use of drugs where supplemental rebates are not provided. Private health insurers and managed
care plans are likely to continue challenging the prices charged for medical products and services,
and many of these third-party payors may limit reimbursement for newly-approved health care
products. In particular, third-party payors may limit the indications for which they will reimburse
patients who use any products that we and/or any potential future collaborators may develop or
sell. These cost-control initiatives could decrease the price we might establish for products that
we or any potential future collaborators may develop or sell, which would result in lower product
revenues or royalties payable to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Similar cost containment initiatives exist in countries outside of the United States,
particularly in the countries of the European Union, where the pricing of prescription
pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with
governmental authorities can take six to twelve months or longer after the receipt of regulatory
marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we
or any potential future collaborators may be required to conduct a clinical trial that compares the
cost effectiveness of our product candidates or products to other available therapies. The conduct
of such a clinical trial could be expensive and result in delays in our or a potential future
collaborators&#146; commercialization efforts. Third-party payors are challenging the prices charged for
medical products and services, and many third-party payors limit reimbursement for newly-approved
health care products. In particular, third-party payors may limit the indications for which they
will reimburse patients who use any products that we and/or any potential future collaborators may
develop or sell. Cost-control initiatives could decrease the price we might establish for products
that we or any potential future collaborators may develop or sell, which would result in lower
product revenues or royalties payable to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Another development that could affect the pricing of drugs would be if the Secretary of Health
and Human Services allowed drug reimportation into the United States. The Medicare Prescription
Drug, Improvement and Modernization Act of 2003 gives discretion to the Secretary of Health and
Human Services to allow drug reimportation into the United States under some circumstances from
foreign countries, including from countries where the drugs are sold at a lower price than in the
United States. If the circumstances were met and the Secretary exercised the discretion to allow
for the direct reimportation of drugs, it could decrease the price we or any potential future
collaborators receive for any products that we and/or any potential future collaborators may
develop, negatively affecting our revenues and prospects for profitability.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Health care reform measures could hinder or prevent our product candidates&#146; commercial
success.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Among policy makers and payors in the United States and elsewhere, there is significant
interest in promoting health care reform, as evidenced by the enactment in the United States of the
Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act in
2010. It is likely that federal and state legislatures
within the United States and foreign governments will continue to consider changes to existing
health care legislation. These changes adopted by governments may adversely impact our business by
lowering the price of health care products in the United States and elsewhere.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We operate in a highly regulated industry and new laws, regulations or judicial decisions, or
new interpretations of existing laws, regulations or decisions, related to health care
availability, method of delivery or payment for health care products and services, or sales,
marketing and pricing practices could negatively impact our business, operations and financial
condition.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and
may be required to limit commercialization of any products that we may develop.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We face an inherent risk of product liability exposure related to our commercial sale of
FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and the testing of our product candidates in human clinical trials and will
face an even greater risk if we commercially sell any product that we may develop. If we cannot
successfully defend ourselves against claims that our product candidates or products caused
injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability
claims may result in:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>decreased demand for any product candidates or products;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>injury to our reputation;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>withdrawal of clinical trial participants;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs to defend the related litigation;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>substantial monetary awards to trial participants or patients;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>loss of revenue; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the inability to commercialize any products for which we obtain
or hold marketing approvals.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have product liability insurance that covers our clinical trials and commercial products up
to a $20&nbsp;million annual aggregate limit. Insurance coverage is increasingly expensive. We may not
be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain
insurance coverage that will be adequate to satisfy any liability that may arise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If our competitors are better able to develop and market products than any products that we
and/or any potential future collaborators may develop, our commercial opportunity will be reduced
or eliminated.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We face competition from commercial pharmaceutical and biotechnology enterprises, as well as
from academic institutions, government agencies and private and public research institutions. Our
commercial opportunities will be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer side effects or are less expensive than any
products that we and/or any potential future collaborators may develop. Competition could result in
reduced sales and pricing pressure on our product candidates, if approved, which in turn would
reduce our ability to generate meaningful revenue and have a negative impact on our results of
operations. In addition, significant delays in the development of our product candidates could
allow our competitors to bring products to market before us and impair any ability to commercialize
our product candidates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Various products are currently marketed or used off-label for some of the diseases and
conditions that we are targeting in our pipeline, and a number of companies are or may be
developing new treatments. These product uses, as well as promotional efforts by competitors and/or
clinical trial results of competitive products, could significantly diminish any ability to market
and sell any products that we and/or any potential future collaborators may develop.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">With respect to our SARM program, there are other SARM product candidates in development that
may compete with Ostarine<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and any future SARM product candidates, if approved for
commercial sale, including SARMs in development from Ligand Pharmaceuticals Inc., and Galapagos NV.
Pfizer Inc., Eli Lilly &#038; Co. and Amgen have myostatin inhibitors in development that may compete
with Ostarine&#153; if approved for commercial sale. In addition, Cytokinetics, Inc. is developing a
troponin activator with a muscle specific mechanism in Phase II studies, with a focus on
neurological muscle diseases (amyotrophic lateral sclerosis and myasthenia gravis). Moreover,
there are other categories of drugs in development, including ghrelin receptor agonists, growth
hormone,
secretagogues, inflammatory modulators and other agents, that may have some muscle building
activity. Helsinn Group is developing anamorelin, a ghrelin receptor agonist, in Phase III
clinical trials for treatment of cancer cachexia in patients with non-small cell lung cancer.
Appetite stimulants such as megestrol acetate and dronabinol are used off-label for the treatment
of weight loss and the treatment of loss of appetite in patients with cancer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are developing Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for first line hormonal treatment of advanced
prostate cancer. Currently, there are several products approved to reduce testosterone levels in
men with advanced prostate cancer that may compete with Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> if approved for
commercial sale, including those marketed by Abbott Laboratories (Lupron Depot<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>),
Sanofi-Aventis (Eligard<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>), AstraZeneca (Zoladex<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>), Ferring Pharmaceuticals
(Firmagon<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>), Endo Pharmaceuticals (Vantas<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>) and Watson Pharmaceuticals
(Trelstar<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Many of our competitors have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining
regulatory approvals and marketing approved products than we do. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining
qualified scientific and management personnel, establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies and technology licenses
complementary to our programs or advantageous to our business.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Employees and Growth</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If we fail to attract and keep senior management and key scientific personnel, we may be
unable to successfully develop or commercialize our product candidates.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our success depends on our continued ability to attract, retain and motivate highly qualified
management, clinical and scientific personnel and on our ability to develop and maintain important
relationships with leading academic institutions, clinicians and scientists. If we are not able to
attract and keep senior management and key scientific personnel, particularly Dr.&nbsp;Mitchell S.
Steiner, we may not be able to successfully develop or commercialize our product candidates. All of
our employees are at-will employees and can terminate their employment at any time. We do not carry
&#147;key person&#148; insurance covering members of senior management, other than $22.5&nbsp;million of insurance
covering Dr.&nbsp;Steiner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In December&nbsp;2009, we announced a reduction of approximately 26% of our workforce in order to
reduce our operating expenses in connection with the receipt of the Complete Response Letter
regarding our NDA for toremifene 80 mg. We also announced a reduction of approximately 15% of our
workforce in June&nbsp;2011 in connection with our decision to discontinue the development of toremifene
80 mg and toremifene 20 mg. These and any future workforce reductions may negatively affect our
ability to retain or attract talented employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>We will need to hire additional employees in order to commercialize our product candidates in
the future. Any inability to manage future growth could harm our ability to commercialize our
product candidates, increase our costs and adversely impact our ability to compete effectively.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In order to commercialize our product candidates in the future, we will need to expand the
number of our managerial, operational, financial and other employees and competition exists for
qualified personnel in the biotechnology field.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Future growth will impose significant added responsibilities on members of management,
including the need to identify, recruit, maintain and integrate additional employees. Our future
financial performance and our ability to commercialize our product candidates and to compete
effectively will depend, in part, on our ability to manage any future growth effectively.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Risks Related to Our Common Stock</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Market volatility may cause our stock price and the value of your investment to decline.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The market prices for securities of biotechnology companies in general have been highly
volatile and may continue to be so in the future. The following factors, in addition to other risk
factors described in this section, may
have a significant impact on the market price of our common stock:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delays in the enrollment or completion of our ongoing clinical trials of Ostarine&#153; and
Capesaris<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, or adverse results in any of our initiated clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to enter into new collaborative arrangements with respect to our product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the terms and timing of any future collaborative, licensing or other arrangements that we may
establish;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to raise additional capital to carry through with our clinical development plans and
current and future operations and the terms of any related financing arrangements;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the timing of achievement of, or failure to achieve, our and any potential future collaborators&#146;
clinical, regulatory and other milestones, such as the commencement of clinical development, the
completion of a clinical trial or the receipt of regulatory approval;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>announcement of FDA approval or non-approval of our product candidates, or delays in or adverse
events during the FDA review process;</TD>
</TR>

</TABLE>
</DIV><P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>actions taken by regulatory agencies with respect to our product candidates or products, our
clinical trials or our sales and marketing activities, including regulatory actions requiring or leading
to restrictions, limitations and/or warnings in the label of an approved product candidate;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>additional changes to the label for FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> that further restrict how we market and
sell FARESTON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the commercial success of any product approved by the FDA or its foreign counterparts;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>introductions or announcements of technological innovations or new products by us, our potential
future collaborators, or our competitors, and the timing of these introductions or announcements;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>market conditions for equity investments in general, or the biotechnology or pharmaceutical
industries in particular;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulatory developments in the United States and foreign countries;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in the structure or reimbursement policies of health care payment systems;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any intellectual property infringement lawsuit involving us;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>actual or anticipated fluctuations in our results of operations;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in financial estimates or recommendations by securities analysts;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>hedging or arbitrage trading activity that may develop regarding our common stock;
</TD>
</TR>


<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD> sales of large blocks of our common stock;</TD>
</TR>


<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sales of our common stock by our executive officers, directors and significant stockholders;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in accounting principles; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the loss of any of our key scientific or management personnel.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The stock markets in general, and the markets for biotechnology stocks in particular, have
experienced significant volatility that has often been unrelated to the operating performance of
particular companies. The financial markets continue to face significant uncertainty, resulting in
a decline in investor confidence and concerns about the proper functioning of the securities
markets, which decline in general investor confidence has resulted in depressed stock prices for
many companies notwithstanding the lack of a fundamental change in their underlying business models
or prospects. These broad market fluctuations may adversely affect the trading price of our common
stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In the past, class action litigation has often been instituted against companies whose
securities have experienced
periods of volatility in market price. Any such litigation brought against us could result in
substantial costs, which would hurt our financial condition and results of operations and divert
management&#146;s attention and resources, which could result in delays of our clinical trials or
commercialization efforts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Our executive officers, directors and largest stockholders have the ability to control all
matters submitted to stockholders for approval.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of September&nbsp;30, 2011, our executive officers, directors and holders of 5% or more of our
outstanding common stock beneficially owned approximately 59.2% of our outstanding common stock,
and our executive officers and directors alone beneficially owned approximately 38.5% of our
outstanding common stock. As a result, these stockholders, acting together, may or will have the
ability to control all matters requiring approval by our stockholders, including the election of
directors and the approval of mergers or other business combination transactions. The interests of
this group of stockholders may not always coincide with our interests or the interests of other
stockholders.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an
acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent
attempts by our stockholders to replace or remove our current management.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Provisions in our certificate of incorporation and our bylaws may delay or prevent an
acquisition of us or a change in our management. In addition, these provisions may frustrate or
prevent any attempts by our stockholders to replace or remove our current management by making it
more difficult for stockholders to replace members of our Board of Directors. Because our Board of
Directors is responsible for appointing the members of our management team, these provisions could
in turn affect any attempt by our stockholders to replace current members of our management team.
These provisions include:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a classified Board of Directors;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a prohibition on actions by our stockholders by written consent;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the ability of our Board of Directors to issue preferred stock
without stockholder approval, which could be used to institute a &#147;poison
pill&#148; that would work to dilute the stock ownership of a potential hostile
acquirer, effectively preventing acquisitions that have not been approved
by our Board of Directors; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>limitations on the removal of directors.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of
Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of
15% of our outstanding voting stock from merging or combining with us for a period of three years
after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. Finally, these
provisions establish advance notice requirements for nominations for election to our Board of
Directors or for proposing matters that can be acted upon at stockholder meetings. These provisions
would apply even if the offer may be considered beneficial by some stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>If there are substantial sales of our common stock, the market price of our common stock could
drop substantially, even if our business is doing well.*</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the 12-month period ended September&nbsp;30, 2011, the average daily trading volume of our
common stock on The NASDAQ Global Market was 243,026 shares. As a result, future sales of a
substantial number of shares of our common stock in the public market, or the perception that such
sales may occur, could adversely affect the then-prevailing market price of our common stock. As of
September&nbsp;30, 2011, we had 62,790,223 shares of common stock outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Moreover, J.R. Hyde, III and Oracle Partners, L.P., two of our largest stockholders, and
certain of their affiliates, have rights, subject to some conditions, to require us to file
registration statements covering the approximately 10.8&nbsp;million shares of common stock they hold in
the aggregate which are subject to registration rights or to include these shares in registration
statements that we may file for ourselves or other stockholders. If any of these large stockholders
were to sell large blocks of shares in a short period of time, the market price of our common stock
could drop substantially.
</DIV>
<DIV align="left">
<A name="C24070112"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 6.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>EXHIBITS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The exhibits listed on the accompanying Exhibit&nbsp;Index are filed or incorporated by reference
(as stated therein) as part of this Quarterly Report on Form 10-Q.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left">
<A name="C24070113"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>GTx, Inc.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: November&nbsp;4, 2011&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mitchell S. Steiner
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mitchell S. Steiner, Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">and Vice-Chairman of the Board of Directors&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:  November&nbsp;4, 2011&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark E. Mosteller
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark E. Mosteller, Vice President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">and Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C24070tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left">
<A name="C24070114"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Restated Certificate of Incorporation of GTx, Inc.<SUP style="FONT-size: 85%; vertical-align: text-top">(1)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certificate of Amendment of Restated Certificate of Incorporation of GTx, Inc.<SUP style="FONT-size: 85%; vertical-align: text-top"> (2)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Amended and Restated Bylaws of GTx, Inc.<SUP style="FONT-size: 85%; vertical-align: text-top">(3)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Reference is made to Exhibits 3.1, 3.2 and 3.3</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Specimen of Common Stock Certificate<SUP style="FONT-size: 85%; vertical-align: text-top">(4)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Amended and Restated Registration Rights Agreement between Registrant and Oracle Partners,
L.P. dated August&nbsp;7, 2003<SUP style="FONT-size: 85%; vertical-align: text-top">(4)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Amended and Restated Registration Rights Agreement between Registrant and J. R. Hyde, III
dated August&nbsp;7, 2003<SUP style="FONT-size: 85%; vertical-align: text-top">(4)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent, Waiver and Amendment between the Registrant and Oracle Partners, L.P., Oracle
Investment Management, Inc. and Oracle Institutional Partners, L.P. dated November&nbsp;29,
2007<SUP style="FONT-size: 85%; vertical-align: text-top">(5)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent, Waiver and Amendment between Registrant and J. R. Hyde, III and Pittco Associates,
L.P. dated December&nbsp;3, 2007<SUP style="FONT-size: 85%; vertical-align: text-top">(5)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.1</TD>
    <TD nowrap valign="top">*&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Executive Officer, as required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a)</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.2</TD>
    <TD nowrap valign="top">*&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Financial Officer, as required by Rule&nbsp;13a-14(a) or Rule&nbsp;15d-14(a)</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.1</TD>
    <TD nowrap valign="top">*&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Executive Officer, as required by Rule&nbsp;13a-14(b) or Rule&nbsp;15d-14(b)
and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)<SUP style="FONT-size: 85%; vertical-align: text-top">
(6)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.2</TD>
    <TD nowrap valign="top">*&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of Chief Financial Officer, as required by Rule&nbsp;13a-14(b) or Rule&nbsp;15d-14(b)
and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)<SUP style="FONT-size: 85%; vertical-align: text-top">
(6)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">

    <TD nowrap colspan="2" align="right" valign="top">101.INS</TD>
    <TD>*&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">XBRL Instance Document<SUP style="FONT-size: 85%; vertical-align: text-top">(7)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap colspan="2" align="right" valign="top">101.SCH
</TD>
    <TD>*</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">XBRL Taxonomy Extension Schema Document<SUP style="FONT-size: 85%; vertical-align: text-top">(7)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap colspan="2" align="right" valign="top">101.CAL
</TD>
    <TD>*</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">XBRL Taxonomy Extension Calculation Linkbase Document<SUP style="FONT-size: 85%; vertical-align: text-top">(7)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap colspan="2" align="right" valign="top">101.LAB
</TD>
    <TD>*</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">XBRL Taxonomy Extension Labels Linkbase Document<SUP style="FONT-size: 85%; vertical-align: text-top">(7)</SUP></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap colspan="2" align="right" valign="top">101.PRE

</TD>
    <TD>*</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">XBRL Taxonomy Extension Presentation Linkbase Document<SUP style="FONT-size: 85%; vertical-align: text-top">(7)</SUP></DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 10pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Filed herewith.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top">(1)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Filed as Exhibit&nbsp;4.1 to the Registrant&#146;s registration statement on Form S-3 (File
No.&nbsp;333-127175), filed with the SEC on August&nbsp;4, 2005, and incorporated herein by reference.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top"> (2)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>  Filed as the like numbered Exhibit to the Registrant&#146;s Current Report on Form 8-K
(File No.&nbsp;000-50549), filed with the SEC on May&nbsp;6, 2011, and incorporated herein by reference.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top"> (3)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>  Filed as Exhibit&nbsp;3.2 to the Registrant&#146;s Current Report on Form 8-K (File No.
000-50549), filed with the SEC on July&nbsp;26, 2007, and incorporated herein by reference.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top">(4)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Filed as the like numbered Exhibit to the Registrant&#146;s registration statement on
Form S-1 (File No.&nbsp;333-109700), initially filed with the SEC on October&nbsp;15, 2003, as amended,
and incorporated herein by reference.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top">(5)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Filed as the like numbered Exhibit to the Registrant&#146;s registration statement on
Form S-3 (File No.&nbsp;333-148321), filed with the SEC on December&nbsp;26, 2007, and incorporated
herein by reference.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top">(6)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>This certification accompanies the Form 10-Q to which it relates, is not deemed
filed with the Securities and Exchange Commission and is not to be incorporated by reference
into any filing of the Registrant under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form
10-Q), irrespective of any general incorporation language contained in such filing.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top"> (7)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>  Pursuant to applicable securities laws and regulations, the Registrant is deemed
to have complied with the reporting obligation relating to the submission of interactive data
files in such exhibits and is not subject to liability under any anti-fraud provisions of the
federal securities laws as long as the Registrant has made a good faith attempt to comply with
the submission requirements and promptly amends the interactive data files after becoming
aware that the interactive data files fail to comply with the submission requirements. These
interactive data files are deemed not filed or part of a registration statement or prospectus
for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not
filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and
otherwise are not subject to liability under these sections.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>c24070exv31w1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">






<DIV align="right" style="font-size: 10pt; margin-top: 10pt">EXHIBIT 31.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">CHIEF EXECUTIVE OFFICER CERTIFICATION
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">I, Mitchell S. Steiner, certify that:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">I have reviewed this
Quarterly Report on Form 10-Q of GTx, Inc.;</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</div></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this
report is being prepared;
</div>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(b) Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting
principles;
</div>
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
</div>
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(d) Disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&#146;s internal control
over financial reporting; and
</div>



<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(a) All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information; and
</div>
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(b) Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.
</div>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Date: November&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Mitchell S. Steiner
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Mitchell S. Steiner, M.D., F.A.C.S.&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Chief Executive Officer and<Br>
Vice-Chairman of the Board of Directors&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>

</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>c24070exv31w2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 10pt">EXHIBIT 31.2
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">CHIEF FINANCIAL OFFICER CERTIFICATION
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">I, Mark E. Mosteller, certify that:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">I have reviewed this
Quarterly Report on Form 10-Q of GTx, Inc.;</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</div></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(a)&nbsp;Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this
report is being prepared;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(b)&nbsp;Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting
principles;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(c)&nbsp;Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(d)&nbsp;Disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&#146;s internal control
over financial reporting; and
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</div></TD>
</TR>

</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(a)&nbsp;All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information; and
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; margin-left: 8%; text-indent: 4%">(b)&nbsp;Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Date: November&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>

    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Mark E. Mosteller
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Mark E. Mosteller, CPA&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Vice President and Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>

</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>c24070exv32w1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="right" style="font-size: 10pt; margin-top: 10pt">EXHIBIT 32.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">CERTIFICATION PURSUANT TO<BR>
18 U. S. C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In connection with the Quarterly Report of GTx, Inc. (the &#147;Company&#148;) on Form 10-Q for the three
months ended September&nbsp;30, 2011, as filed with the Securities and Exchange Commission on the date
hereof (the &#147;Report&#148;), I, Mitchell S. Steiner, Chief Executive Officer of the Company certify,
pursuant to Rule&nbsp;13a-14(b) or Rule&nbsp;15d-14(b) and 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.</div></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Date: November&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Mitchell S. Steiner
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Mitchell S. Steiner, M.D., F.A.C.S.&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Chief Executive Officer and<br>
Vice-Chairman of the Board of Directors&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>

</TR>
</TABLE>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the
Securities and Exchange Commission and is not to be incorporated by reference into any filing of
the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934
(whether made before or after the date of the Form 10-Q), irrespective of any general incorporation
language contained in such filing.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>c24070exv32w2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="right" style="font-size: 10pt; margin-top: 10pt">EXHIBIT 32.2
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">CERTIFICATION PURSUANT TO<BR>
18 U. S. C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In connection with the Quarterly Report of GTx, Inc. (the &#147;Company&#148;) on Form 10-Q for the three
months ended September&nbsp;30, 2011, as filed with the Securities and Exchange Commission on the date
hereof (the &#147;Report&#148;), I, Mark E. Mosteller, Chief Financial Officer of the Company certify,
pursuant to Rule&nbsp;13a-14(b) or Rule&nbsp;15d-14(b) and 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.</div></TD>
</TR>

</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Date: November&nbsp;4, 2011
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Mark E. Mosteller
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>

</TR><TR>
    <TD colspan="3" align="left">Mark E. Mosteller, CPA&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>

</TR><TR>
    <TD colspan="3" align="left">Vice President and Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>

</TR>
</TABLE>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the
Securities and Exchange Commission and is not to be incorporated by reference into any filing of
the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934
(whether made before or after the date of the Form 10-Q), irrespective of any general incorporation
language contained in such filing.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>gtxi-20110930.xml
<DESCRIPTION>EX-101 INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:gtxi="http://www.gtxinc.com/20110930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="gtxi-20110930.xsd" />
<!-- Context Section -->
<context id="BalanceAsOf_03Nov2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<instant>2011-11-03</instant>
</period>
</context>
<context id="BalanceAsOf_30Jun2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<instant>2010-06-30</instant>
</period>
</context>
<context id="BalanceAsOf_30Sep2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<instant>2011-09-30</instant>
</period>
</context>
<context id="BalanceAsOf_31Dec2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<instant>2010-12-31</instant>
</period>
</context>
<context id="ThreeMonthsEnded_30Sep2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<startDate>2011-07-01</startDate>
<endDate>2011-09-30</endDate>
</period>
</context>
<context id="ThreeMonthsEnded_30Sep2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<startDate>2010-07-01</startDate>
<endDate>2010-09-30</endDate>
</period>
</context>
<context id="NineMonthsEnded_30Sep2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<startDate>2011-01-01</startDate>
<endDate>2011-09-30</endDate>
</period>
</context>
<context id="NineMonthsEnded_30Sep2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<startDate>2010-01-01</startDate>
<endDate>2010-09-30</endDate>
</period>
</context>
<context id="BalanceAsOf_31Dec2009">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<instant>2009-12-31</instant>
</period>
</context>
<context id="BalanceAsOf_30Sep2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
</entity>
<period>
<instant>2010-09-30</instant>
</period>
</context>
<!--Unit Section-->
 <unit id="USDEPS">
   <divide>
     <unitNumerator>
       <measure>iso4217:USD</measure>
     </unitNumerator>
     <unitDenominator>
       <measure>xbrli:shares</measure>
     </unitDenominator>
   </divide>
 </unit>
 <unit id="Shares">
   <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>

<!-- Element Section -->
<!--Document Information-->
<dei:EntityRegistrantName contextRef="NineMonthsEnded_30Sep2011">GTX INC /DE/</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="NineMonthsEnded_30Sep2011">0001260990</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="NineMonthsEnded_30Sep2011">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityWellKnownSeasonedIssuer contextRef="NineMonthsEnded_30Sep2011">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="NineMonthsEnded_30Sep2011">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="NineMonthsEnded_30Sep2011">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory contextRef="NineMonthsEnded_30Sep2011">Accelerated Filer</dei:EntityFilerCategory>
<dei:DocumentType contextRef="NineMonthsEnded_30Sep2011">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="NineMonthsEnded_30Sep2011">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="NineMonthsEnded_30Sep2011">2011-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="NineMonthsEnded_30Sep2011">Q3</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="NineMonthsEnded_30Sep2011">2011</dei:DocumentFiscalYearFocus>
<dei:EntityPublicFloat contextRef="BalanceAsOf_30Jun2010" decimals="0" unitRef="USD">56844168</dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_03Nov2011" decimals="INF" unitRef="Shares">62790223</dei:EntityCommonStockSharesOutstanding>
<!-- Instance Elements for BALANCE_SHEETS -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">73296000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">58181000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:HeldToMaturitySecuritiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">9715000</us-gaap:HeldToMaturitySecuritiesCurrent>
<us-gaap:HeldToMaturitySecuritiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">450000</us-gaap:HeldToMaturitySecuritiesCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">830000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">683000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">150000</us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">171000</us-gaap:InventoryNet>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">1351000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">875000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">85342000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">60360000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">1302000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">2040000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">264000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1850000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:Assets contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">86908000</us-gaap:Assets>
<us-gaap:Assets contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">64250000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">829000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">848000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">4367000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">3112000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">0</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1345000</us-gaap:DeferredRevenueCurrent>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">5196000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">5305000</us-gaap:LiabilitiesCurrent>
<us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">0</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6721000</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">240000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">497000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:CommitmentsAndContingencies unitRef="USD" xsi:nil="true" contextRef="BalanceAsOf_30Sep2011" />
<us-gaap:CommitmentsAndContingencies unitRef="USD" xsi:nil="true" contextRef="BalanceAsOf_31Dec2010" />
<us-gaap:CommonStockValue contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">63000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">52000</us-gaap:CommonStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Sep2011" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">120000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">60000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">62790223</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">51719187</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">62790223</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">51719187</us-gaap:CommonStockSharesOutstanding>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">456901000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">404555000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">-375492000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">-352880000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">81472000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">51727000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">86908000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">64250000</us-gaap:LiabilitiesAndStockholdersEquity>
<!-- Instance Elements for STMNT_OPERATIONS -->
<us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">2029000</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">960000</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">4903000</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2358000</us-gaap:SalesRevenueGoodsNet>
<gtxi:CollaborationRevenue contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">336000</gtxi:CollaborationRevenue>
<gtxi:CollaborationRevenue contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">8066000</gtxi:CollaborationRevenue>
<gtxi:CollaborationRevenue contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">56450000</gtxi:CollaborationRevenue>
<us-gaap:Revenues contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">2029000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1296000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">12969000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">58808000</us-gaap:Revenues>
<us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">311000</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">216000</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">780000</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">501000</us-gaap:CostOfGoodsSold>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">8181000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">5593000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">23075000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">22720000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">2904000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">4066000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">12058000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">12900000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">11396000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">9875000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">35913000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">36121000</us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-9367000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-8579000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-22944000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">22687000</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">23000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">4000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">332000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">136000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-9344000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-8575000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-22612000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">22823000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USDEPS" decimals="2">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="NineMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="NineMonthsEnded_30Sep2010" unitRef="USDEPS" decimals="2">0.63</us-gaap:EarningsPerShareBasicAndDiluted>
<gtxi:BasicAndDilutedWeightedAverageNumberOfShares contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">62778575</gtxi:BasicAndDilutedWeightedAverageNumberOfShares>
<gtxi:BasicAndDilutedWeightedAverageNumberOfShares contextRef="ThreeMonthsEnded_30Sep2010" unitRef="Shares" decimals="0">36424971</gtxi:BasicAndDilutedWeightedAverageNumberOfShares>
<gtxi:BasicAndDilutedWeightedAverageNumberOfShares contextRef="NineMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">55529320</gtxi:BasicAndDilutedWeightedAverageNumberOfShares>
<gtxi:BasicAndDilutedWeightedAverageNumberOfShares contextRef="NineMonthsEnded_30Sep2010" unitRef="Shares" decimals="0">36422273</gtxi:BasicAndDilutedWeightedAverageNumberOfShares>
<!-- Instance Elements for STMNT_CASH_FLOWS -->
<us-gaap:DepreciationDepletionAndAmortization contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">819000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1222000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:ShareBasedCompensation contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">3178000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">3771000</us-gaap:ShareBasedCompensation>
<gtxi:DirectorsDeferredCompensation contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">141000</gtxi:DirectorsDeferredCompensation>
<gtxi:DirectorsDeferredCompensation contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">141000</gtxi:DirectorsDeferredCompensation>
<us-gaap:RecognitionOfDeferredRevenue contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">8066000</us-gaap:RecognitionOfDeferredRevenue>
<us-gaap:RecognitionOfDeferredRevenue contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">51450000</us-gaap:RecognitionOfDeferredRevenue>
<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">1598000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1687000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">147000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">103000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">27000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">103000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">476000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">5301000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-19000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-115000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">1062000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-1746000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-24549000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-29174000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">45000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">88000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">12450000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
<us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">8119000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">3185000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">14779000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-9310000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">6572000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">48982000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<gtxi:PaymentsOnCapitalLeaseAndFinancedEquipmentObligations contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">63000</gtxi:PaymentsOnCapitalLeaseAndFinancedEquipmentObligations>
<gtxi:PaymentsOnCapitalLeaseAndFinancedEquipmentObligations contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">67000</gtxi:PaymentsOnCapitalLeaseAndFinancedEquipmentObligations>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">55000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">48974000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-67000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">15115000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-22669000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2009" unitRef="USD" decimals="-3">40219000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2010" unitRef="USD" decimals="-3">17550000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<!-- Begin Block Tagged Note -->
<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock--&gt;
   &lt;div align="left" style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;div align="left"&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;&lt;b&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;1. Business and Basis of Presentation&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;GTx, Inc. (&amp;#8220;GTx&amp;#8221; or the &amp;#8220;Company&amp;#8221;), a Delaware corporation incorporated on September&amp;#160;24, 1997
   and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery,
   development and commercialization of small molecules that selectively target hormone pathways for
   the treatment of cancer, cancer supportive care, and other serious medical conditions.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company is developing selective androgen receptor modulators (&amp;#8220;SARMs&amp;#8221;), including
   Ostarine&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;TM &lt;/sup&gt;(GTx-024). SARMs are a new class of drugs with the potential to prevent and
   treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss
   conditions, including chronic sarcopenia (age related muscle loss). The Company has commenced two
   pivotal Phase III clinical trials evaluating Ostarine&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;TM&lt;/sup&gt; for the prevention and treatment
   of muscle wasting in patients with non-small cell lung cancer.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Additionally, the Company is developing Capesaris&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;TM&lt;/sup&gt; (GTx-758), an oral nonsteriodal
   selective estrogen receptor alpha agonist. The Company is developing Capesaris&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;TM&lt;/sup&gt; for
   first line and second line hormonal treatment of advanced prostate cancer. With respect to first
   line hormonal therapy, the Company has completed enrollment in a Phase II maintenance dose finding clinical trial and
   has initiated a Phase II loading dose finding clinical trial evaluating Capesaris&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;TM&lt;/sup&gt; in
   men with advanced prostate cancer. The Company will also initiate a second line hormonal therapy
   Phase II clinical trial evaluating Capesaris&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;TM&lt;/sup&gt; in men with castration resistant prostate
   cancer.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company markets FARESTON&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt; (toremifene citrate) 60 mg tablets, approved for the
   treatment of advanced metastatic breast cancer in postmenopausal women, in the United States. The
   Company previously determined to discontinue its toremifene 80 mg and toremifene 20 mg development
   programs.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The accompanying unaudited condensed financial statements reflect, in the opinion of
   management, all adjustments (consisting of normal recurring adjustments) necessary for a fair
   presentation of GTx&amp;#8217;s financial position, results of operations and cash flows for each period
   presented in accordance with accounting principles generally accepted in the United States for
   interim financial information and with the instructions to Form 10-Q and Article&amp;#160;10 of Regulation
   S-X. Accordingly, information and footnote disclosures normally included in financial statements
   prepared in accordance with accounting principles generally accepted in the United States have been
   condensed or omitted from the accompanying condensed financial statements. These interim condensed
   financial statements should be read in conjunction with the audited financial statements and
   related notes thereto, which are included in the Company&amp;#8217;s Annual Report on Form 10-K for the year
   ended December&amp;#160;31, 2010. Operating results for the three months and nine months ended September
   30, 2011 are not necessarily indicative of the results that may be expected for the entire fiscal
   year ending December&amp;#160;31, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The preparation of condensed financial statements in conformity with accounting principles
   generally accepted in the United States requires management to make estimates and assumptions that
   affect the reported amounts of assets and liabilities, the disclosure of contingent assets and
   liabilities at the date of the condensed financial statements, and the reported amounts of revenues
   and expenses during the reporting period. Actual amounts and results could differ from those
   estimates.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company recognizes revenue from product sales of FARESTON&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt; less deductions for
   estimated sales discounts and sales returns. Revenue from product sales is recognized when
   persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and
   collectability is reasonably assured. The Company accounts for rebates to certain governmental
   agencies as a reduction of product sales. The Company allows customers to return product within a
   specified time period prior to and subsequent to the product&amp;#8217;s labeled expiration date. The
   Company estimates an accrual for product returns, which is recorded as a reduction of product
   sales, based on factors which include historical product returns and estimated product in the
   distribution channel which is expected to exceed its expiration date. At September&amp;#160;30, 2011 and
   December&amp;#160;31, 2010, the Company&amp;#8217;s accrual for product returns was $978 and $802, respectively.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Collaboration revenue consisted of non-refundable upfront payments, license fees,
   reimbursements for research and development activities, and milestone payments associated with the
   Company&amp;#8217;s former collaboration and license agreements. Revenues from the Company&amp;#8217;s prior
   collaboration and license agreements were recognized based on the performance requirements of the
   specific agreements. The Company analyzed agreements with multiple element arrangements to
   determine whether the deliverables under the agreement, including license and performance
   obligations such as joint steering committee participation and research and development activities,
   could have been separated or whether all of the deliverables must have been accounted for as a
   single unit of accounting. Revenues from milestone payments for which the Company had no
   continuing performance obligations were recognized upon achievement of the performance milestone,
   as defined in the related agreement, provided the milestone was substantive and a culmination of
   the earnings process had occurred. Due to the termination of the Company&amp;#8217;s license and
   collaboration agreement with Ipsen Biopharm Limited (&amp;#8220;Ipsen&amp;#8221;) in March&amp;#160;2011, the Company recognized
   collaboration revenue of $8,066 in the first quarter of 2011 as the Company has no further
   performance obligations.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Research and development expenses include, but are not limited to, the Company&amp;#8217;s expenses for
   personnel, supplies, and facilities associated with research activities, screening and
   identification of product candidates, formulation and synthesis activities, manufacturing,
   preclinical studies, toxicology studies, clinical trials, regulatory affairs activities, quality
   assurance activities and license fees. The Company expenses these costs in the period in which
   they are incurred. The Company estimates its liabilities for research and development expenses in
   order to match the recognition of expenses to the period in which the actual services are received.
   As such, accrued liabilities related to third party research and development activities are
   recognized based upon the Company&amp;#8217;s estimate of services received and degree of completion of the
   services in accordance with the specific third party contract.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents and Short-term Investments&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company considers highly liquid investments with initial maturities of three months or
   less to be cash equivalents.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;At September&amp;#160;30, 2011 and December&amp;#160;31, 2010, short-term investments consisted of certificates
   of deposit with original maturities of greater than three months and less than one year. As the
   Company has the positive intent and ability to hold the certificates of deposit until maturity,
   these investments have been classified as held to maturity investments and are stated at cost,
   which approximates fair value.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company reviews long-lived assets for impairment whenever events or changes in facts and
   circumstances are present, both internally and externally, that may indicate impairment of
   long-lived assets held for use. An impairment loss is recognized when estimated future cash flows
   are less than the carrying amount. The cash flow estimates are based on management&amp;#8217;s best
   estimates, using appropriate and customary assumptions and projections at the time.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Based upon the Company&amp;#8217;s decision to discontinue toremifene 80 mg development and after
   analyzing future cash flows and estimates of fair market value from a market participant
   perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and
   recorded an impairment charge of $1,598 during the three months ended March&amp;#160;31, 2011. The impaired
   intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion
   Corporation (&amp;#8220;Orion&amp;#8221;) related to the Company&amp;#8217;s toremifene 80 mg program. This license fee was paid
   under the amended and restated license and supply agreement for the Company&amp;#8217;s exclusive license
   from Orion to develop and commercialize toremifene-based products.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The impairment charge was included in research and development expenses in the condensed
   statement of operations for the nine months ended September&amp;#160;30, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities
   for the expected future tax consequences of events that have been included in the financial
   statements or tax returns. Under this method, deferred tax assets and liabilities are determined
   based on the difference between the financial statement and tax basis of assets and liabilities
   using enacted tax rates in effect for the year in which the differences are expected to reverse. A
   valuation allowance is provided when it is more likely than not that some portion or all of the
   deferred tax assets will not be realized. Accordingly, at September&amp;#160;30, 2011 and December&amp;#160;31,
   2010, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income
   taxes are described more fully in Note 9 to the Company&amp;#8217;s financial statements included in the
   Company&amp;#8217;s Annual Report on Form 10-K for the year ended December&amp;#160;31, 2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other Income, net&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Other income, net consists of interest earned on the Company&amp;#8217;s cash, cash equivalents and
   short-term investments, interest expense, foreign currency transaction gains and losses, and other
   non-operating income or expense.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company has evaluated all events or transactions that occurred after September&amp;#160;30, 2011 up
   through the date the condensed financial statements were issued. There were no material
   recognizable or nonrecognizable subsequent events during the period evaluated.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;2. Share-Based Compensation&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Share-based payments include stock option grants under the Company&amp;#8217;s stock option and equity
   incentive plans and deferred compensation arrangements for the Company&amp;#8217;s non-employee directors.
   The Company recognizes compensation expense for its share-based payments based on the fair value of
   the awards over the period during which an employee or non-employee director is required to provide
   service in exchange for the award. The Company&amp;#8217;s share-based compensation plans are described more
   fully in Note 3 to the Company&amp;#8217;s financial statements included in the Company&amp;#8217;s Annual Report on
   Form 10-K for the year ended December&amp;#160;31, 2010.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The following table summarizes share-based compensation expense included within the condensed
   statements of operations for the three and nine months ended September&amp;#160;30, 2011 and 2010:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Research and development expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;503&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;442&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,410&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,742&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;General and administrative expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;623&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;677&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,909&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,170&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total share-based compensation
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,126&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,119&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,319&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,912&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Share-based compensation expense recorded as general and administrative expense for both of
   the three months ended September&amp;#160;30, 2011 and 2010 included share-based compensation expense
   related to deferred compensation arrangements for the Company&amp;#8217;s non-employee directors of $45.
   Share-based compensation expense related to deferred compensation arrangements for the Company&amp;#8217;s
   non-employee directors of $141 was included in share-based compensation expense recorded as general
   and administrative expenses for both of the nine months ended September&amp;#160;30, 2011 and 2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The fair value of options granted was estimated using the following assumptions for the
   periods presented:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected price volatility
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;65.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;66.2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;64.9&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;64.6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Risk-free interest rate
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.5&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3.4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Weighted average expected life in years
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="0" nowrap="nowrap" align="right"&gt;6.5 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="0" nowrap="nowrap" align="right"&gt;6.5 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="0" nowrap="nowrap" align="right"&gt;6.5 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="0" nowrap="nowrap" align="right"&gt;6.5 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The following is a summary of stock option transactions for all of the Company&amp;#8217;s stock
   option and equity incentive plans since the Company&amp;#8217;s most recent fiscal year end:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options outstanding at December&amp;#160;31, 2010
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,430,495&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;10.91&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Options granted
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,393,500&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.81&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Options forfeited or expired
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(843,662&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8.21&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Options exercised
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(13,000&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4.20&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options outstanding at September&amp;#160;30, 2011
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,967,333&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9.12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:EarningsPerShareTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:EarningsPerShareTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;3. Basic and Diluted Net (Loss) Income Per Share&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Basic and diluted net (loss)&amp;#160;income per share attributable to common stockholders is
   calculated based on the weighted average number of common shares outstanding during the period.
   Diluted net (loss)&amp;#160;income per share also gives effect to the dilutive potential of common stock
   consisting of stock options.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Weighted average options outstanding to purchase shares of common stock of 5,113,943 and
   4,515,006 for the three months ended September&amp;#160;30, 2011 and 2010, respectively, and 5,455,700 and
   4,501,002 for the nine months ended September&amp;#160;30, 2011 and 2010, respectively, were excluded from
   the calculations of diluted net (loss)&amp;#160;income per share as inclusion of the options would have had
   an anti-dilutive effect on the net (loss)&amp;#160;income per share for the periods.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:EarningsPerShareTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:StockholdersEquityNoteDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;4. Common Stock&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On May&amp;#160;6, 2011, the Company filed a Certificate of Amendment to the Company&amp;#8217;s Restated
   Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the
   number of authorized shares of the Company&amp;#8217;s common stock, par value $0.001 per share, from
   60,000,000 shares to 120,000,000 shares. The foregoing amendment was approved by the Company&amp;#8217;s
   stockholders at the Company&amp;#8217;s 2011 Annual Meeting of Stockholders held on May&amp;#160;5, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On June&amp;#160;28, 2011, the Company completed an underwritten public offering of 10,000,000 shares
   of its common stock at a price to the public of $4.75 per share. The Company also granted the
   underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to
   cover over-allotments, if any. The underwriters exercised this option and purchased an additional
   1,023,000 shares of the Company&amp;#8217;s common stock on June&amp;#160;28, 2011 at a price of $4.75 per share. Net
   cash proceeds from the public offering were approximately $49,000 after deducting the underwriting
   discount and offering expenses.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:CollaborativeArrangementDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;5. Collaboration and License Agreements&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;University of Tennessee Research Foundation License Agreements&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company and the University of Tennessee Research Foundation (&amp;#8220;UTRF&amp;#8221;) are parties to a
   consolidated, amended and restated license agreement (the &amp;#8220;SARM License Agreement&amp;#8221;) pursuant to
   which the Company was granted exclusive worldwide rights in all existing SARM technologies owned or
   controlled by UTRF, and certain improvements thereto, and exclusive rights to certain future SARM
   technology that may be developed by certain scientists at the University of Tennessee or
   subsequently licensed to UTRF under certain existing inter-institutional agreements with The Ohio
   State University. Under the SARM License Agreement, the Company is obligated to pay UTRF annual
   license maintenance fees, low single-digit royalties on net sales of products and mid single-digit
   royalties on sublicense revenues.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Additionally, the Company and UTRF previously entered into an amended and restated license
   agreement (the &amp;#8220;SERM License Agreement&amp;#8221;) pursuant to which the Company was granted exclusive
   worldwide rights to UTRF&amp;#8217;s method of use patents relating to SERMs, including toremifene for
   chemoprevention of prostate cancer. In light of the Company&amp;#8217;s decision to discontinue further
   clinical development of toremifene 20 mg, the Company exercised its right to terminate the SERM
   License Agreement with UTRF during the first quarter of 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Ipsen Collaboration and License Agreement&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In September&amp;#160;2006, the Company entered into a collaboration and license agreement with Ipsen
   (the &amp;#8220;Ipsen Collaboration Agreement&amp;#8221;) pursuant to which the Company granted Ipsen exclusive rights
   in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of
   Independent States (the &amp;#8220;European Territory&amp;#8221;) to develop and commercialize toremifene in all
   indications which the Company has licensed from Orion, which include all indications in humans
   except the treatment and prevention of breast cancer outside of the United States.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In accordance with the terms of the Ipsen Collaboration Agreement, Ipsen paid the Company
   &amp;#8364;23,000 as a license fee and expense reimbursement. In February&amp;#160;2008, the Company earned a
   milestone of &amp;#8364;1,000 (approximately $1,482) with the achievement of the primary endpoint in the
   Company&amp;#8217;s completed pivotal Phase III clinical trial evaluating toremifene 80 mg to reduce
   fractures in men with prostate cancer on ADT. This amount was recognized as collaboration revenue
   in the first quarter of 2008. Under the Ipsen Collaboration Agreement, the Company recorded
   deferred revenue of $29,330 related to the Ipsen upfront license fee and expense reimbursement
   which was being amortized into revenue on a straight-line basis over the estimated ten year
   development period for toremifene in the European Territory.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In March&amp;#160;2011, the Company reacquired full rights to its toremifene program following the
   termination by the Company and Ipsen of the collaboration and license agreement, as amended (the
   &amp;#8220;Amended Ipsen Collaboration Agreement&amp;#8221;). During the first quarter of 2011, the Company recognized
   as collaboration revenue all of the remaining $8,066 unamortized revenue that was deferred as of
   December&amp;#160;31, 2010. This amount is included in collaboration revenue in the condensed statement of
   operations for the nine months ended September&amp;#160;30, 2011. The Company recognized as collaboration
   revenue $336 and $1,595 for the three months and nine months ended September&amp;#160;30, 2010,
   respectively, from the amortization of the Ipsen deferred revenue.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;&lt;i&gt;Merck &amp;#038; Co., Inc. Collaboration and License Agreement&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In December&amp;#160;2007, GTx and Merck &amp;#038; Co., Inc. (&amp;#8220;Merck&amp;#8221;) entered into a global exclusive license
   and collaboration agreement (the &amp;#8220;Merck Collaboration Agreement&amp;#8221;) governing the Company&amp;#8217;s and
   Merck&amp;#8217;s joint research, development and commercialization of SARM compounds and related SARM
   products for all potential indications of interest. In March&amp;#160;2010, the Company reacquired full
   rights to its SARM program, including Ostarine&lt;sup style="font-size: 85%; vertical-align: text-top"&gt;TM&lt;/sup&gt;, following the termination by the
   Company and Merck of the Merck Collaboration Agreement.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Under the Merck Collaboration Agreement, the Company granted Merck an exclusive worldwide
   license under its SARM-related patents and know-how. The Company conducted preclinical research of
   SARM compounds and products, and Merck was primarily responsible under the terms of the agreement
   for conducting and funding development and commercialization of products developed under the Merck
   Collaboration Agreement. Merck paid the Company an upfront licensing fee of $40,000 and purchased
   approximately $30,000 of the Company&amp;#8217;s common stock. In addition, Merck paid the Company $15,000
   in cost reimbursements for research and development activities in equal annual installments over a
   three year period.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company deferred the recognition of the upfront licensing fee of $40,000 and the $10,800
   in equity premium received that represented the difference between the purchase price and the
   closing price of the Company&amp;#8217;s common stock on the date the stock was purchased by Merck. These
   payments were being recognized as collaboration revenue over the period of the Company&amp;#8217;s
   performance obligation, which the Company estimated to be ten years. The $5,000 of cost
   reimbursements received in both December&amp;#160;2008 and December&amp;#160;2009 were being recognized as
   collaboration revenue over the remaining period of the Company&amp;#8217;s performance obligation. In March
   2010, the Company reacquired full rights to the Company&amp;#8217;s SARM program following the termination by
   the Company and Merck of the Merck Collaboration Agreement. In the first quarter of 2010, the
   Company recognized as collaboration revenue all of the remaining $49,856 unamortized revenue that
   was deferred as of December&amp;#160;31, 2009, as well as the final $5,000 research and development
   activities cost reimbursement due under the terms of the Merck Collaboration Agreement in December
   2010 for which the Company had no further performance obligation. These amounts are included in
   collaboration revenue in the condensed statement of operations for the nine months ended September
   30, 2010.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!--Footnote Section-->

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>gtxi-20110930.xsd
<DESCRIPTION>EX-101 SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
    xmlns:xbrli="http://www.xbrl.org/2003/instance"
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    targetNamespace="http://www.gtxinc.com/20110930"
    xmlns:gtxi="http://www.gtxinc.com/20110930"
    elementFormDefault="qualified"
    attributeFormDefault="unqualified"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xmlns:us-types="http://xbrl.sec.gov/us-types/2011-01-31"
    xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
    xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.gtxinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
  <link:definition>00 - Document - Document and Entity Information</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/BalanceSheets" id="BalanceSheets">
  <link:definition>01 - Statement - Condensed Balance Sheets</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
  <link:definition>011 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/StatementsOfOperations" id="StatementsOfOperations">
  <link:definition>02 - Statement - Condensed Statements of Operations (unaudited)</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
  <link:definition>03 - Statement - Condensed Statements of Cash Flows (unaudited)</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>

<link:roleType roleURI="http://www.gtxinc.com/role/BusinessAndBasisOfPresentation" id="BusinessAndBasisOfPresentation">
  <link:definition>06001 - Disclosure - Business and Basis of Presentation</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
  <link:definition>06002 - Disclosure - Share-Based Compensation</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/BasicAndDilutedNetLossIncomePerShare" id="BasicAndDilutedNetLossIncomePerShare">
  <link:definition>06003 - Disclosure - Basic and Diluted Net (Loss) Income Per Share</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/CommonStock" id="CommonStock">
  <link:definition>06004 - Disclosure - Common Stock</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.gtxinc.com/role/CollaborationAndLicenseAgreements" id="CollaborationAndLicenseAgreements">
  <link:definition>06005 - Disclosure - Collaboration and License Agreements</link:definition>
  <link:usedOn>link:presentationLink</link:usedOn>
  <link:usedOn>link:definitionLink</link:usedOn>
  <link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>

<link:linkbaseRef xlink:type="simple" xlink:href="gtxi-20110930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
<link:linkbaseRef xlink:type="simple" xlink:href="gtxi-20110930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
<link:linkbaseRef xlink:type="simple" xlink:href="gtxi-20110930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
<!-- elements -->
<element name="DocumentAndEntityInformationAbstract" id="gtxi_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />

<element name="CollaborationRevenue" id="gtxi_CollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
<element name="BasicAndDilutedWeightedAverageNumberOfShares" id="gtxi_BasicAndDilutedWeightedAverageNumberOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
<element name="DirectorsDeferredCompensation" id="gtxi_DirectorsDeferredCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
<element name="PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" id="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>gtxi-20110930_cal.xml
<DESCRIPTION>EX-101 CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#DocumentAndEntityInformation" roleURI="http://www.gtxinc.com/role/DocumentAndEntityInformation" />
<calculationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
<roleRef roleURI="http://www.gtxinc.com/role/BalanceSheets" xlink:href="gtxi-20110930.xsd#BalanceSheets" xlink:type="simple" />
<roleRef roleURI="http://www.gtxinc.com/role/BalanceSheetsParenthetical" xlink:href="gtxi-20110930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />

<roleRef roleURI="http://www.gtxinc.com/role/StatementsOfOperations" xlink:href="gtxi-20110930.xsd#StatementsOfOperations" xlink:type="simple" />
<roleRef roleURI="http://www.gtxinc.com/role/StatementsOfCashFlows" xlink:href="gtxi-20110930.xsd#StatementsOfCashFlows" xlink:type="simple" />
<calculationLink xlink:role="http://www.gtxinc.com/role/BalanceSheets" xlink:title="01 - Statement - Condensed Balance Sheets" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="1" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_HeldToMaturitySecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_HeldToMaturitySecuritiesCurrent" order="2" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_AccountsReceivableNetCurrent" order="3" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_InventoryNet" order="4" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="5" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="6" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="7" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_FiniteLivedIntangibleAssetsNet" order="8" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="9" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="10" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRevenueCurrent" order="11" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_LiabilitiesCurrent" order="12" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_DeferredRevenueNoncurrent" order="13" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_OtherLiabilitiesNoncurrent" order="14" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="15" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="16" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="17" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="18" use="optional" weight="1" />
</calculationLink>
<calculationLink xlink:role="http://www.gtxinc.com/role/StatementsOfOperations" xlink:title="02 - Statement - Condensed Statements of Operations (unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="loc_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_SalesRevenueGoodsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Revenues" xlink:to="loc_SalesRevenueGoodsNet" order="19" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_CollaborationRevenue" xlink:label="gtxi_CollaborationRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Revenues" xlink:to="gtxi_CollaborationRevenue" order="20" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_Revenues" order="21" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_CostOfGoodsSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_CostOfGoodsSold" order="22" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="23" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CostsAndExpenses" xlink:to="loc_SellingGeneralAndAdministrativeExpense" order="24" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_CostsAndExpenses" order="25" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_OperatingIncomeLoss" order="26" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_OtherNonoperatingIncomeExpense" order="27" use="optional" weight="1" />
</calculationLink>
<calculationLink xlink:role="http://www.gtxinc.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Condensed Statements of Cash Flows (unaudited)" xlink:type="extended">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NetIncomeLoss" order="28" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="29" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="30" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_DirectorsDeferredCompensation" xlink:label="gtxi_DirectorsDeferredCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="gtxi_DirectorsDeferredCompensation" order="31" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_RecognitionOfDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RecognitionOfDeferredRevenue" order="32" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_ImpairmentOfIntangibleAssetsFinitelived" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ImpairmentOfIntangibleAssetsFinitelived" order="33" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsReceivable" order="34" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInInventories" order="35" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="36" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="37" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccruedLiabilities" order="38" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="39" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="40" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_PaymentsToAcquireHeldToMaturitySecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireHeldToMaturitySecurities" order="41" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:label="loc_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" order="42" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="43" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="44" use="optional" weight="1" />
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" xlink:label="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" order="45" use="optional" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromStockOptionsExercised" order="46" use="optional" weight="1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="47" use="optional" weight="1" />
</calculationLink>

<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#BusinessAndBasisOfPresentation" roleURI="http://www.gtxinc.com/role/BusinessAndBasisOfPresentation" />
<calculationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/BusinessAndBasisOfPresentation" xlink:title="06001 - Disclosure - Business and Basis of Presentation" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#ShareBasedCompensation" roleURI="http://www.gtxinc.com/role/ShareBasedCompensation" />
<calculationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/ShareBasedCompensation" xlink:title="06002 - Disclosure - Share-Based Compensation" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#BasicAndDilutedNetLossIncomePerShare" roleURI="http://www.gtxinc.com/role/BasicAndDilutedNetLossIncomePerShare" />
<calculationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/BasicAndDilutedNetLossIncomePerShare" xlink:title="06003 - Disclosure - Basic and Diluted Net (Loss) Income Per Share" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#CommonStock" roleURI="http://www.gtxinc.com/role/CommonStock" />
<calculationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/CommonStock" xlink:title="06004 - Disclosure - Common Stock" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#CollaborationAndLicenseAgreements" roleURI="http://www.gtxinc.com/role/CollaborationAndLicenseAgreements" />
<calculationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/CollaborationAndLicenseAgreements" xlink:title="06005 - Disclosure - Collaboration and License Agreements" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>gtxi-20110930_lab.xml
<DESCRIPTION>EX-101 LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">

<loc xlink:type="locator" xlink:label="gtxi_DocumentAndEntityInformationAbstract" xlink:href="gtxi-20110930.xsd#gtxi_DocumentAndEntityInformationAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="gtxi_DocumentAndEntityInformationAbstract_lbl" />
<label xlink:type="resource" xlink:label="gtxi_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document and Entity Information [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xml:lang="en-US">Short-term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xml:lang="en-US">Held-to-maturity Securities, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible and other assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue - current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, less current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value: 120,000,000 and 60,000,000 shares authorized at September 30, 2011 and December 31, 2010, respectively; 62,790,223 and 51,719,187 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Product sales, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Sales Revenue, Goods, Net</label>

<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_CollaborationRevenue" xlink:label="gtxi_CollaborationRevenue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gtxi_CollaborationRevenue" xlink:to="gtxi_CollaborationRevenue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gtxi_CollaborationRevenue_lbl" xml:lang="en-US">Collaboration Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gtxi_CollaborationRevenue_lbl" xml:lang="en-US">Collaboration revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gtxi_CollaborationRevenue_lbl" xml:lang="en-US">Collaboration revenue consists of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company's collaboration and license agreements. Collaboration revenue is recognized based on the performance requirements of the specific agreements.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of product sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of Goods Sold</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Costs and Expenses, Total</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) income from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) income from operations</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net (loss) income per share:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average shares used in computing net (loss) income per share:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_BasicAndDilutedWeightedAverageNumberOfShares" xlink:label="gtxi_BasicAndDilutedWeightedAverageNumberOfShares" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gtxi_BasicAndDilutedWeightedAverageNumberOfShares" xlink:to="gtxi_BasicAndDilutedWeightedAverageNumberOfShares_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gtxi_BasicAndDilutedWeightedAverageNumberOfShares_lbl" xml:lang="en-US">Basic and Diluted Weighted Average Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gtxi_BasicAndDilutedWeightedAverageNumberOfShares_lbl" xml:lang="en-US">Basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gtxi_BasicAndDilutedWeightedAverageNumberOfShares_lbl" xml:lang="en-US">Basic and diluted weighted average number of shares.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>

<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_DirectorsDeferredCompensation" xlink:label="gtxi_DirectorsDeferredCompensation" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gtxi_DirectorsDeferredCompensation" xlink:to="gtxi_DirectorsDeferredCompensation_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gtxi_DirectorsDeferredCompensation_lbl" xml:lang="en-US">Directors Deferred Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gtxi_DirectorsDeferredCompensation_lbl" xml:lang="en-US">Directors' deferred compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gtxi_DirectorsDeferredCompensation_lbl" xml:lang="en-US">Fees earned by non-employee directors under the Company's Directors' Deferred Compensation Plan which will be paid out in the form of Company common stock.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Recognition of Deferred Revenue</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue amortization</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="us-gaap_PaymentsToAcquireHeldToMaturitySecurities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities_lbl" xml:lang="en-US">Purchase of short-term investments, held to maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities_lbl" xml:lang="en-US">Payments to Acquire Held-to-maturity Securities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireHeldToMaturitySecurities_lbl" xml:lang="en-US">Purchase of short-term investments, held to maturity</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_lbl" xml:lang="en-US">Proceeds from maturities of short-term investments, held to maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_lbl" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>

<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" xlink:label="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" xlink:to="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations_lbl" xml:lang="en-US">Payments on Capital Lease and Financed Equipment Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations_lbl" xml:lang="en-US">Payments on capital lease and financed equipment obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations_lbl" xml:lang="en-US">Payments on capital lease and financed equipment obligations</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations_lbl" xml:lang="en-US">Payments on capital lease and financed equipment obligations</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of employee stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Business and Basis of Presentation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business and Basis of Presentation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business and Basis of Presentation [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Compensation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Compensation [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net (Loss) Income Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Common Stock [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Common Stock [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaboration and License Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_SalesRevenueServicesNetAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueServicesNetAbstract_lbl" xml:lang="en-US">Collaboration and License Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueServicesNetAbstract_lbl" xml:lang="en-US">Collaboration and License Agreements [Abstract]</label>

<loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
<label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
<loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
<label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
<loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
<loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
<loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
<loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</label>
<loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
<loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
<loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
<loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</label>
<loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</label>
<loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
<label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</label>
<loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
<loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
<label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Balance Sheets [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Statements of Operations [Abstract]</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Statements of Cash Flows [Abstract]</label>

</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>gtxi-20110930_pre.xml
<DESCRIPTION>EX-101 PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
<roleRef roleURI="http://www.gtxinc.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="gtxi-20110930.xsd#DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#BusinessAndBasisOfPresentation" roleURI="http://www.gtxinc.com/role/BusinessAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#ShareBasedCompensation" roleURI="http://www.gtxinc.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#BasicAndDilutedNetLossIncomePerShare" roleURI="http://www.gtxinc.com/role/BasicAndDilutedNetLossIncomePerShare" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#CommonStock" roleURI="http://www.gtxinc.com/role/CommonStock" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#CollaborationAndLicenseAgreements" roleURI="http://www.gtxinc.com/role/CollaborationAndLicenseAgreements" />
<presentationLink xlink:role="http://www.gtxinc.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" xlink:type="extended">
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_DocumentAndEntityInformationAbstract" xlink:label="gtxi_DocumentAndEntityInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="5.03" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="5.05" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="5.04" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="5.01" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="5.02" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="5.08" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="5.09" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="5.10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="5.11" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="5.12" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5.14" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.13" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5.07" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gtxi_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="5.06" use="optional" />
</presentationLink>
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#BalanceSheets" roleURI="http://www.gtxinc.com/role/BalanceSheets" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#BalanceSheetsParenthetical" roleURI="http://www.gtxinc.com/role/BalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#StatementsOfOperations" roleURI="http://www.gtxinc.com/role/StatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="gtxi-20110930.xsd#StatementsOfCashFlows" roleURI="http://www.gtxinc.com/role/StatementsOfCashFlows" />
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/BalanceSheets" xlink:title="01 - Statement - Condensed Balance Sheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="1." use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="2.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_HeldToMaturitySecuritiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_HeldToMaturitySecuritiesCurrent" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_AccountsReceivableNetCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AccountsReceivableNetCurrent" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_InventoryNet" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_InventoryNet" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_FiniteLivedIntangibleAssetsNet" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_FiniteLivedIntangibleAssetsNet" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="12.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="13.2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRevenueCurrent" order="16.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRevenueNoncurrent" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OtherLiabilitiesNoncurrent" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_CommitmentsAndContingencies" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CommitmentsAndContingencies" order="20.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="23.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/BalanceSheetsParenthetical" xlink:title="011 - Statement - Condensed Balance Sheets (Parenthetical)" >
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="12.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="22.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="22.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesIssued" order="22.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="22.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/StatementsOfOperations" xlink:title="02 - Statement - Condensed Statements of Operations (unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_RevenuesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_RevenuesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_SalesRevenueGoodsNet" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RevenuesAbstract" xlink:to="loc_SalesRevenueGoodsNet" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_CollaborationRevenue" xlink:label="gtxi_CollaborationRevenue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RevenuesAbstract" xlink:to="gtxi_CollaborationRevenue" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="loc_Revenues" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RevenuesAbstract" xlink:to="loc_Revenues" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_CostsAndExpensesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_CostsAndExpensesAbstract" order="5.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_CostOfGoodsSold" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_CostOfGoodsSold" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_SellingGeneralAndAdministrativeExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_SellingGeneralAndAdministrativeExpense" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_CostsAndExpenses" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CostsAndExpensesAbstract" xlink:to="loc_CostsAndExpenses" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OperatingIncomeLoss" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OtherNonoperatingIncomeExpense" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLoss" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_EarningsPerShareAbstract" order="13.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_WeightedAverageNumberOfSharesOutstandingAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingAbstract" order="15.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_BasicAndDilutedWeightedAverageNumberOfShares" xlink:label="gtxi_BasicAndDilutedWeightedAverageNumberOfShares" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="gtxi_BasicAndDilutedWeightedAverageNumberOfShares" order="16.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Condensed Statements of Cash Flows (unaudited)">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetIncomeLoss" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="3.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_DirectorsDeferredCompensation" xlink:label="gtxi_DirectorsDeferredCompensation" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gtxi_DirectorsDeferredCompensation" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_RecognitionOfDeferredRevenue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RecognitionOfDeferredRevenue" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_ImpairmentOfIntangibleAssetsFinitelived" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ImpairmentOfIntangibleAssetsFinitelived" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="9.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_IncreaseDecreaseInAccountsReceivable" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsReceivable" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_IncreaseDecreaseInInventories" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInInventories" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInAccruedLiabilities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccruedLiabilities" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="16.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_PaymentsToAcquireHeldToMaturitySecurities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireHeldToMaturitySecurities" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:label="loc_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="21.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="gtxi-20110930.xsd#gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" xlink:label="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations" order="23.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromStockOptionsExercised" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/BusinessAndBasisOfPresentation" xlink:title="06001 - Disclosure - Business and Basis of Presentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/ShareBasedCompensation" xlink:title="06002 - Disclosure - Share-Based Compensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/BasicAndDilutedNetLossIncomePerShare" xlink:title="06003 - Disclosure - Basic and Diluted Net (Loss) Income Per Share">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_EarningsPerShareTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/CommonStock" xlink:title="06004 - Disclosure - Common Stock">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityNoteAbstract" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.gtxinc.com/role/CollaborationAndLicenseAgreements" xlink:title="06005 - Disclosure - Collaboration and License Agreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="loc_SalesRevenueServicesNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_CollaborativeArrangementDisclosureTextBlock" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SalesRevenueServicesNetAbstract" xlink:to="loc_CollaborativeArrangementDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E6KAC"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) (USD $)<br /></strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td><td class="nump">$ 0.001<span /></td><td class="nump">$ 0.001<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td><td class="nump">120,000,000<span /></td><td class="nump">60,000,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td><td class="nump">62,790,223<span /></td><td class="nump">51,719,187<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td><td class="nump">62,790,223<span /></td><td class="nump">51,719,187<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E1IAG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (unaudited) (USD $)<br />In Thousands, except Share data</strong></div></th><th class="th" colspan="2">3 Months Ended</th><th class="th" colspan="2">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td><td class="nump">$ 2,029<span /></td><td class="nump">$ 960<span /></td><td class="nump">$ 4,903<span /></td><td class="nump">$ 2,358<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gtxi_CollaborationRevenue', window );">Collaboration revenue</a></td><td class="text">&#xA0;<span /></td><td class="nump">336<span /></td><td class="nump">8,066<span /></td><td class="nump">56,450<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td><td class="nump">2,029<span /></td><td class="nump">1,296<span /></td><td class="nump">12,969<span /></td><td class="nump">58,808<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of product sales</a></td><td class="nump">311<span /></td><td class="nump">216<span /></td><td class="nump">780<span /></td><td class="nump">501<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td><td class="nump">8,181<span /></td><td class="nump">5,593<span /></td><td class="nump">23,075<span /></td><td class="nump">22,720<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td><td class="nump">2,904<span /></td><td class="nump">4,066<span /></td><td class="nump">12,058<span /></td><td class="nump">12,900<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td><td class="nump">11,396<span /></td><td class="nump">9,875<span /></td><td class="nump">35,913<span /></td><td class="nump">36,121<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td><td class="num">(9,367)<span /></td><td class="num">(8,579)<span /></td><td class="num">(22,944)<span /></td><td class="nump">22,687<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td><td class="nump">23<span /></td><td class="nump">4<span /></td><td class="nump">332<span /></td><td class="nump">136<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td><td class="num">$ (9,344)<span /></td><td class="num">$ (8,575)<span /></td><td class="num">$ (22,612)<span /></td><td class="nump">$ 22,823<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (loss) income per share:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td><td class="num">$ (0.15)<span /></td><td class="num">$ (0.24)<span /></td><td class="num">$ (0.41)<span /></td><td class="nump">$ 0.63<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares used in computing net (loss) income per share:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gtxi_BasicAndDilutedWeightedAverageNumberOfShares', window );">Basic and diluted</a></td><td class="nump">62,778,575<span /></td><td class="nump">36,424,971<span /></td><td class="nump">55,529,320<span /></td><td class="nump">36,422,273<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gtxi_BasicAndDilutedWeightedAverageNumberOfShares"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted weighted average number of shares.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>gtxi_BasicAndDilutedWeightedAverageNumberOfShares</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>gtxi</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gtxi_CollaborationRevenue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration revenue consists of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company's collaboration and license agreements. Collaboration revenue is recognized based on the performance requirements of the specific agreements.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>gtxi_CollaborationRevenue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>gtxi</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 2<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.2(a))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CostOfGoodsSold</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CostsAndExpenses</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 9<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.9)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 730<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Research and Development<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 86<br /><br /> -Paragraph 11<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 86<br /><br /> -Paragraph 3<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 2<br /><br /> -Paragraph 8, 12, 13<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 1<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Revenues</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RevenuesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 1<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.1(a))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 43<br /><br /> -Chapter 4<br /><br /> -Paragraph 5A<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 4<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.4)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 330<br /><br /> -SubTopic 10<br /><br /> -Section 30<br /><br /> -Paragraph 8<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EAWAE"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information (USD $)<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1" /><th class="th" colspan="1" /></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Nov. 03, 2011</div></th><th class="th"><div>Jun. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gtxi_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td><td class="text">GTX INC /DE/<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td><td class="text">0001260990<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td><td class="text">10-Q<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td><td class="text">Sep. 30,
         2011<span /></td><td class="text"><span /></td><td class="text"><span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td><td class="text">false<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td><td class="text">2011<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td><td class="text">Q3<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td><td class="text">--12-31<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td><td class="text">No<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td><td class="text">No<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td><td class="text">Yes<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td><td class="text">Accelerated Filer<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 56,844,168<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td><td class="text">&#xA0;<span /></td><td class="nump">62,790,223<span /></td><td class="text">&#xA0;<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_AmendmentFlag</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:booleanItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_CurrentFiscalYearEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gMonthDayItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:fiscalPeriodItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalYearFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gYearItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentPeriodEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:dateItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentType</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:submissionTypeItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCentralIndexKey</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:centralIndexKeyItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCurrentReportingStatus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityFilerCategory</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:filerCategoryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityPublicFloat</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityRegistrantName</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:normalizedStringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityVoluntaryFilers</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gtxi_DocumentAndEntityInformationAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>gtxi_DocumentAndEntityInformationAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>gtxi</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net (Loss) Income Per Share<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net (Loss) Income Per Share</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:EarningsPerShareTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>3. Basic and Diluted Net (Loss) Income Per Share</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Basic and diluted net (loss)&#160;income per share attributable to common stockholders is
   calculated based on the weighted average number of common shares outstanding during the period.
   Diluted net (loss)&#160;income per share also gives effect to the dilutive potential of common stock
   consisting of stock options.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Weighted average options outstanding to purchase shares of common stock of 5,113,943 and
   4,515,006 for the three months ended September&#160;30, 2011 and 2010, respectively, and 5,455,700 and
   4,501,002 for the nine months ended September&#160;30, 2011 and 2010, respectively, were excluded from
   the calculations of diluted net (loss)&#160;income per share as inclusion of the options would have had
   an anti-dilutive effect on the net (loss)&#160;income per share for the periods.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 52<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 128<br /><br /> -Paragraph 40<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.21)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business and Basis of Presentation [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Business and Basis of Presentation</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-->
   <div align="left" style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <div align="left">
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b>
   </div>
   <div align="center" style="font-size: 10pt"><b></b></div>
   <div align="center" style="font-size: 10pt"><b></b></div>
   <div align="center" style="font-size: 10pt"><b></b></div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>1. Business and Basis of Presentation</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Business</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">GTx, Inc. (&#8220;GTx&#8221; or the &#8220;Company&#8221;), a Delaware corporation incorporated on September&#160;24, 1997
   and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery,
   development and commercialization of small molecules that selectively target hormone pathways for
   the treatment of cancer, cancer supportive care, and other serious medical conditions.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company is developing selective androgen receptor modulators (&#8220;SARMs&#8221;), including
   Ostarine<sup style="font-size: 85%; vertical-align: text-top">TM </sup>(GTx-024). SARMs are a new class of drugs with the potential to prevent and
   treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss
   conditions, including chronic sarcopenia (age related muscle loss). The Company has commenced two
   pivotal Phase III clinical trials evaluating Ostarine<sup style="font-size: 85%; vertical-align: text-top">TM</sup> for the prevention and treatment
   of muscle wasting in patients with non-small cell lung cancer.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additionally, the Company is developing Capesaris<sup style="font-size: 85%; vertical-align: text-top">TM</sup> (GTx-758), an oral nonsteriodal
   selective estrogen receptor alpha agonist. The Company is developing Capesaris<sup style="font-size: 85%; vertical-align: text-top">TM</sup> for
   first line and second line hormonal treatment of advanced prostate cancer. With respect to first
   line hormonal therapy, the Company has completed enrollment in a Phase II maintenance dose finding clinical trial and
   has initiated a Phase II loading dose finding clinical trial evaluating Capesaris<sup style="font-size: 85%; vertical-align: text-top">TM</sup> in
   men with advanced prostate cancer. The Company will also initiate a second line hormonal therapy
   Phase II clinical trial evaluating Capesaris<sup style="font-size: 85%; vertical-align: text-top">TM</sup> in men with castration resistant prostate
   cancer.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company markets FARESTON<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> (toremifene citrate) 60 mg tablets, approved for the
   treatment of advanced metastatic breast cancer in postmenopausal women, in the United States. The
   Company previously determined to discontinue its toremifene 80 mg and toremifene 20 mg development
   programs.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Basis of Presentation</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The accompanying unaudited condensed financial statements reflect, in the opinion of
   management, all adjustments (consisting of normal recurring adjustments) necessary for a fair
   presentation of GTx&#8217;s financial position, results of operations and cash flows for each period
   presented in accordance with accounting principles generally accepted in the United States for
   interim financial information and with the instructions to Form 10-Q and Article&#160;10 of Regulation
   S-X. Accordingly, information and footnote disclosures normally included in financial statements
   prepared in accordance with accounting principles generally accepted in the United States have been
   condensed or omitted from the accompanying condensed financial statements. These interim condensed
   financial statements should be read in conjunction with the audited financial statements and
   related notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year
   ended December&#160;31, 2010. Operating results for the three months and nine months ended September
   30, 2011 are not necessarily indicative of the results that may be expected for the entire fiscal
   year ending December&#160;31, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Use of Estimates</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The preparation of condensed financial statements in conformity with accounting principles
   generally accepted in the United States requires management to make estimates and assumptions that
   affect the reported amounts of assets and liabilities, the disclosure of contingent assets and
   liabilities at the date of the condensed financial statements, and the reported amounts of revenues
   and expenses during the reporting period. Actual amounts and results could differ from those
   estimates.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Revenue Recognition</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company recognizes revenue from product sales of FARESTON<sup style="font-size: 85%; vertical-align: text-top">&#174;</sup> less deductions for
   estimated sales discounts and sales returns. Revenue from product sales is recognized when
   persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and
   collectability is reasonably assured. The Company accounts for rebates to certain governmental
   agencies as a reduction of product sales. The Company allows customers to return product within a
   specified time period prior to and subsequent to the product&#8217;s labeled expiration date. The
   Company estimates an accrual for product returns, which is recorded as a reduction of product
   sales, based on factors which include historical product returns and estimated product in the
   distribution channel which is expected to exceed its expiration date. At September&#160;30, 2011 and
   December&#160;31, 2010, the Company&#8217;s accrual for product returns was $978 and $802, respectively.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Collaboration revenue consisted of non-refundable upfront payments, license fees,
   reimbursements for research and development activities, and milestone payments associated with the
   Company&#8217;s former collaboration and license agreements. Revenues from the Company&#8217;s prior
   collaboration and license agreements were recognized based on the performance requirements of the
   specific agreements. The Company analyzed agreements with multiple element arrangements to
   determine whether the deliverables under the agreement, including license and performance
   obligations such as joint steering committee participation and research and development activities,
   could have been separated or whether all of the deliverables must have been accounted for as a
   single unit of accounting. Revenues from milestone payments for which the Company had no
   continuing performance obligations were recognized upon achievement of the performance milestone,
   as defined in the related agreement, provided the milestone was substantive and a culmination of
   the earnings process had occurred. Due to the termination of the Company&#8217;s license and
   collaboration agreement with Ipsen Biopharm Limited (&#8220;Ipsen&#8221;) in March&#160;2011, the Company recognized
   collaboration revenue of $8,066 in the first quarter of 2011 as the Company has no further
   performance obligations.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Research and Development Expenses</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development expenses include, but are not limited to, the Company&#8217;s expenses for
   personnel, supplies, and facilities associated with research activities, screening and
   identification of product candidates, formulation and synthesis activities, manufacturing,
   preclinical studies, toxicology studies, clinical trials, regulatory affairs activities, quality
   assurance activities and license fees. The Company expenses these costs in the period in which
   they are incurred. The Company estimates its liabilities for research and development expenses in
   order to match the recognition of expenses to the period in which the actual services are received.
   As such, accrued liabilities related to third party research and development activities are
   recognized based upon the Company&#8217;s estimate of services received and degree of completion of the
   services in accordance with the specific third party contract.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Cash, Cash Equivalents and Short-term Investments</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company considers highly liquid investments with initial maturities of three months or
   less to be cash equivalents.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At September&#160;30, 2011 and December&#160;31, 2010, short-term investments consisted of certificates
   of deposit with original maturities of greater than three months and less than one year. As the
   Company has the positive intent and ability to hold the certificates of deposit until maturity,
   these investments have been classified as held to maturity investments and are stated at cost,
   which approximates fair value.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Impairment of Long-Lived Assets</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company reviews long-lived assets for impairment whenever events or changes in facts and
   circumstances are present, both internally and externally, that may indicate impairment of
   long-lived assets held for use. An impairment loss is recognized when estimated future cash flows
   are less than the carrying amount. The cash flow estimates are based on management&#8217;s best
   estimates, using appropriate and customary assumptions and projections at the time.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Based upon the Company&#8217;s decision to discontinue toremifene 80 mg development and after
   analyzing future cash flows and estimates of fair market value from a market participant
   perspective, the Company determined that its toremifene 80 mg intangible asset was impaired and
   recorded an impairment charge of $1,598 during the three months ended March&#160;31, 2011. The impaired
   intangible asset consisted of the unamortized portion of capitalized license fees paid to Orion
   Corporation (&#8220;Orion&#8221;) related to the Company&#8217;s toremifene 80 mg program. This license fee was paid
   under the amended and restated license and supply agreement for the Company&#8217;s exclusive license
   from Orion to develop and commercialize toremifene-based products.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The impairment charge was included in research and development expenses in the condensed
   statement of operations for the nine months ended September&#160;30, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Income Taxes</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company accounts for deferred taxes by recognition of deferred tax assets and liabilities
   for the expected future tax consequences of events that have been included in the financial
   statements or tax returns. Under this method, deferred tax assets and liabilities are determined
   based on the difference between the financial statement and tax basis of assets and liabilities
   using enacted tax rates in effect for the year in which the differences are expected to reverse. A
   valuation allowance is provided when it is more likely than not that some portion or all of the
   deferred tax assets will not be realized. Accordingly, at September&#160;30, 2011 and December&#160;31,
   2010, net of the valuation allowance, the net deferred tax assets were reduced to zero. Income
   taxes are described more fully in Note 9 to the Company&#8217;s financial statements included in the
   Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2010.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Other Income, net</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Other income, net consists of interest earned on the Company&#8217;s cash, cash equivalents and
   short-term investments, interest expense, foreign currency transaction gains and losses, and other
   non-operating income or expense.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Subsequent Events</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has evaluated all events or transactions that occurred after September&#160;30, 2011 up
   through the date the condensed financial statements were issued. There were no material
   recognizable or nonrecognizable subsequent events during the period evaluated.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - us-gaap:StockholdersEquityNoteDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>4. Common Stock</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On May&#160;6, 2011, the Company filed a Certificate of Amendment to the Company&#8217;s Restated
   Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the
   number of authorized shares of the Company&#8217;s common stock, par value $0.001 per share, from
   60,000,000 shares to 120,000,000 shares. The foregoing amendment was approved by the Company&#8217;s
   stockholders at the Company&#8217;s 2011 Annual Meeting of Stockholders held on May&#160;5, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On June&#160;28, 2011, the Company completed an underwritten public offering of 10,000,000 shares
   of its common stock at a price to the public of $4.75 per share. The Company also granted the
   underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to
   cover over-allotments, if any. The underwriters exercised this option and purchased an additional
   1,023,000 shares of the Company&#8217;s common stock on June&#160;28, 2011 at a price of $4.75 per share. Net
   cash proceeds from the public offering were approximately $49,000 after deducting the underwriting
   discount and offering expenses.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 29, 30, 31<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 310<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 4<br /><br /> -Subparagraph (SAB TOPIC 4.C)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Preferred Stock<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 5<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Article 4<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 4<br /><br /> -Section C<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 4<br /><br /> -Section 08<br /><br /> -Paragraph d<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 4<br /><br /> -Section E<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br /><br /><br /><br />Reference 17: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br />Reference 18: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(d),(e))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br />Reference 19: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 43<br /><br /> -Chapter 1<br /><br /> -Section B<br /><br /> -Paragraph 7, 11A<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 20: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 21: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 22: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br /><br /><br /><br />Reference 23: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:CollaborativeArrangementDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>5. Collaboration and License Agreements</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>University of Tennessee Research Foundation License Agreements</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company and the University of Tennessee Research Foundation (&#8220;UTRF&#8221;) are parties to a
   consolidated, amended and restated license agreement (the &#8220;SARM License Agreement&#8221;) pursuant to
   which the Company was granted exclusive worldwide rights in all existing SARM technologies owned or
   controlled by UTRF, and certain improvements thereto, and exclusive rights to certain future SARM
   technology that may be developed by certain scientists at the University of Tennessee or
   subsequently licensed to UTRF under certain existing inter-institutional agreements with The Ohio
   State University. Under the SARM License Agreement, the Company is obligated to pay UTRF annual
   license maintenance fees, low single-digit royalties on net sales of products and mid single-digit
   royalties on sublicense revenues.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Additionally, the Company and UTRF previously entered into an amended and restated license
   agreement (the &#8220;SERM License Agreement&#8221;) pursuant to which the Company was granted exclusive
   worldwide rights to UTRF&#8217;s method of use patents relating to SERMs, including toremifene for
   chemoprevention of prostate cancer. In light of the Company&#8217;s decision to discontinue further
   clinical development of toremifene 20 mg, the Company exercised its right to terminate the SERM
   License Agreement with UTRF during the first quarter of 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Ipsen Collaboration and License Agreement</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In September&#160;2006, the Company entered into a collaboration and license agreement with Ipsen
   (the &#8220;Ipsen Collaboration Agreement&#8221;) pursuant to which the Company granted Ipsen exclusive rights
   in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of
   Independent States (the &#8220;European Territory&#8221;) to develop and commercialize toremifene in all
   indications which the Company has licensed from Orion, which include all indications in humans
   except the treatment and prevention of breast cancer outside of the United States.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In accordance with the terms of the Ipsen Collaboration Agreement, Ipsen paid the Company
   &#8364;23,000 as a license fee and expense reimbursement. In February&#160;2008, the Company earned a
   milestone of &#8364;1,000 (approximately $1,482) with the achievement of the primary endpoint in the
   Company&#8217;s completed pivotal Phase III clinical trial evaluating toremifene 80 mg to reduce
   fractures in men with prostate cancer on ADT. This amount was recognized as collaboration revenue
   in the first quarter of 2008. Under the Ipsen Collaboration Agreement, the Company recorded
   deferred revenue of $29,330 related to the Ipsen upfront license fee and expense reimbursement
   which was being amortized into revenue on a straight-line basis over the estimated ten year
   development period for toremifene in the European Territory.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In March&#160;2011, the Company reacquired full rights to its toremifene program following the
   termination by the Company and Ipsen of the collaboration and license agreement, as amended (the
   &#8220;Amended Ipsen Collaboration Agreement&#8221;). During the first quarter of 2011, the Company recognized
   as collaboration revenue all of the remaining $8,066 unamortized revenue that was deferred as of
   December&#160;31, 2010. This amount is included in collaboration revenue in the condensed statement of
   operations for the nine months ended September&#160;30, 2011. The Company recognized as collaboration
   revenue $336 and $1,595 for the three months and nine months ended September&#160;30, 2010,
   respectively, from the amortization of the Ipsen deferred revenue.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Merck &#038; Co., Inc. Collaboration and License Agreement</i></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In December&#160;2007, GTx and Merck &#038; Co., Inc. (&#8220;Merck&#8221;) entered into a global exclusive license
   and collaboration agreement (the &#8220;Merck Collaboration Agreement&#8221;) governing the Company&#8217;s and
   Merck&#8217;s joint research, development and commercialization of SARM compounds and related SARM
   products for all potential indications of interest. In March&#160;2010, the Company reacquired full
   rights to its SARM program, including Ostarine<sup style="font-size: 85%; vertical-align: text-top">TM</sup>, following the termination by the
   Company and Merck of the Merck Collaboration Agreement.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the Merck Collaboration Agreement, the Company granted Merck an exclusive worldwide
   license under its SARM-related patents and know-how. The Company conducted preclinical research of
   SARM compounds and products, and Merck was primarily responsible under the terms of the agreement
   for conducting and funding development and commercialization of products developed under the Merck
   Collaboration Agreement. Merck paid the Company an upfront licensing fee of $40,000 and purchased
   approximately $30,000 of the Company&#8217;s common stock. In addition, Merck paid the Company $15,000
   in cost reimbursements for research and development activities in equal annual installments over a
   three year period.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company deferred the recognition of the upfront licensing fee of $40,000 and the $10,800
   in equity premium received that represented the difference between the purchase price and the
   closing price of the Company&#8217;s common stock on the date the stock was purchased by Merck. These
   payments were being recognized as collaboration revenue over the period of the Company&#8217;s
   performance obligation, which the Company estimated to be ten years. The $5,000 of cost
   reimbursements received in both December&#160;2008 and December&#160;2009 were being recognized as
   collaboration revenue over the remaining period of the Company&#8217;s performance obligation. In March
   2010, the Company reacquired full rights to the Company&#8217;s SARM program following the termination by
   the Company and Merck of the Merck Collaboration Agreement. In the first quarter of 2010, the
   Company recognized as collaboration revenue all of the remaining $49,856 unamortized revenue that
   was deferred as of December&#160;31, 2009, as well as the final $5,000 research and development
   activities cost reimbursement due under the terms of the Merck Collaboration Agreement in December
   2010 for which the Company had no further performance obligation. These amounts are included in
   collaboration revenue in the condensed statement of operations for the nine months ended September
   30, 2010.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 07-1<br /><br /> -Paragraph 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 808<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNetAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SalesRevenueServicesNetAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EDJAG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (unaudited) (USD $)<br />In Thousands</strong></div></th><th class="th" colspan="2">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td><td class="num">$ (22,612)<span /></td><td class="nump">$ 22,823<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td><td class="nump">819<span /></td><td class="nump">1,222<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td><td class="nump">3,178<span /></td><td class="nump">3,771<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gtxi_DirectorsDeferredCompensation', window );">Directors' deferred compensation</a></td><td class="nump">141<span /></td><td class="nump">141<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenue amortization</a></td><td class="num">(8,066)<span /></td><td class="num">(51,450)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td><td class="nump">1,598<span /></td><td class="nump">1,687<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td><td class="num">(147)<span /></td><td class="num">(103)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td><td class="num">(27)<span /></td><td class="num">(103)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td><td class="num">(476)<span /></td><td class="num">(5,301)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td><td class="num">(19)<span /></td><td class="num">(115)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td><td class="nump">1,062<span /></td><td class="num">(1,746)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td><td class="num">(24,549)<span /></td><td class="num">(29,174)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td><td class="num">(45)<span /></td><td class="num">(88)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchase of short-term investments, held to maturity</a></td><td class="num">(12,450)<span /></td><td class="num">(8,119)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Proceeds from maturities of short-term investments, held to maturity</a></td><td class="nump">3,185<span /></td><td class="nump">14,779<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td><td class="num">(9,310)<span /></td><td class="nump">6,572<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td><td class="nump">48,982<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations', window );">Payments on capital lease and financed equipment obligations</a></td><td class="num">(63)<span /></td><td class="num">(67)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of employee stock options</a></td><td class="nump">55<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td><td class="nump">48,974<span /></td><td class="num">(67)<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td><td class="nump">15,115<span /></td><td class="num">(22,669)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td><td class="nump">58,181<span /></td><td class="nump">40,219<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td><td class="nump">$ 73,296<span /></td><td class="nump">$ 17,550<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gtxi_DirectorsDeferredCompensation"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fees earned by non-employee directors under the Company's Directors' Deferred Compensation Plan which will be paid out in the form of Company common stock.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>gtxi_DirectorsDeferredCompensation</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>gtxi</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments on capital lease and financed equipment obligations</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>gtxi_PaymentsOnCapitalLeaseAndFinancedEquipmentObligations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>gtxi</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 1<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7<br /><br /> -Footnote 1<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 8, 9<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7, 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash Equivalents<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 142<br /><br /> -Paragraph 46<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 350<br /><br /> -SubTopic 30<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ImpairmentOfIntangibleAssetsFinitelived</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from financing activity for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from investing activity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and held-to-maturity securities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquireHeldToMaturitySecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 16<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (j)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph A240<br /><br /> -Subparagraph i<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 13<br /><br /> -Section A<br /><br /> -Subsection 1<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 605<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RecognitionOfDeferredRevenue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ShareBasedCompensation</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>2. Share-Based Compensation</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Share-based payments include stock option grants under the Company&#8217;s stock option and equity
   incentive plans and deferred compensation arrangements for the Company&#8217;s non-employee directors.
   The Company recognizes compensation expense for its share-based payments based on the fair value of
   the awards over the period during which an employee or non-employee director is required to provide
   service in exchange for the award. The Company&#8217;s share-based compensation plans are described more
   fully in Note 3 to the Company&#8217;s financial statements included in the Company&#8217;s Annual Report on
   Form 10-K for the year ended December&#160;31, 2010.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table summarizes share-based compensation expense included within the condensed
   statements of operations for the three and nine months ended September&#160;30, 2011 and 2010:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Nine Months Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Research and development expenses
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">503</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">442</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,410</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,742</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">General and administrative expenses
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">623</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">677</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,909</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,170</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Total share-based compensation
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,126</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,119</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3,319</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3,912</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Share-based compensation expense recorded as general and administrative expense for both of
   the three months ended September&#160;30, 2011 and 2010 included share-based compensation expense
   related to deferred compensation arrangements for the Company&#8217;s non-employee directors of $45.
   Share-based compensation expense related to deferred compensation arrangements for the Company&#8217;s
   non-employee directors of $141 was included in share-based compensation expense recorded as general
   and administrative expenses for both of the nine months ended September&#160;30, 2011 and 2010.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The fair value of options granted was estimated using the following assumptions for the
   periods presented:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Nine Months Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected price volatility
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">65.3</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">66.2</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">64.9</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">64.6</td>
       <td nowrap="nowrap">%</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Risk-free interest rate
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">2.3</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">2.4</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">2.5</td>
       <td nowrap="nowrap">%</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">3.4</td>
       <td nowrap="nowrap">%</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Weighted average expected life in years
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td colspan="0" nowrap="nowrap" align="right">6.5 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td colspan="0" nowrap="nowrap" align="right">6.5 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td colspan="0" nowrap="nowrap" align="right">6.5 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td colspan="0" nowrap="nowrap" align="right">6.5 years</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following is a summary of stock option transactions for all of the Company&#8217;s stock
   option and equity incentive plans since the Company&#8217;s most recent fiscal year end:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="72%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average Exercise</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Number of Shares</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price Per Share</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Options outstanding at December&#160;31, 2010
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">4,430,495</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">10.91</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Options granted
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,393,500</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2.81</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Options forfeited or expired
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(843,662</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">8.21</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Options exercised
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(13,000</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">4.20</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Options outstanding at September&#160;30, 2011
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">4,967,333</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">9.12</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
   <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Number 93-6<br /><br /> -Paragraph 53<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 14<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph 64, 65, A240<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 40<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 50<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0000950123-11-095255-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950123-11-095255-xbrl.zip
M4$L#!!0````(`%MU9#_*-%\EBBX``)4V`0`1`!P`9W1X:2TR,#$Q,#DS,"YX
M;6Q55`D``RXRM$XN,K1.=7@+``$$)0X```0Y`0``W%U;=^,VDG[?<_8_8+TS
MF>0<RR)UE^WN.6I?$F^Z;8_MGF2><F`2DI`F"0U`VE9^_58!)$72DDA)E)W=
MEVZ+%]2'JD+=<.'IWU]\CSPQJ;@(/AS81]8!88$C7!Y,/AQ$JD&5P_G!WS_^
MYW^<_E>C07[]=/>9_,@")FG(7/+,PZF^]H7*;^1,S.:23Z8A^?[L!_(X)W=W
MY%P$`?,\-B>-1M+()ZK@71&8UEI'=GSOY5%Z!/`$ZL/!-`QGQ\WF\_/S$5X^
M$G+2;%E6N\D#%=+`80?FR6./!]_6/(ZW'X%>\OC+J^>?V_II>S@<-O7=Y-%)
M^,)S3^*%P#ERA`]MV[8U;%O)LUR)3LONK\-MGDA>`-9.*)VE+XRI>M0/QS<T
MA89E-]IV"AW:XQMP!N^ZBQ>R#_>:YF;RJ,L*SRGF'$W$4Q-N+$.B^#(60L-V
M\]<OG^^=*?-I(\4#LB7D%%E[K/2M.S8FFM7'X7S&/APH[L\\Q*VO324;?SA`
M9C<2-A^]*/>`-!,%.A-!R%Y"<L^<$/0V5A\GOLK=#P>?J(>D1^IF_)O5OA9/
MV!(".65!R,,Y_L5=_'O,F20:%LOU*>'`V=7/!Q\MZ%FK9PV'UFES\1HVTERT
M-V.2"U>WK'L>?M2<0^:U3YO)-7QG\60S!KT.?]OZGRB`IJSWP&\UK%ZC;>V&
M_Y[-WH__UG!7_/8Y<]Z/_W8+1MZF^!]@$+$O<&&J+@*7N>\@!(`KPW-P$[$8
M^F!#3IN+JQJ&FWG`R"FYMF,_WTY8N7Y:9?VTMNOG-0_^9.*T]R'.5=U\/VFN
M[^:6TEQB7:SA.U@7`+^5=5EFW=_+.U6U[A`W?`UX&C/HD(&<1G@)N_3U_OSB
M]MZ$*N34Y4\`Q/P@YJGKR,>@5\CD*ESW&5619!_CV.X8&CEM)A=)\G9SZ>NZ
MT7,6")\'*YK5`=^QFE+)U*IV7[5PVER`-X_D.WJOFTLZNIZ4CMO2-O+<BELH
M84*NA3AZN_!`&X)B]`9WSH43Z3M7P5A(GZ9R.H4P]/A"J\(=FW`52I#U-?49
MB05\AQ'C&AOYX\.OY.KZC#3/+YJGS56MY2F=`1))O2MHZ^5GR%\JDLHJ\\K&
M$DIGD91PYY(KAWK_8E1>&#M2E5@C&;_K&LMWZQ?(QGX.Q'-P#R(2`7.OE(I@
MD%:D>"VRW5K16)[B/X47!6!`YY?<@T1S.TJ%1@JB,CV_8S,A0\A<[T,:1I4)
M_0M5OJRQ/$$-X@QX.Q&RLF:,'(=Y<>*L&\A2S;68$$L&Q`-D256I@$W\AVDX
M^W;2X@@NN'CQTJ.3JDV.J:>8:3/W/IJB',Y;;7DWU.%LM+"RL2)'C)*;1R[A
M6F5A_Z.=I_*JH5>=6HRGC0CAO\M(I0VEA(P"W$:/'G<N/4'#'(GEF2!QF<-]
MD,N'`_B!]E4_K.URMS?H=.S>(*M>F=8+0T?XO@CN0^%\,Y[A)@K1E6(!:"6.
M14:=P7%U?9E!DKB97JL_M%JM=FZ$K:&9I/A7<?$@\1:*@$L@GT:?1]=G%[_=
M_W1Q\7`?>XZX8G)\1M5T%+CXW\6_(_Y$/7QO%)Y1*>?0]#^I%[$UO$U$EV=G
MIH>-]L''?KLU[(&-/VUN1+9&G&DVNA9G=V`/[-UP_L0\]T%\`>LG06C@K?%_
MSE1L('?EY+!O=W,`2^C5`JT:\SH(;#MD8.0%."IUQQP&/'[TV#4+:^+8H)V'
MM8[6[IBJL:JG06V.Z2IX@BO@Z^#VKGRQ"^+*MKTYS6K]MOMV)9JWDLTH=R]>
M9BQ0#,;?33AE<J04"^L:2':[F\=2@69M$*MQ:]#O[H*P5G8-NNU.*Z^S.]*M
M.%*L=L^J1O=6"DABP6L#D1"X@_9ZAEZPCL'2MEH%6:PFMCNH:KQI61UK*U"7
M'%IEG_D3I!Z0'@03#A;'\+4&7K5ZG1RJ]=3JP%71^`P*%J\Z,'-QYS'4&UJ#
M);J\":6*HZ;3ZBX;-<O\VRV=H\.IRTZTADL]6Y[*+C@JVL[.8',<,F+N9TX?
MN5=GR-9I]_I%+,LI[0BG&F?:MMW:',XY&S.XZ-XQ\-A17=J20;&<P"X0*EJ%
M=B?O9<N!U*\B7;N0'JT71OU*T6U;W0T`%'AT+0)GWPJQH+$CD(H6M-^RUZG%
M<C@Z(,NPKC[&M`JN?C6E7?%43/:&_2WP8`V#A[HR@4DU0(`4F@4.O%"@]J+X
M<<"]#P<AV*:#*MQK[I?0@BVO",55F5HJ);U\8EAL?CO2%6U`:QO2MU3>2*SV
M,E<_=LND+D]MR@B<1RK4Q3Y:1Q;.(VY`M3:0RUFV5Y"FJC>*PJF0_`_F;L3!
MN')8!*==O;5*KD6*.P-;PK45P'JUX=*3)[4P:U%U+2&V$Y[J/.K:?7MH#_J[
MX:E2FJZ7287"]&[(:F77"F0CU^4X;4J]6\HA%SRC,QY2+_/ZSCE`%W*_?$!1
M3K0NB!4]NM7I=KL[0+QC(>4!<R^H#(#!"O**R(\\-'\0/'&'[QP$-=K];F>8
M=U/E5.O"6(V-C7:W-1A8.V#4C)T*SV52804GG.^<E-N=?IYKKVELBZ!B;&'W
M6_T-$&0B28C?]L"15Z68,HKUH-NV?%,%W>H)P/N'+]</O]W<7MR-'JYNKHM3
M@/?48RK.:WX4PGU5;%NS+K*D0%FH!BVC5`^2$HX."T7DG8&LGL,N29NL]ML`
M*:L=M[N#2D!P13DX4L^CCT+JQ47Q0[7(I=TV=8^55*I#V%(B`ZNW=PAEQK&7
M3)VNQ;#P)OJ2VL\035K?GF)9P:VX%*`RQ2TEC`2W[..V`H4`8%!*\4RH\&:L
MQ]H]V/):Q-FV"\L7\C1V)E]F5>Q>'>2W%'1_4,PH:Z5>)G2K,NOOF&)4.KBP
MY!P4PQ-ZDBZ>U[UX<;P(,Y21`ZY=XMS4K10.4PI;K$5+7JURV0'0F_:K3`3=
M8?O/W*\M];K5M@HK`?Z/]*O,6K1T5E)_O^Z9Y\%S9L>E!XV-7)\'>LURR)]8
MW%X]_G-HY6>[J]'>%]K2'+_7>WNT6_MMJQBCOB?:\K"F4-#<'"WJ,>9W\:UZ
M(CS;;A?77A;([`ZA+/LJKF3:&L&6JM3N#NWBQ$K-",H2G9[=>AT?K$)P,\,5
M[Z`\5X$C?/99J'ITH3$LKD580JD6(&55LD&W/ZP3R):*T6BUAIW.6P`I]86]
MP6:2P0G7:Q&(_&.U^K;\D%E/L6YLI9YL[]"VM37MUOMA*UWLTML2VS4+Z[=%
MA9&7H[$C\0KVI[LK\>UM3J^P!*M&XJ5V9E`8UBMI)[,5R;3U)ZJX@Y$Y]Z*0
M;5>O*$R@MX`;UI'=7:`I(5H[OO43_`9?J[-W?!55:2F\COUN\$JY9QWUVANA
MTQ70PO5?&!Z/P]S1$UBI";N._$<F;\9F2G=S-7P]?6SI:>T^VH2X!KL)@CW"
M7C_K;6%8V6EUAGW[76!74=JEJ+O=;FL(;O)/A;H2KUNM?GM+U&73<V>C^Y]^
MN_Q\\TMQ>NZ<S23@T-,!\+?'\`],)WW<:ON'OE[+3(B=C\BKT-T+SM),N]7:
M"6AB>YA[)GR,=&IC8=ON%RH62TG5!*8LY>P7=ENM!J,5^IP#%T,A5;+4M6[N
MV!U[,<NUEEJ-F,J4:2-,BSJE(R:!7AMS,RZL#*YU4K(*P5J!E:[C*.[RK(KL
MRI]1+M'HW8R+NVW,1AP/-^+4HF?=87X45J2]+[AE*EC,_+>!&SB2P<@^9^;_
MJ^#UEM)ZAG`!:@6Z>\%9QM/",HO=<29;57D]%<E6&1\S].H%MC/G*B.+]ZLF
M1F'IOM5:%M7T>R60JR!YH[Z4;\0I;I&NOS.%S7"U%#4*P6,IT?H1EI5\[,+)
M";M#+&R;J\7`6KU6.<H"X;T`+65GOU,V[-8CQ2,.J)K>2H$G;[F?YE\5SNFF
M=>^1$_*GVAC;:'6ZG6&Q\E41P!YAE[&Y-01&UP`;=%IGG`\BGCY?N5F\%I-<
M.+F@,O$]0B[;,3S8!^15AZ#4,T%>#,8KD]\?YC(NVP5'L1UD7/?!7'4IA1\_
M"4]HQSA/-_U1SU,WXWT*H&V.%,@=P+`KKO?H9FF.W"],UM;<SQ46#0--M0=/
M,&S;5A6+NH3^'E&7[0GH]E_-&6T!.BLYW#R&U<B;\:IM1-M:_\%P\.JXE/5D
MTXI/8@]NDMU&GS&6`'V"S!??6MC=FT>/3W1IIA:UB'?>;@_B#;I0NFF]ABXL
M$YD6T<U,/W/QPJ3#53VEFNYJ^[F49H7Q9_I7N]4`G:X6ARVAOT?49>%C8;G/
M=IB7'X)GCG\L1OWU%/"*N=HF"/:*O#1<;_4*FPWJA;[A@8?6L&P93<NN`G=_
M!S-6#$'ZW4*H6QFG_G8*F_"`?/+0OSW0R02,U[4(66&B[49.:!#/%YV!U1$>
M=_4/G.H#L!#?*"!B+D4*-$2I<Z8<R6?)C),I(`#Y6W@93YMX@$X;NM7&Q<?O
MO/`$3W6^.7OXU^T%F8:^1VZ_?OI\=48.&LWF+^VS9O/\X9S\^M/#E\_$/K+(
M@Z2!BO?I-IL7UP=DR5=&'NZ:+]B6C2_'?S;"S)M';N@>`$.^FX0G^HSJ&,A*
MWMFD0=Z$<P5,+G\B%#Q6\.'`8^/P@*AP[K$/!V/@9V-,?>[-C\G?'K@/%O2:
M/9,[X=/@;X?ZPJ&"83<^(3Z5T*D&OG],+!Z<D(-7_<;#O0_!+R]AB;GU4KQ5
M1):[B0>,KWK:`=XPF>^)XG^P8V);LS"%&XH9H)V9AK&)Q^2/YF--M%8U_?^I
MU==:LXK7KZG81R317T(#EVC])F),LAJ^H41VP8-_</PC0:6)\2WT8C,4)P1M
M68,'^.&!8]+YJX;UX\/+(0&?=D2^_X[ZLY/_'K1:%EY-?]DG1$@23AG)/("S
MK#289Q[ZX9!0<LX\^FP.:9&S>#LDX4'RRWP,"^QFR'"IA7G;[EDGK<XAL8?#
MONXE"FG*J/OOB$K0)7@)C-D7YL^F7!V2!Q8@TQ@[)"!&2AZYF$VI]*G#HI`[
MU`/:&ANX(Q=^(]%0:/PN5XYX8G)^J.FXB^TJFB:\YV/,"MR-5SZ`DBAP:![Q
MA0=9L`?F*9S2D"CFX9'^\/J<A,!F%I*ID)`7,3*CX?29SO4J$4T%"8<0*>B3
MC;!%!QVI/(S_)RJ:Z?/7GX!IP+E##47@M`!!RR<B17S=$>Q88`YW4$=OIA\/
M`#\6-O([YAD>_Y$R`1%+,6$!D<P!V8*V^,+%LQ*$5#FUNA_=?5%YG0'E,#N$
M=`=N\/LC,"BP(\"8)=@'W;^>X&?<M*@;NJ/'!CATQ"#^8A@#[^//[T&7&U:K
M\\,1T>0)JB<E`;@9QZ-*6P)71A-EOO&&XIJ!KP2_!AP'Q9E)G!C7&F+DB;(D
M?J0<CY%GJO-V5%`0/-?+@W0SL7`7LL07(D^H;\`UR.S2-X5,VH*;2E-8B#G#
M'N),I0BX0Q25CIBQ@%/R/9TPX+D^E"+;"G0U*[8I54:W,84DX;/05&;\22"0
MVRG&T5=75\`.'F@]"R7T71$&`5JDR],UR24K%KV*2C/;\!>'&W(K'2H:),BF
MC-.!"!IFD#H,_O$BY)7F_ML-DL6A*][\4/=J^9"!M)Z!_+BJD8]:O_O=`=I?
ML%@2Y`<L4:%.5JBGN[P8JDR%A:%*/3"?A$X$;G/**\[^P2=&<LRE"@GHGS8F
M@!?'@/EM#*O6RHP1I>Z3KHB`^@@5ZH\P&)F37U`IP+//H,<X?G73FDBA.1B5
M=%805SQ4<#T:M,T"*3Q/DP2UH^E0`:W@$.7HF@QQ!5P;\_A(I-P02FT&-HN+
M0+@>J9F&/$'U>^L:R0S#?8B`!QHB]-*,I]6<S:K&,X>Q!D9"I/V";BT7F^&S
M)I+V^ZV[N.B>0\UF/H%#``)!_)A2VE5C?M_8>&39"F]\PU4)EZ.[B_N'F^M=
MF!!'5_W.2=Y>P*!G/A\S$)+#D1?L!]*SB#^!4.81%!^\#IT!1W"I5&RD%X[O
MU?CSP9LA[\`S/6(])$Q<'QIJX"J\(&8T4NCR!/Q`EZ:'W%=<%.42?=:>TLJE
MJ22<0+>`P8^'<1P8,Q\/8\+QK(,XS#HC1CBP*M.=@>Z%]B*+BRU],1/K&>\'
M5E!2?R^!U*IP?V7>\5ZQ/VH>=>)P&0=?%%`(-N*=!"XN47'1*F&=$>2GAXA9
M`BW9&#U**DST$"9@-L:$!A":X*.@2V@HW-\C98[V)-]#TSCN=/`S!E\%H;N'
M[BB2$J]EGOT!HC3<*T[E7&LB)6/*92R_!0^QF4S"8O=/5`8U**'VS8<XWB,O
MU"*(-T]A#5]'_E1-R=@3SV9Q-Z/.E)B/JV6)F40$&29=;?J-O4RK(/`<A&M\
MAFG"Q.P@!NV%^YCON$OU/G6`Z$\D]S.X^>+38!IC&IWB%^!DY!CT,"`NX3&"
M'T/2CXW0(GALD5K9%G;XCDTP((=W-+G[QJ]'9*1[`L`Q:"F2&PL1!E@SPO$&
M066$:_*-L*!3)BPUG5JF(`G;9E3N@VM3"J',(V-!&B\;7079"9^'^.18"E^_
MF5/P]6JMK9!BJ3#2I^,89<E`4%,1>2Y@`>VB&BV\]'L4F`^^I3)+AM72-I(H
M(8GDD>U*^TT6BD/R/.6@CIBU9+F>B5IRBC\*@@B:-Q_UPFP[48^?TXA[SJA1
M.H:%3,C9G4(VWK8/"=9WCTBZ0"4=/$DC(>Y_@3P/"Z):80+T^O%OTW":YVMB
M;4LW:NN>0!?3L<VU/NE4'2-44%9L/Z&G\VV?SI'%[`6#NH5;(I@W2`R<\'M3
MF@KV#<DCY)4=L]_0ZG]5NDL78/!\U-UW-_AF5*:&L\30&X5&TX!GY*T>NAIQ
MU>$KF5XUHC)^`@V93[_I!,4P2BL5Y.>1/XM-'6B"J0^-QSJVUUJ":HXQM:]7
M`>K0Q"SLI#H235>Q':85(&/,XKZ;,Z;#S$MQJK!8>$<-*1=CW%@YUS/-E'!6
MP9/QL5)IJ8LE1Q:XD7:`BQ<UB[4;0F,=XKA.&L(7DR'B:!/D<F"+3.P>Y!-F
MB"?L7*/R6!Z_%!X7R^KFS:5WEK9Q._KQXM/=Q>CG947V/53\=ZS&I^T4QN`;
M5X&3G1Z931GO;B.2(%P:3'_H,6M@:OV"Z-F%"(0H/(`0E7J/^8J'=7MP)TG$
MDT1,B6:[,0J=%Z1CPUP#!QK)`/SZW6KT7"VZ"5'6-`XJ8-RI"")VK)G@O#M&
M+FA<()21D@:QU6(O$,FB;>&AA[5?L"*QI0'3"&]PC$1?3&22I#&89!VFEL81
M'D;2QMS,#1K\PB@\-=?F#P*H?.H=VU_CBB5[U,82S"<D77AD+9E@B3M`>+%/
MI,DI^A3KY3)A)78GQXH"&4_'PPX$XY"W24W"\#-]"]T!QG:FQ@2^&3]G#)8/
M!G%LMY`-Z*N%$4KTJ,#TQ^;><$FWE(M@//K(/*;M(H_]%-K>UREBUE4@5R0:
M2&1*@B\6?Q)"Q9*6&)NL9(7I"[+CD#Q2968LQE1O,4O:,6$8F8+LA=1EC`)%
M8]=3!4WN&F=HYA[P3"'^&)D]<5,:!,Q;P$P#'6`3>\'E-3K5?<614;AL,F41
M:<4ZMCK".UP91Z[A)]9BR5^&_8'NYE\&5NLP*;CI*9&W*YWDCMU,352<8*+H
MQKH\#-EJ%+AZ4T(T`Q.`%9]XJ=4AN'I'']4Q9B#R.`[G_F,D56:[KXP/.=,]
MSLT;I8MOC-<'QP9R-Q-!\SB\5THXIO*7Y`-9-<ZGK1!HZ4\49_ME(AF#DDX@
M[(Z3E?3XRS376=:D'H&IJ2EKE3Q#UI$UB.D8T,.529TEHC&,@SCSEHF+LG;`
MR4'-&9:`>G-L.DL5&>-#-(/!)&'Q=[,SEA;-3SQI%Q>#T%3KF14=G.GM=1)%
MC!\+<>/+*87L1$K::6!`ID-FOB&SN$]%*&]%?A>0#X*B,B9-"NGK%!,EC-Z,
MSQ;\K*(FL2@P9$O36*),3&X<1=(QK)S$`6>N?SZ8Y,R[L3^(TR(T;$8.F-@S
MO4)'.ZXT:B\JSA*5'6L4:(SRQ7',39.4&RMP<8":ZD26?45%BF;()&?*@7A2
M12SJ5`K%<(FBXQ_KPE^<1R0I<D:PLWA=G+Z_Z`O:*/0W6-^-YRC!XCN1I[\A
MGZE5Z3PR/N0"&\.D5'=5./_;WK4UMVTDZ[^"RBI53A7$PZLD;FH?G-C9]:EX
MG;*=.L\@"5%8DP`7%U',KS]]FQL(0*`D4I3,ASCB#=,ST]/]]66ZJ1L.:-]W
M(%1$88D*5TJC[M!9/%9U]!3US/<?5AELXR\2Q_9^CY9D+-F!4_J*'3BED#BR
MFA5#!Y'O1C/,ZE<0H:0ES.+LRN]>7*@UYEB,!-_Q8]8EV5:@)$Z\ZR)%5E6(
MJ8H1#FAK?[:/GU6,TE/UVIX56'^N$P[:`!1@`<"CR+6;9"'L@*Z@.G;33U#@
M&-%K@IC"I_R"A=9/@&2T75O22T9X63HMFP*KQN27%59&+)RC@`_*('**73H0
MF,#OD!/$X<C0;Q,#\>@`MY\.S%(@MB+#UU=.0QT<RG*0V`2HD[L(N#>9;\Q[
MI6@U0I`YYQQLT$,0`!<[8P%#(\(6P0*XFAC5?,-1B`@&7*VEES@G%^$4*P&J
M$R-8%UZ1T%1B9:.<=B)&G,=I[(K`SG8W-,(-BU587Z6DZM!WDHNT3HT=B9MC
MZ$ZJ:!47*?D6P.R^A?ESAD1*=ZR!;!KG+:M#GV%AZ'A6M%"F$:)T1HIQTT89
MXD@"N4J`@[1%+;O+XE%^CB):$2S#H8AE'\]2JHLX($7]JL(UC:-J$&-/")5>
M"L0?4*)AJJSOX;^>E3%+4_QRDZ1@/(,^\OC^"*GNHW$=$`C'9A=@)LUOP)9=
M1#`!9#Q-*R\WQX\7R,'J_A-ME.5>%J%&G@!@LDG(`9O0K,@!4SWN-;D:S:W,
M[)J]$H[)@H8\"UCQ$F*&4DAQ+%XR,#J!TJTUFV.`EI!O$&_[YWGU\".$1^@G
M[^"Q+EDCI-@Y!PK#9K<<#)$$.>6D@#W`3B;L"K6(M0E%K*D)E(2[7*(K9MX&
MQ5(N%OL/@(*;<#$3L4:_=WY$I("((H_K#/VS*(UY"`F68/SZ3@0LJ@(/$PS"
MDP_T2'V@IGH*LM#O23P_IQ;/'E=&.!JAACD)X1KT-5+(Q60D<(!:.S*S0#<B
M:+S4H]PVE&#DY)FSQD'(8V(-TRB=%DLN,L:Z5^+-@`,3$I"PK3&'52A<H%[Z
M)C@F\;/0ID'LFVU:Z7`AP46&/J38_A&F#U:X1"UGUG618_C$A,P94<%;1L*0
M8)!+'1*R8/BC?V4[[^"GVLM@(D*.QI^$DL.E?^9[F#T]YZ.^2CD#"4/YY*_$
MC`$[=D2V?IK\)Q0GLL1TT%-Y.-7QR_W(!F_09(A52HDN6TDNY=SEX#H7,XS=
M*[@T6SOEN"5)6I-LY*0C%I'L$@C4>]K%H=)F0*&+G\\U->T<'63*RLR<2!=&
M8E8D(YV9CW&;QH+LHW4X$\Y/.F=SM>>/QE=VN,Q1=AQ\+AG'.O)+;*C&5*D7
M+E6.,L;'%W'`9>G0EXM_2.B4+VG2V[;AX&&I%]S!3ZG*M_C52H>W[7KZAF/7
M.V"ZFDFVUE62F7!N46:30@N,U!`1EE]LR8LD/BO6H[9?C(S&C>6H4!'W:NL3
MS%:*E,@C.%T"&8GF1\S,_+J59V^S]CE+`3$G#YSCOLUIQ)Q6QD4;H\R-#K.I
MH>+"I;PCM:(->1/;^/*`I@<7&/:^!G='D+10&?N:234E+T<:O<FF;/O:7ZA)
M"V!65>DD.K^$)2?^#(4!Q:RF+#%%H9.0,^BUG)FCTP)<%B`@@$_5@<D_Y4Q&
M>,LCOTEF?ANJ26<:D4N#.(YZ3@:@H.4DS-=(HD.6Q964JP`C351Z8L-"L<H-
MXX"#4S@1]F$`0."D##O'R'4R&)*8?#O&A;[(E,`(#2/9P.@ZPB`DF>919CR]
MA$C`QL!%2Q!X1-_H)@Y"#W29\1T=Y%XMK6UONL01ME>9DIKQ`9S.19*]E"87
M/-#\HS'9!(Q#[?NNF"BK5?Q.)87L5`?YR`OW5Y@F'8^/*IM8=!28/?"NY@13
M='&-K@O.V^.+H.,F_5*3".1P>&T$JV7^V?VY9X>3=%2#31:1MN=9Q1U3$QEJ
M%!ZAPTG&`&AL"EF8\UZU$U/R'94])1IF57LB?&L$5FODRPUA>A[Y,>,I'#2\
M@QQPY'P>1(*OT710;N9$1P4P_JI;%<BT\#C*TP^XS5],]L'[VZ/RE:'/1:Y`
M("A;+"RST5IKT3HJ+L68OU$<%2OQNZ1),;\Q:6SWY["QI(FH53EA9GA%;\7D
ME`E3I=N4H4C1=:`7]MMYR\KYD$E9N%V<T7KN#=Q@WK!:8>SS"KNJ0_`>KPS7
M5"%H7Z?@G4X\I!(ZND+Q9X;[U%C(U'K6!;9>;26"OE6)X)%K<W!'VV.D4;_C
MT53.V1E@3_<9A!"3(F:7"OZK]*:,2DLE*Q;SL-FYG5I1I7&<7Y"O@1I=BY6-
M_DDT$E>+0#2&1CA3NT*XD_719'>B:@F7JT6R"1%>2AUPEB$U68S.0**"V'='
MN?P5J^'`:N-*MK,'\,;[#(3UK2R-2#61<^*1AN$4J2PEMTEGOQOW2>2;QX1W
M[8`5(>T[=B7JM:'QG?"BNRO6M)SYRT9L846VB1R\.'@L7FR%%6G@I\>+)]_^
M07S[]3CG.D'KAI2^8((E_)@.9"USJL.I^4B231L<+.6;7>Y5E7ONJ-08<\A:
M?V^U6+)%SL<RW9H%I.623&A>:KS!GJT"K.J%[4N\"<7WZ4_\:!7,9NJC=33+
M;_[Q0Z_;_7&[#@YKW:\T^K_P7E*)87.28D3V),GS9&D>X:FOS-000]E)LT*T
M%/FLX3>#W7_2V_TGXX.,<IK+:2Y/.PJ_3LM'LJ9D4HNCVI;"UC.)DW4:K/[Q
M`___A[(:FB8HIN"-"Q?=4E,LCVT3CXP3HW$>3]6^J4>[ZHF)?TT[K:AFI73.
M-`+EJSN/+&_O;]1,N>LNJE:P>`'TR+GA*&;X>EBF_\`%1?!UU)SRB(EU7^O$
M3CNVVY%6KL5ZD%X&\K\DL\W]0%[/,YA^FZ=)$<_^[OUM.@W#Z^LZX5!EQ]JV
M:6^TNG.-NW-\JUU2^Y;M]`2[7B[8>7;_=U/L]$A?'G4'!V301Y$Z'/9?"JD]
M?R@GY440>_GPE:W1S^WT\&..VC^YN@*G>\V6$=9K2[EFQAX/VZX[8E;YHG_`
M@_8(,B\O7P*9/7_<';\$0OM^[_+!DJ`]^)5#\<1GS%"V#[U51BLV/''6L016
MV,5:C52>8\]/\SC-XXGTY('AZE<J>5L7=#@ZK-KS>_V+EX.J>KT#:JC'$3OP
M!R^)V''OJ?'J2U>I3R7^!B#^9DF!!O;SR?'39$Z3><+C[?J6JOQ&_T.1:?>M
M`^8:54;Z[=I,\WMM78KNT_TX*Q.GXAY0FP"_23*X+QV!1K*NZ.PE@XGN.`U'
MG-'28MF>B!H:KH&BWK"W=2?FWO2-BDVE<1J<&/;.[GY#1F_J8:\/.9EAD@*7
M<=8<YJX$F76#DF]1Y$YBC'U9T2ZZS;EDF2E!?$I&^8X2!4YS.<UEWW-I;Q\<
M>[SYE(SR_>ST4:1JO/X9OAZ6.:4VG))17O[$3LDH3:[&]^I*.1??ODVP`*$N
M^F?;3/O;;>WA?6`T>M1IB)J7!\6O_'B\<[GH-'BM7]A<AIV&<,&+FTM#4*G5
M7&IPP?Z38#Y'V;?S:P3V^IYZJAJWO8@#WG\]Y[O?&;Z>J8Q>RU0&C]Z5=H?[
MP+K]_T*<(3J2L0[ZW*H?LXBNZ5XL7A-]U@PX#?"Z/]3MK26$.R.F^'`$GB9R
MFLCKBBFZEXNI'3S?+=Y0:6B['(%31^7:J0=57\N`Z-ZJ9[!5RR##-VJ?M$P0
MI(13*J-'G>KTC?;O/)ASV?^>'.VO:2XU$.%X_(+'_KT=G$4*Q4QL&$1/?MVN
MW6/_WD.W\*T`V/=W6`0U"[^#K=R[:_3?!<4\0)]3ODSV^#4]PDG^05[-/[#F
M&TYR/WSS2ES!GR27)BERK*Q.C;^"O*%^T',:CML7__SAH.L/QPU.B7T1\<#<
M[VYGW'MB\?4TSL1!]WXFD32MHV*!GC\8#_Q1]X"7*A].;+]SM>?=WX/X:,,9
M8"A>AY'TY:/VFWMADSVY`M]<#0?^Q<6.09B?GI.3KCK]ERM'0D%T+XE%>@._
MVR1DCHY#AIW^Z7II*PXYBFN`Q_Z]9U,_#T"O#6GO1X5=AO[XXM(?#%[$_?]Q
MYW2WKD3)298<6]RDJOKY(\MF/VU]\_?20?F/,*4Q7V_E\H%5N;QVUB^J)OF@
MXV'!_"EW+XD6!=H[_PYS[\WO29;]))TQJAQ/]0S[]*W3A+Z9T(>-,=Y@RXF?
MS'F4[A(K()0NIH'.S--H4G"P+$^H\U02<VP/.UAB>]*(<P:FP6):\$TZI^3W
MNIQW$&M7HWH:>1P=7;W5XH`OH[W;B?9%EGCSZ!8>+;UUI`0WK0`%'Q/LS(EU
MMRUB=-A2NH8@':58Z`$[:VUE;205R`9+G1?I]`:672^F.R%\/?)[8*N,AP/=
MP63HCWHCL%XN2I6>=[XJB+VC55L[:O(#[X_\X6CD7W:[]G#='@S7?UCKKMK1
MJ*T&]5##)V#;-!J.>R@R4_*27>_(_')5,[-ZU:OE7R?%8L;]JVX"GEZ`(>X\
M.M?L)5PGYZ#5D&IAY-;BJ2;[$]5DKU+_M;KG:17[%TM6OJ?T!_R2P1ZO5]$/
M+47?>A5>E.(?=C!A!:4LS>\9]/JGV/L8;(Q$N6!9Z?86O8X6J$&\7TVK:91G
M;[&))=6:;.A-\5FZ6]($2@]`7&/:<NK>[U_":1KFDD/T)9<OTR?JQ3N`V&L4
M>#`R",$T1-6EKFP;@!`4^4V24G]0H]=JVW59^L['QJMRG?RLV^EV>T;(^D9%
M7'31=X?_J><#/;U^^5UN#8)=O.8)-^15"X?WTJF!+G8'GFP:*P,XH$GZYU;-
M@W2==/;X&(8*@-@GB#L0)Z6]'^VOQ64M\_UO$8>&@OY5%?MA78-%F'-#6FJ`
MLTZC'*`7H);)`F!I@HT-99J]\N(3\=BX+7>W&)<PD(LJPK_Z<=[9L',Y,EON
M]'818"B5!133:;IH=[Q!]WP6;'3NFP6PBA6^1&4_FXED]'H89[+9J`R_\D0@
M);:XP7_.L5^A[A@'G!YOF$B'#NT/YP:75B*=(F?F4D*C`,;J#TK4M#DTR%#5
M^VFO==7J@JTC-D!V@UUWIF$XR[B!K;,OLLT$V*P6\XL-/'),%'-+MADV:,R5
M!:"7!-Z@8:BQ<R&M-_535?F+'7N@M=9,3PL+?DT6BV"2<.F.MZ;"R/<`#$86
M,-AA'5X4-!@A--!3DU/[NW2(?JO:0F=[A0PN1?@'-6O\,XZP6RPFXL)A_AK&
MV-8/S#Y=BOHW],\SU344'T/31^J["Z]WF8[=.OS/KY]_TR^Q<SCB$>K7SC@@
MT%X`;HL8SOQ[^G[K9M]OD"YKJ"]O/W_<7DIG<!#H61$0%J-Q3=]?-5_$&DIK
MF8[AZR1=S-;1+/3(G4RMA*D!YIWX+FCL/)S>Q,DBF>/<DC4U/DW5_/(4&)7Q
M"ZX)F^]3@'I!1`WD$=TLI6DS2.X\X6\8&F1D]`_)KZ3_,X[-MK@:?\,M.)>@
M6R>AJG?.8ZO?9M,(O3+8KU504MT.RQ1,ATQ0)+(95,X)9R,=]]3#];+0[3=@
M+WB5%Z+&]09F#&:1VS[=1+PAC%T-*:;U-,]S>W]=%(3Z&]3@7-6:6@6\W+"6
M"/5H#,5)RP#)BZEO\W6(/6$7R1JSY.>+\'P6S:/<2Y--L"!6!;9&WT(6+%C5
MJ_;OM$G+:.;\CH9Q?IN1<I9:4[=A7#1JT"<^SV\U<D%'3EXZW;0\*Z`J2HH,
M]I;\!50W2Q!8PVEDETS]B7R_RXEL>QKYY)9/I'"B>Z>!>I7C=A492IV<N(Y*
MD8E'#RFD;L+HU^+WTG`978<QF2)\>&_"9;*B;5,MVV'W:2$`BP'WI-C;&I8$
MZ&A"@;,04*8`70)7V-&UP)[7J>Y#/%U$<81W+^PF!?A,0U:_ZRWG[C8:!(OX
MG1:$T#HU7E>=='&J-,;6AO`Y)#ZP7,+749KEWG\+D-5L)^[+[*E1H!]6&1@O
M+=3[L^I*V/@*;VJ_V[TH;9%SJC!069K6MGZC7:%5(.++AZMJ?1YRQM3YXN>5
M]0T-+0T-WQ<IJ!$0"2"?D]CWO@"%?X7I`LCW`7.FZP#$RX=IR&_`/MW`@<OR
M,(I]C2/8D[,.033JFH@?8$E7(:TK*X!L:[)ZZ*]A"C9*DFZ<&5)503HPK%9A
M$#P1L,]_A?;98;4M<YJABX7]S%N+@KVNM9(C$^M32G/FKZKFLX@![`?!\V\*
M0,.\;+"6P!KL\D_#@`Q1MBL=83)!QTPNHH1"#BC61)#`4N/F\+(<3F4`6P=3
MK(E(VE$[G5"B:$NWD0%]^7@51#-[99E@WKO!Q?!GL:'1PZ./P+7TP335&:/E
M!'B8'DRR]K=PDH)@VC@G[JITXKCU/`-,,%I`=24QK:LU?(]&?U,RDWO^\*K_
MDYEV,+V)0H9G:O)@IM,%/F#;50*'6LX(._"J70#BGEE%MU3>^P]R='SX\,$(
M_1S[E:L^XR5M=(5B'QD]1;-=NM^FP10A(#$>4,<4EY03PH^W[[ZBXP.O'B[)
MID?%JAL.4]E+5R()2+%/?X4^Z%[9^.P>?K#W1M7;9$>#J@<J@Y+SHS_V!X.N
M73;4#%&LX$3")%KQBX7S<=*3D'V+"5@@?REYK`>.\6HF6-TH^LX7&#>;8(]V
MTS39E,=$SQI>D)0I&&TM?94IR.1('D>$:CEVBCX=9T?@#^CW!</6%C%EGRL(
M[JDTPL9&U!84C>A_>O?A2(*:7=HMAD56*(R&A\5U;1-+,\.+S&D!&GR2I(+8
MWZA!+$7Z5CYKC1XZWKM[,.'VT6:IPL9!C62Q+S;#,H$IAF.<7?G=BPNP)LT!
M5=\GBQ9/L!870:8`1$._;4?J16Y9X&K"RMV;3>=F-5Q%\^:=8NR=ZK[OVV*8
M[4BAZVPPN*!-!_4T&H^JLPEV;1_=]64,.]2O7<JR"X%"*D8$EV7V`>V"CX#L
MO@E+=P=7/\-"=GR,DK7R!3ZWL;#-JJ!&+WWOGU_OB."&V=EN-?J:`X%+!L9\
MD4P02V@X[UCLA)&=M:JUX9F@-F;&'+5DK$1%%0A2.2H.]?3)?PA#I>),]!V%
M6D;TFAW)(83`"EV/F3@H&"]HGYCVTZAB"B8=R0;N&/J22DT$,+=%?[=1]/,I
M<L0_42>"W_8P?`)Y`@*5\M.R8E7!4E>C'W_V;C$*#*!0%4@@?@+^8@_M1V)7
M^#F^\EV]4J%3;%AJL9D<Z<8M/IS-89!D(T'N/BCKE7\2Q%5.6\?KQYY*M4'G
MBF&4<P@7YUN<K,]ODK4KIU$A%%*W+]207;&LT@T5/*E8T+=6'A49FQ``N$C\
M8AX<YO\5>A4<8TL?4`;^P,Q"#\'9&+E0DOK:G!Q]*HQON'!77SBFFB5D$F7;
MCB+/#C9'@A"=4SB38[=.7)6ED6M\#?A[+<.I=%I5:-:O(^R,,O"ZRIR9<JT3
MRTI@^9#6M0G%BBRW$3EST;W]WX*:/E#R`#JW0:[P0\A.""0Q#M4RE5"QDRL/
M';_1BIJ!%D$-6YVWVB_\XAE(P"NSA%)C9H40MUA2X9CHEH8)<&EU(P#)!<7P
M<8BNA$F8K\,PEHBU1/LYYBTCB1\T(6)T-+QM:)V&4RY/?I?.FH[D@T`D)J'#
M+?IP)5GG'#-G$[&%=6S,0K'YZNGD8<(4N&Q)+A6)4E@^)<=W8<S,!$,XRMB4
M))FSD3HBR,F"X!QNUOL!6T5-*BIQQQ7G4E=]-*Y="PEH-:Z'0?3WKDS-JA@M
M3./=JX`MY5LWD*V0&S6F3FQ]H,9$TNNL)9Z%HX_;<%JUM30<^U>C>G.)71];
M)E.MN=0=D_FX#F&P(),I8,A.^*U./+(4-R)R6[QZLZ)6LS6N)?*O(E<S`LGJ
M*I\M7@A2X91:OJ)C+Q9A1N%HRR9L8.Y&NW!'FY"&42;8CJDT.^1RM$RF^2U)
M\AC?^1)2Y3'Z`(>\FZ0+^//_`5!+`P04````"`!;=60_I+TY&_$(``#_70``
M%0`<`&=T>&DM,C`Q,3`Y,S!?8V%L+GAM;%54"0`#+C*T3BXRM$YU>`L``00E
M#@``!#D!``#M7%%OVS80?A^P_Z!Y+^V#8SMIMZ58-B1.T@5PZ\!9A[X-C$3;
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MIEE77>H.#KM'@X.5C#K*!X)3/,'30#_^7;Q>XI..)(LE5;#UM;G`TY/.+%X1
MD!\,^L='?27]XSD/DP5F\2F++EA,XO45FW*QT)@[@=+[:7*5`Z]TL/`@Y(N>
MNMVKU]!3\$)$PX3J*R,`DX.)5S%F$8X,4*5SA^=EJDFLM/3[03<P[3=_(A8%
MJ7!01FN<Z6+\&:(J.&[F&,>RR=?6QGFR=@-PC018-\<Q`8]OA<8J68:V);B;
M&/J[<K@<3\=+U?O!RXUNJI?:T5^;RH=(SB\IO]\*44G(`L@>[XV1;8^/+)1A
MN`L><,#O(8=>P]20F(D%MKAZZ%UZI.1A[B958Q,7>>LS?'H`FB)YJT<A&-)G
M""U[RBL]3&-IKF@_=?N#;##Z,;O\]ZF4@&68"!56Y@$4W6*J'UN\WWMA>(I$
M&#_4GXM_$G*'J"+W-!XB(=8PB?V%:((ML!WEBD%P*O*6(1$:Y?"S%!?YP3]K
MT9/)(AVFN@2"P,A/!5]879H]CV\%G(L("YC0.T$B`1-?JN>I`>$>JQE:WWEI
MKO[`-/J3?T!Q(F"\OL&A^DMP37`U2OC'3R/DC)E#GY@Y#4.>0!A-<(@AI&XI
M_HCCFCY?V]P_3NKQ9H0<^43(%;L#;%RL`:B%@/QM_QR>QY<Y^(U/#KX6>(E(
M=+%:JJD7!M0QY$RB:;)SDO*/#B?8&4MO?6(IA5B9=;3JZ](@8W7G3SZY\UIP
MR,+C]36DF7K5!0G$4F6A]E&FOKE'KJ\'FC'QLT],7!(&!H[('8ZN6(S8C,"D
ME!IGYZ))P",VFJ!F?/SB$Q\C@FX);<A&;8W:RM2NT5KE,<TY6K%A*X%2[=YB
MBE:$FP7+L4_!`EA%@B.GF*EIZR\358C-HK+O$QOG>(H!7S3!D',F-3VBJJ&G
M/%3!-21XM;3?,`?FWYN8AU_FG`)0J>;B>%T_FE:(M$U,K26&IKI^XM4:OQ!/
M'SD+7;O*9MN](*4&O^'&J^6^7H]M&%E+3EWCO6"GS@!#CU?%`J?QK'($>\EJ
M.%\L.--(*@O?I2:MQ$QSE)2!FMCPJT01122%<8T(+'B&:$EB1#?0V[)"!R%/
M:7&!;HCRJO@QP3$B#$<72##"9A+RW&2A?(LCF"Y(2&QCK8N0IT2Y0#=$-==&
M?)]3;"V,=<V5AEYAGW>'K=^&/>]L#_BP<@_X43[@T^!10_`J82B!OH>CUW[L
M#&?)E:T\^WCKQ:=J1+','O^>\ZBBG&9OUDJD%]WX$-%6B":FGZD@4CXAH:[`
MW$O!63P-O0Q#P8LU[;QQ8PU&LPOK52DCZ^UL=L5@/,$C+FV=R]JJ%9_7X'V<
MA0PMQN->U2V&7,9J@LFVQFSN+C=I`^1XJL>`&YCA*C#F6K02#E7.?,SH"RA-
M2'A5)YE@B<%B=<CF'(*7<KV3E-ETL0IIH@['GH:09`BUPW$M>(BE5,999\(=
MM'G)XDX6&<:]JK[<8`HZ9^FQ9@IVG48+PHB,U>!VAS/3;%F$HZ"7/+J"-Y0U
M5V0\G'[*3C#F5!<1NBV$(.1VM7-^X7XK[K9B?*CIV;@POO:J#J"KCQ\YXWG$
MU;V\2<!#,AH0&UZ:E_U?:6%</GJ=K8N/'-?%2D&@-?BW+E9G"P$>S'MW!!Y_
MMOXDU3SXT$-.0QA?=67#WM&=A?\?I*S]8DOGFTY30&_ZB%?'5,[Q4N"0:`?`
M;XJU7V'J7G`1DW]S;\[DMO-<Q/:,+S>C#(U>'2"YF2.!]5MP0[Y08W(5<54-
M]XRJ*C/,R>MG*L)4%+/.81T20F-I=H5KG.XBL$?.=S''D.!576:"0SYC>J-I
M/"WLYEM7V77-]XBP9F,,7=4UDS;6+U>+)2)"I6?C:?'09WH>E*KSH!;JG"7W
MC$5GNPRA7I5$(!,2&`;L<YS^O6+E=VAL9#J)[1N33D89&JO+)*WTRQ)V\VJ.
M??G1T'[OF<M98RCSJQ14!IV]OF.F`NMK/$Y<NBG:>Y+=S#3L5Q>G_&"_<#)^
MJU'W06;O.2U99.CSZK4>*^[":7I7`DMBWP*'):,,C5Z56>SOV%]C07A4-,NV
M&[N5>#N;0T^P<*-0YAP2AEZORB\5!JC<0#ZU0&L5?O'W.]%:5\C_Y-GV:^6+
MD1;#MA'V:2BJH>WA_=`M3#,OJU?7I-I("TH65'UFPH78:ME]Y[7:,D-K=96K
M%5K5V0@<R4MP1H8:T.K\-;5,C]&4RO%T&\*?0^N^A<)SV&R"I/D\TC<P7UN=
M:CS@53&JPH!+PA`+GSA?6X7;[/Y74B;JXU_C:?VK(PXR/G7=&I)L7;?"(A.6
MS_166,5&D9E.QN:EEI'J3M#M4B/P8YHPOJ5DEC_9O[F!]$1%>\3;+F8:,OTJ
MNVU&H8ZZL88E+U98A$1:]RX<9/:(4T>+#'W-A[J^@4G2ZC+C@2<=G]KI&Z]G
MB20,2Y7,G"%)()F!#$>"E=E>KM-W1AMT//]W7IN>F"G/CH#]U-=?R#PG,J1<
M)@+#/T:#_MRKUJ$.@5EP/]VU56<4G#Y%ZGA,8W=7UI\<V7#A8=&%6K*;?GK9
M@G*'F`0Z0G48G-`DQA%T)'6`*CU*!7U//]<Q,ITT?87X='INR<5'I2A5>G2(
M9IH"4!6\4LI>!ZFZ`/0%FX8\W>^Y!,G%O;4YXNY>M*2M&\YZ4W16VCS8A+.+
M+S;>\0(F1R346SXS@=,SHZX>:E3S-?S6^-"2-]^6O;FA1(=@IB8H@7_X2CG\
M\Q]02P,$%`````@`6W5D/RU[K"D*&0``5$`!`!4`'`!G='AI+3(P,3$P.3,P
M7VQA8BYX;6Q55`D``RXRM$XN,K1.=7@+``$$)0X```0Y`0``U5UM<]LXDOY^
M5?<?<-FK2J9*BNVD;N:2FV1+D>T=UWABK^7,[M;6UA1%0A)O*%)'4+:UOW[Q
M0E(@"9#@B]"\#ZG(4G?C::`;:#3>?OSCRS9`3S@F?A1^>G7Q]OP5PJ$;>7ZX
M_O1J3Z8.<7W_U1\___N__?@?TRGZZY>'6_0G'.+82;"'GOUDP[_[Q8E_1_-H
M=XC]]29!;^;?H>4!/3R@RR@,<1#@`YI.,R%?'$)YHU!(>_?V(OTM\,/?E_0W
M1#&%Y-.K39+L/IZ=/3\_OWU9QL';*%Z?O3L_?W^6$;X2E!]?B%^@?GZ?T5Z<
M_?67VX6[P5MGZH<D<4+WR,7$J/@N/GSX<,9_I:3$_T@X_VWD.@FOI49<2$O!
M_IIF9%/VU?3BW?3]Q=L7XKUB=1!'`7[`*\2+_Y@<=OC3*^)O=P&#S;_;Q'BE
MQA#$\1GC/POQFC4/D_^!R;_XGLG_0_KUK;/$P2O$*+\]W&C5^5"0E3*=6<+X
M&"5.T`FHS,G0,KMB?]U27`7$^"7!H8>]##,34M.VO`QN$ZG0R"V("YAY1'$F
MC9?YZ=4Z>?%_NXS<_1:'R2STKL+$3PXWX2J*M]R:9DN2Q(Z;%&N.L=&:N;@X
M__#^G-=+"T&\C7CYL[B(T8G=K!SZL4'AE.+,C:C/[))I(.I4L*_B:-M!NR1J
MP?1;L`QD;0JJQ)A$^]C%7>M;"*<=`>5D71T.I]\6K4R!5\?GK"SDA!X2I2&I
M./3WK,!__"A8C*RGX#^\\)5#EAP![9/7CK,[8]9QAH.$9-]P>YF>7Z2]R1_2
MKW^;$8(34FZ)M+YT1/9LJ!XF,Q@U168=R,@\3%J4CH++B.!;&6-M-:EMZ/-L
ML;AZ7!R;>R!X06]<G$AID?;M<;Z/8^:B)F99H86R3@WHJI&6"`%M58FD8AHI
M%7(XST<`VS7#*6@G*,,+;<MSAVSH*,/^N_J_O?_D!!05F25S)XX/-(3^U0GV
MY2&J):]]6V^EE&S[1HRM1O6!7*$%L*IK4"8^N+OL`SZR6W62033@'R3V"7(2
ME$E`7`14D/(3#FCD_HN3[&,:02VPR_[W<=8M:&JED<N^\Q@J(KM-`PN$PQA!
MJAC:8A/%R33!\1;YX1,FR=:ZGW0#SKBF233=IGSHR)B/-6#AN^M&>UJ-#]C%
MU'&7`?Z*DWJWJ&<!")X,5"C$4#7T$-[0C*<:J*0L*,YY)BC$B=W(J@?N!PDW
MY0)W@QO:H814]H&"T:A;)+%OYBJ(LEG+OT.8<;7\2O/G)%;MM`TP;HU01G@?
MXYWC>U<O.QP23..QNV2#X\($1J.B$:=]DVVAD&S)!FP0!FX,JV)>*2?"@I7P
M<#EBW,@M3(VM^D5_?5)6K@YG1J49-&Q2LB&,@?:.1C\`MW@36^`+(I!F;`*R
M9)83Q%$7K7,0H(FT/'2B*K4])D4['">'>XJ0KWC0^?V.3;ST@5(]"\0HU*Q"
M<?C1T\.,.TUX%!VT8.$],\[H[4\1>D"?(,XD%KZ.&@"&9]=^Z"?XUG_"WDV8
M4,P^G;X(?]8[0Q.3?7<P4T-VB'H.")<P0:0(\C-**?YRTI'!MF=TTD`P33D7
MDM3)AC=`YQ`0:@<]N!A+'US!156U8S]8&-40/P&'3:WJS*[]W_K.T@]X3I>.
M<XLD<G_?1(&'8\(&K^30L!)MSF[?A]JJ)GN9*2_($G8[<!6SN[V9?;FYO7F\
MN5J@V==+M'B\F__\T]WMY=7#XC6Z^O.WF\>_677AOOH<V?.HBX:0T(O@$BRS
M71UU#*#>8["_0T\-[2'M=GH$1T:[VSU:(Y88QK/Q(ULGN7<.;(W$;#VN3`RW
M$J>&K5J#*U)"KKZID.C7KW:"&F2]K1W2E!H^)>NZ\1Y[5?_4:ZNC!S'L>O`E
MVU83`YEW'1B5W3#ZNJ4*J6^W;?^=5%'U\%!><(E7F`+P'O`3#O<-';N.V+[]
MU\.6C5]-"6'Y=4@JMI(1HUA0HVEN[KLH9EOMK9IZ-^PI-;B1&_?QX^C<S7KU
M<73GQIU?<0T)JLLVAJOJHP'334-6,^@`\Y6:?YLQ1J8''V:JX&M&FB/Q"`:;
M,IC&\6:"`DS(F,8<<Q7R8>?(`F7]?!.*Y+R-YE_'8-_^F^'+#J"GAO"`)C05
M^Q$;AH(H7(L]W5!C5$?@A1$+WO+GT7;KBQWQ["!'%"9^N,:A2^%I]*[E`#@6
MU*Q`X3"0GASD"%`3G&JF],@ASO_(/'8/__3&/E=CM^L!K=?<QK7*UFY=;60K
M::W7FF2&UWR'4G*PNU#0$W*Z.#9+DMA?[A.68D5)A.Z=4:P?,`>-0HZX]HQH
MA0RFWU=!+7?V,@U4#U_%H.P:HQ`11C=!_WG^]OS\`NV<&#TQIH_HXMWYY/R<
M_^-=Y_?'/\F&&@_M4/?))HK]?]+(VDG0@E8?WBYIP/'^?()8<W.V2^RFWU[P
M;^EOE'>'W<1_PL'A?]#W[R8_?#B?O'OWGM/_U\7DAXL/DXO__B$KQB>$)4=Y
M>G>?L*MKV*4\W8NT/F29-\9"-`:GG*`;KCADG)8BIWW%7;Q(V*TR'-H]CA>L
M;9IUUG."^F^30AJ7UK$!>WD]K`;'SST>RBVZH4\]A3*C*$:"7?@-H@(0ES`"
MS^$XR"SO*)NKH\H!ZBDZ!30>4B8']@PUG`:/J(QN4)[1#GWJ$8()S13H@;U`
M#&>F:F?4([#^(O!:RQ>DH[!Z&8J9Q?NE>`/"VDU0%RQ]1&&2`'1WC%%-E2ZP
MC,#@%2K46KU$/PK3K^`QLW]I=@'K!,;X2YYPIU+`\N8IS_/9@I`3W#N^=Q/.
MG9V?.(&DHF[/C`$CP'8J8W4*^ZH:N4`V6!FBJFY/RAD1.TP]]4/D"EZ[NZH&
MP,\X$<6?\DZ0[$A0/O.`$\</L7?EQ"%U73)SW?UV'[`IS25>^:ZORPN;,-KW
M&7-U9)]IYH+P&5-4JBU]&2'R!*559^D,/&-$&2=Z(^N2,G\WGK43XZSY.-9*
MS-9((&Q=AT*SE8@H%D:`UT7ZKX<`[N0:M/K'=:10HW$SV_B.$*K<MXD'>/ME
M#2:-;4D;7/B""KBK=]1&?4YP'+LU3]TJMD-8OK.NZ7;U*AE$>*J&6@Q&BS0@
M6Q74(!0!FR"SNRFA)3CP?08+)\`D1?.G*/)J+D)1DP+$CC60"]&C@@XD?M3B
M4%V=X^W=!!'&8O]*DQ9(.>EQXS"G[GA]B>8MDWD44$E1S)_)2`LJX:ZAL_S&
M21W8_$T3%='@!JEJWX;2%5E4B31KY,$ML<9U^@&.3P382Y]RX:6<`C';0DI\
MDA`4K5`8A5/J'_O0XU.Q_8Z:&SM8X!RVXF[VP'?YW8TKS/J*&/O;Y3XF6&SJ
M7$4QV]R#J0&+N]T]6D00[<13-&S'3[KQF?VV]:DS)U&(<^GL+I;(]8]O>"4;
MS'*".R<\O"84IXR>B<C`..L8"PAOD5I'G]]Y'*U#OD%JF3WUQ0K8X9@_C$-]
MC=+0P"U.M:'5P7YG>Y7\E>_*I4!'=@UQ`&0D5Q?!P20-Y;(UT7QJ)G8W4#<@
MRWX&G"%UK#O;:[Z$[T!/;Y5MFO7HR2'6>NNA%]=YU;0@LZ%Z,(IQAZ1;_K/[
M`>S.CSK#S1C`9TP,TMV*![R+*-#OVRE1P9BT`FC9DB42F$T*"@A*.V!1P$Z>
M(%DW7'.<G`XQ0KCX1`1_U-<NCZ%?ZD57+VZP9]LA9BZ/LKR;D$X]74P(4T`[
M!/60"!$%]:Z`8N#461Q,K-43KB((TLPFLH'$<L1V4OTDF?D=^6]RL2B3R[9,
MI)(1$PVW_(L#*G,M'EX.:*7,O*T?^FR@9(<[4A5T:1]#9H!47RNU"LD_(TZ0
M=&`+9!4C3;FXC3H%/A@W[*5,RCQ!LE9%`9GSC65&8QC5CF$&8S)S@0KXJAAT
M][)4IBN@LQ7C60I@IF"P^K5\\<<.,Y</US>A&VWQ;41TSJ:D!+CJ0P^X<,='
ME0SD<@\=C(IAO&&_?4<C&T:'F,XH$LQ1:/E>#V/,.242I$@H`>%^@U<TP/T[
M7Z,P*JI1'T`V,0'=P].H1N4N'BT'V'T\#8@T5]L(F[*_@-P#LLR5>W'*"#:M
M^HJ3QN&H1&/?UI4@9=,N$$!8L@)`Q0HH#7H32#VB5<,U15@87C1[92%&G9XU
M;->KLAWTV8GVAF4B/;E]7VN"+KN=CA9DF:@>3+.ML+5Y<1[0[GI12]SYX8S\
ML@/P]:*R!E\<XKLL;>D'^T1[[KN1"][V-8K4N4")!6(L,H)4L2M.)3+?@@[4
M"<PP5WUA@HYZ7);UL.L5?\'^>D/+G]$F<];XZYY=3'2WJISS;1@;VHNQ[S==
M594=J:T,D#&F&\B*W69BD"/D9,?0]T0LN-#A:+?GTX1P+*/4T)JG<I`0Q!:4
MT^M+)%F3S(5[C'":K;>E_J56NU*-=."WO%6WBW+Y%MXVS/:V]K9'53/`95;5
M:(S6-P0/JN:IQO'&3<*GT`(]E_O,,&\LT7N"[9.E,XFY0S;W<?3D>]C[<OA&
MV'I\GB:=Y7N1&X;Z+H)`DC$=U2UE;%I*`1GPN\*L+J!1*6@51,^DD`=GMUGF
M(NR.Z(.IQF;27+U,%%H>T)MO(I;Y#AU7+HX2P:>L,^]_]T3<#LWN1:?H;Q*\
M)8_1`V8NX`>XD&]ZC(;Q\-,7"W%1CIVJ+%ZS<]HR0?H:.THI[LC)BV49WC@K
M3#'WH#^S+QFT?*X"WY'!UYMX7('5"B]YPBHJ+QQ5L^KTY_]O'>8EWE'+\'G,
M1S\'F'U@NZ&V[!F8?ZIBP7:L$"_YF*M4?-2GF0_F?1]37(IW<HZL8N>=Q&/Y
MA9]!E)B@G%GLN5/J8WD':YK8Q!X[9HA#4N<T.F*`':JUL`L[4I64(#M0:Y!4
M-VDRXJDXINE*Y':WF79%/%<B[ID>N_2I)U%BDCV@56.Q)@R6$V!&\/.,5RVU
MO127`8QJEY?QH/RE,[4]6,I?]=+A-;LN3RAQ4C=LS%]UT>(:TR`-.W$HHCEV
MM!UO=T%TP!AY>2OM0P_'I9/FDO[*1D3WM"#TO/'=#7KV@P`M,;^,DUU:RP)P
M)HV=*6>9L%0JJ[_\DEO`\^/\##S3X6Y5>KE/TPO6LT"<L&I6H7B$2D\/<T:J
M"4_S*\-@H6`'\!(+<X?R\X]#[EOZ(!0(\9I=(0'3"';]^8;V+7[,>LZ[U0WM
M/L.UOPSPC!"<D&N?*H@#_TF[W<.8V[Z7MU1,=GA#5@C?;P6M8H%';N9(?L[/
MKDVA`JQV!$-J<N1'0L`$"1%3+@/,MT(WQC2>O\3B?RDAE5Y8W9!9;B,`P,-:
MJU=P,F-ND+QM6WC5M:$-_8N]PA&FWI7>-Y1?^F@WG]I;GTP`>I.)8!ED*:^9
MB@%/:E8UG;ENM`\30L=L[#^Q7<_&E:1B'8.GZ56J][$J'\@H9HQ+=1$[)V1+
M&BFE_?,B/?!KW"A7ZR@`)JX]:=-`=P0W(0V\:6GZMZD;>,;@^@HEZGU>8AB'
MLU<`*;Q$4-B]EKH;4J4_2XQC\>-.M0[ML?<Q9FFQ;.J<'JR;A1X_?2>"?>,:
M,!,V!A]OHW:]\YM(&D>O8(Y4<?\P9\TO`Q"/"_/SF1`SVR%5T_0OF<;9)3],
M87$@=592&+;3L=.HT+U4%OG<.X=.LXN<;PQ]CT89LWE%RC2.'D4)2A^V[@39
M2&82]:";IA'W95U&X"+QGO8>Q_Q'FQJIL([$430J-?I*B6\T[J+$I?(81JCJ
MF:7\%KP?F6FC=R6NY*U*H[&>1=#43AL!8SY[H/(O<VZ@*R1:H5/NPV_<FCO2
M(P;#'2T`NIO":M.-HD]A*0`RQ/FF6D&CZ6,,U#7H:VJDC.E\4R/,QO--?B9A
M;.>;VJO6T`GE`L>T7?\^?>7D,4HO\J78:9>2'-AFLH3=G4B_Y9?_:FJOC0#[
M/MI>/=DWS;DAXH"VZ*K9$`IJPZ)4<9L\YQ478&:,5OVPOS[9BSU)E%U+C3(9
M$[X[,IGDCSR6]+.9TK+:<,#=R4\X\!ZC7YQD'_O)88%=]K]^5M&"?P2=29-R
MM7V)CGD474D]N%J#))LH3J8)CK.Q/3WYMJ$BF6=N4Z&P?4M;!15="Q,Q3:)I
MIA`Z2AE)OV*U%2UW-.RI`>R1:^JAJ8)4,9[?%Y5`N]&Y$P3D;M6V"QI",D#G
M-%R%%+JM_F)!.K2A8*O>)>62Q>QEF\L>;]=GJ2J.LB=(DL[C$BZ?U9!QGSG&
MK$7O^>.XLQ3]LA,CRH1JT>G3:6_VV2Q])\W=5;F)D:8FADM)C"@O:JDA1]'?
M7/NA$[H#9$EK!8VF_S%0UZ`?JI$RIBQI(\S&+.DJDS"V+&E[U1JZI%S@J+*D
M4@QU0\B>/<M\MYKSP[,+=G;6(/;2\,'.%&J5T<T#E$S047X-J(;`U4\Y67PJ
MGX<&B]*[JW(CJ2)XT:*H2L_['K(4PUV8'LVY99L;Z`Q"N"T^IB[OEH&_%@^X
ME%3N(\CR_1"]U,WOC>@DQ=Y]$CW@Z?-DU/*RPUM<')\&9@*/"7@DB;1^"<6I
M%'=3Q8-<\56F>)Z@1]$)%6^\N&)\FMO(DXY8=9A0AH\-=SN.Y^H%QZY/M,?R
M#?A@0YE:972AC)().I2I`=4P_N.4FHW_^:TR/)A!T<[^JW7#*,4Y4<J*<M[Q
MS]][SZ3&/5_O-T\?4;Y0BTZ?9I*32\>4DVJ6/M))^G"3\Q'E"RTUI-W^ABG*
MEVC(AH4F3T[`0HY['/N15]ZBKJFN=B(`WFONH&+A+><6_"#O/+?&IS18/S]5
MX,FG"K@=LX"3?\#'`NR^#]U?QWFF"/\@29D@(0<ISE6`O"L-W9Z#J;KCF!>)
M$R?M%9[13CB.#[2;_-4)M%>4S77J3-`2K_V0/<S%-[)Q*"?3\2JLW3MS(@TQ
M.\6DULWB0\;QV@G3.^'F-(:.`M_C?[#'4\C=ZI[6:I8M^+(G?H@)N<3$C?U=
M=JFR.`-(Z^&>,KMT-'S$+\F70)_Y/G&9`,\HVZC$PBO,IRP0Y!'GTRM4?1XH
ME</=DY?#W%$NR>ZCT`!5()<Y0852)^HJH5]GU285+JY'SXM'6?GH[PP!XA#^
M,;HNCE:9K-K=*ITC.`$=]!(L-D#5K[,/)'M$75:72C'JFMH(!EF@'Q!YA[Y&
MLXX-U^W`:6WY41*?N$%$]K%84\VOS'[``5LLF$<D(<>+]?-]U`TQ3F^I`$^9
M#%,1A5=.^HD$>0!E",B:QQ8XRVDOUZ]S]=.H=I2:71Z?7SJ?"D9<\@3)+T[D
MRV-CB!",*V8I5TQ#:-!7Z(@[@-IJZ.3_2HD@4<`0D(W='VK0AU?2KH.77X9O
M&KUKZ.V[92-XV>.TQ!!C:0,8@]>562HT?>\N??V.RA(#B56'::M)1G^$.XJ!
MCB^7;Z+`PS%AJ<SD\#5*\+$W:/*+%OP`;XRU5:[P[)@I,\A+9.W`59/0RNV>
M-AXDZPE<YG^-A`3$1"`IZARO8S5$B$U,8W&AN@BOG@,D@C.!5.LB4%'9:8!;
MWI$0!;3@B-T[]81G<<P>I6#!H_D8TTH"P'Z$]@H6MB.8LX/L1F@+3V&/N81T
M7>#6=_F=P;-UC$7:T.[F@R%5>J)J'$6,;A1R`DS21\$6.'ZB%4]H!-TT##5Q
M`8Q#9HH4!J)Z%IB1R`13)P\"&Z+L:M3L/BD^#_N_S:@<C\FZ#IRUWKT(=M^N
MHZ<SRB(\BWXH.Y1"G#TGT.K"S+WR8ZM10E=;ZG9K;3.?<Z&(234_CRGAFN_C
MF*&B/:L3_`T[\57H73H)[M^@>LEVV[9)PZR9=71=6[Q>7O_&3^4C40!B):`K
MELNA970RA<OTJ-)]MDEK&#O0B+5K!+6Z91:@).K:_#7"^K=])CS;C#E(NS]2
MNN&:6TB#:659DW+CLM_ZMNE1QH!-R81V:K^K,*%SUSF5$3O!3>CAEY_QH7]#
M:L3:;=%:W;*F51)U;>,:8?T;6PA'J73$Q2,JOT^['\^E\\0WN=LG)*%!GQ\.
M$)69E`%B$09:E\RCAJ.GK31*'LYPI.Q3NL!/D%1<'SL2X<0#WK%7J\,UVW6T
M)X-9D$8ZB.W4:EJR&B5M3WNID3F<I:3185X*$L7TL)!K/\#QG$89ZR@>;'PI
M"86P!Z5>13,HD/1K?86HP1J=RT:9\!Y-_8#7/LL.A,E79SM`4*B6"M'8:LV*
MK5VDZ=?<*EF#M?=1.&+2>S3XKU&P#Q,G%N8Y6+=?$0O1Y!K=BFU>(NK7Z$IA
M@[5Z+EWX>Y\N_2\X"'X.H^=P@1T2A=ACMQ;AFF1YN^;7BH<P@P9=B^:@(>YG
M%K5"!S,/5LKT=U8,RLI!HJ`>AG*_7P:^>QU$3C*4<11$0AB$0J>B$4@$_1J^
M(FBPQA:2$1?=*_DCLH@BG71-OQM@"*@1#9,6TNI8SA%5"/LFC#0"!\P>I5G@
M-!_(RQC`'EA2^236(`F&M(6*?FI+R,F&L8.2N.&M@*\%E&S`]@:M],R2=([I
M/B(^/^G4M$W+A!5BLY:Y2L4M6\U\PR^7UZXJ&R-2+"V''EM)9N?+`GZ]Y6*#
M<>?EY($?I8VV.->MP<JTU"!/S]8!+[TVJR*U:SZU(&HLYGB.D9U<2A]:9/>(
MP=N.Y!'L!HEK=MNS>3>E8`'MGK0J:+JE"CU8=Z1!8FQ4_/H/+D!G5.+S+87Q
MF?]%/[!#-_2/?P%02P,$%`````@`6W5D/Y;U0X9Q#@``A,H``!4`'`!G='AI
M+3(P,3$P.3,P7W!R92YX;6Q55`D``RXRM$XN,K1.=7@+``$$)0X```0Y`0``
M[5U9<^,V$GY/5?X#5WF9>9`EV9/#4YE-:7QD77$LE3PY]BE%D9"$#44H`"E;
M^?7;`$GQ`B#(DL4C\V1;0K>[^VLTT(WK^Q^>EYZU1I1AXG_H#,[Z'0OY#G&Q
M/__0"5G79@[&G1_^_>47W_^KV[5^_SBYMWY$/J)V@%SK"0<+\=G/-OW3NB*K
M#<7S16"]N7IK33?69&)=$]]'GH<V5K>;,/EH,Z`E?L3M_&P0?^=A_\\I?&>!
M3#Y[_\SPA\XB"%;O>[VGIZ>SIXLS0N>]\WY_T/O]Y_M'9X&6=A?[++!]!W4L
M:/^>B0_OB6,'0J$,^?.4>@F#B][V?RE;\+^Z2;,N_Z@[..]>#,Z>F=N)1#3@
MWTF4X1_(U!E<7E[VQ+<=;@-*/#1!,XO__&5REZ.8!\_8=\X<LNSQKWO7Q`F7
MR`^&OGOC!SC8W/DS0I="=?B_G.?[8+-"'SH,+U<>2CY;4#3[T.'<0*W!H']Y
MT>=*?:7GU\N*MS_SCR'#/F(,F`/^F(UF8XH8_+>8O8G"NW@<*.+CPJ9(..<5
M6:Z0S_80345[J-5`30?4O<9>"!WN`07WA+$[Z*%+-$94_%=#VQEQ.E!<T'U)
M_,>`.'^:294C./B?>YX])518'C2]QP[@@(9SBA!W:V8JTDXV0M!5QO7N0:Y8
M.L[C\%Z+`\ZEW[>Z5M(^^ZOMNU9$;"G[/'H.D.\B5X05CSBY+ST>(0G=95+^
MR1\Z@8=3%E#;"1)&8#GD19P,Z7K&XL4V%7&6(>=L3M8]%^$>EYC_(D3O]@=Q
MC/X*/MK*\`G8%F0L?UV"=4CS8MG429C`KR6D\R-`W**W@H[E!UUG@3TWH9Y1
MLMS+2K$41"8VH2ZB'SI?G_4O.E;(0":RXM2V]]K6'8(0+A?DUK/G$O,6OF^,
M?0MRIP;^^L0&3H2'`(T)R.]>P[1+X\>%=HTQN$+^U/#O3FSX2/()FF,NL!\\
MV$N9W>7-&F-VN?BIU0>56/T*M*"V=P>#U_-/:*,T>ZE=P^Q>DC\U_/F)#7\5
M4J[D+6:.[?T7V50=:M1-&V-^M0HI`M]5XOJ_0:K\DT^>_$=D,^(C]XZQ$%%E
M%U"V;PP6._1(`;FL!)!?B1>"!>GF%GN(,B40I78-`Z`D_];P@WXU@T#41R=H
M16B`_?DC6#%4VU_5O&$PJ-1(T:AF2!9><04A<DZH>D`NM&J8[0O2IR8_]6`<
MNT):&1&U&38*`U[IY)59=3?0$C4,$+TR*3[5Y`;C<.IAY]8C=K'XH6C3,.OG
M9$^-?>H20Z)`-%F+\L-;^$PV%&C:-L;X&AW2N="WE8+`9\QF$&1:-A2`C`:I
M^;^1F[]7K`@?6OKW^+K6XP(AT])U@>3@M8<,M[&P]`(%V.$*[RU-@?[0E1HP
M<E2,'\U&*Q35Z@V-I*(]HDA7-EM`Y'QZ@4094MTJ0Z'$;[KV4'"0_&+#P.I:
M6U'@]RL"O'V^5!N363'=BV+-S&93T8%#UIW;]BH*.,@+6/)),?+$'_^QE6DT
MN\4^"((A,!*&->L/((TAV<L"Y\N5&3(&)M2(76QPZL!I;KHT;LKDCL/EX*P4
M+$&9&8(\Q[V/M%8**R1=(SHE#(FVG!83"H$<&'/36%85Z,59VDX02^VJP%+N
M<'G42H+&X)V?E=/-!J/'8RM,!?B/F[]"O+8]'G.'P95-Z0:2BE]M+RR6/+F1
M#.FJ0U?AD`G(AO+'H%^<E2L^.>`.\8!3A]O_(,_]1'ZV@Y"+_X@<_A.CQ&(2
ML'=2U!;FG9+'`+]K$\!#QR$A>/,$.0@\>^JA!Q2HT=4WKRVT>K'3S*0]N-[Y
M:]"-T`TH*L$Q_W5M<<N+&>/T39MP&E.TLK%[\[P2FZ1\=P1)'LT91P*?$55M
M4362/@;[VS:!O0O6I@`HA^J[XT(5D,#V*NN59(5HL!E#WBZJ7S#M6_&$3AY-
M]<WKE[7HY8WAO&Q3SX,T'`?H'J^1>P<H^',,<X#(2')(=Q'4#]1=$B<%A7Z;
M<(WT4X;2.N*42);@,6A/V+S']A1[(FF"J")6'A?$`S49CS#!1E/Q,2=M2D'/
M7*/$$UI6+LH88'?%3]>X"L3W=64)ZJJJX.#BK+PEHL$X)\GUV-[PS'IW\:#8
ML&)\#6L'1:D3--M6#J(A2%JRCAQ.5=O:(ZH2/`&U5;6@ZUC4"5HC/]1T4%7#
M>L.IDCK!LE7U(J.>V;PNJ>N+1RX!53E!+KCJ`_$=T\Z8;=ND"9%&C03@(Q>.
MJNV@HI:9,9868UWC)H&LTR-!N57U)+ZW%@=BSQ%?&28^WVV.("]$LF*$MG63
M<-8JDFQZZ$O3V(8"O5<1HVYEBY?";%"L.)>7K1J;Q&8VRRNWL92:5%.*VJ>S
MYN5-L#MO4R@>NBZ.E!C;V+WSK^P5AAE>[F:,<NYJ0%1O=$TT2/!NU9:D"0IL
M["/WQJ8^C#X,LOEP&7K\/B68:V('RR*S"5&]\3;1(,&[526ILHF,1MZZXRF3
M.,'OR-6G.B\)O6`IJ%ESJ=W:)*@?N4Y50EUZON85ST<4CJS$C)/#$J:G):PW
M.3YO.];GXQ.?5V@_K]!^3FX_)[<O2&XAF(ZHZ"RN2`K3JPMU^:Z:JMZ3+",5
MTJRX176KTN'_81@L0)6_T]%<#G6Y=6,@+HN>0BO;<=$6:,5E/T:P)BT;!FDB
M=@IG^1J%]L"IOJA$:IQ*KR@Y$%C9C22`;OE&DN.B>X),2'5*/I\%G2N3H)3>
M(C,KY6"]"7T[=#$,8V]/?9`\NNQX*YEFKJAL>?IBH5AUUAT8+S>IHA/ML&U:
M!2P*NSTGWJ[,Q/80BY7]D1!7L4M?WJP*_%2.MLTZI))NSXG7HEZKN+\Z=Z%W
MK$(!"TV[NH&A$;6-![@34V@"7_TPRDOW.L>NJRR*7Q$F-E#$)R!UHY.Z:8U'
M*;70Z45H;1JMN+ZCF0CKC\239V*%%E6@M\OMLO#EA&WCP>L)F![,QB_VN(90
MXQ%Q`#(VS<VSXX4\*QDZD-!0?J)N3(F#&..VD<;2`[C5V1<.4JR-9[@?D0<\
MY]$;3AZ89>@NL2\N@`_P&L66D<U5#0GK[`VF.KS.B?"JZS1Y&QD,UO4&LRSM
MZYS\KG*F%1=._'DT<^%/-LFV8<M:U7A^)97WE<YW5XH>WU;^0'R2UU<=8W<1
MU!G3':*_TG'Q:F/J`PJT';/P?8WA*TB:;AAH36=,-AXF"Z>:I%7=M,8(JH5.
MSVVW*FLM*EQXX=``UQ)%%?#N\DL5OB7A6WF@^S?$'Y1%[A#$L.?H(5Q.$1W-
M2LMOFMZ\/XL:]_+]E4F/A->D]RO*]`5_UBHJ*]_O1U\%Q"_UY6W9?S\53W=^
M_,3KT9D[TO/+T1>&R]&<@24X5+D<G=GRN=7(;$.NI'D%,U\NQ9B2-08</VY^
M8;Q\MLWLADZ`U]'F1K5*+V%2\>9<)5*9B?3>.K5S#;P!R='+O5B?-]5D0?Q8
M!Q3_%[+HT#0_%P_VNH/>P#Z1"7+@;RPN(TZ-\(D<'AA>_U\VT]M>WR[;/02M
M"D77"(1WL``:?O>00-QWATO^SM[?N=?3<U>8F)!5<D7CB?ID>@N*B27:>,%\
MDFLC]XHL>2U3Y2RJAO\$]U#I7J^;Z16)YS4&UX;&++GJ1P.T"4';`3>Q03MW
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M`VR?,-Q#PV,_)%&+26;)`*KGJTW<0TW;$N]0*WCL1RCJX1S\%"9RV2W8-%8:
ME!4IV69[>[_M>6PTV\=MCL&UH0YU#-5;^1*&N6T/FL,TU7'VT3!]0*/M,]WX
MBM;#9KI:)@V=Z6IU2F\G;==,-Q-;^4U__/)GL*#V_08#FAK%"P-WEPTT"L5J
M]HJ'8E=0,@4;)2]3W/,2$`R3D3%0.D$?33T\S]^/E]TM]$)&S8/_$&V/_=)'
M[6:QPO='0B=V\XRH@YET'X@!3?,\PU"Q5C[_86ZY@V8.376+?31LX?,B7'>1
M>K$%#XQKV^/!<XQ`&[>X_"#QC_W(ZSZGW$^;4ST[4KDW#*&'4+J!SJ!\V<V,
MKIGXE]1(@#_RM5PKX6<@+PW:"/\?@Y8X`%<D<8$C;_R,7.#&STT83_'L4,BP
MCQ@OPO$CWFPT&V?X;ZT4GW+^IM_GCP]=8^9XA(44P1\)!\OV^0-$P(.?<\YQ
M.?7=1W1N^_')H"N8YQ$/NW9\:B@K5^:]F_20MJ:8<B2^)[\*2B6V!/`$S&O$
M'(I7R5&K:/L)=(,Q$/,G:S^!HWWTY`6&5_Y_5422HWK4]MJJU[73]F1W&ZY@
MT)Z$RT2G\V)T$I1=06KE:$_]?/U6*%&2VLHQ0>(=2G&AH)!URD5-2AF:8'0H
MPU-'(6-Y/V;EU<69@SE6$4F.XP?;L[&'FJ!-0:)P10VD]_P<1W2BH_A65R9D
M7)0F-)R/F,W$G"Q@9;WAS-Y:$3L+^$6AY=1QY'A7R54HM*Y7:]HVZ8JTEO8Q
MR=)2IBN]*W:EJ+D5M:_\\>,'$NCZRRZ"ZE]OYO*D]M7UHCUHZ_'NE0P;];.3
M2F7:U=<R+ZW`N':/'7$.9$Y1E%A(>N#7Y1Z882(&M9B-E>%S:L?./.CSB.@:
M!.)O^NBZYBZ*T]]HOC7K&@TIM?VYL*59[]R+NI+^:890>AWZ'OI4VT5[7'`^
MMX8_OOSB_U!+`P04````"`!;=60_TGDK7"X%``"W'```$0`<`&=T>&DM,C`Q
M,3`Y,S`N>'-D550)``,N,K1.+C*T3G5X"P`!!"4.```$.0$``.5936_;.!"]
M%^A_X.J4`BO+CK<%$L0I$KLI`KA)X'2QO16T-+:)2*1*4G'\[W=(2K$D6Z[M
M;+#;=0Z!1,Y[G'E#\6-\]O$IB<DC2,4$[WF=5MLCP$,1,3[M>9GRJ0H9\SZ>
MOWUS]IOODV^7HR'Y#!PDU1"1.=,SV_:%R@?2%^E"LNE,DZ/^.S)>D-&(#`3G
M$,>P(+Y?D%Q2A5C!'=MQJY/WJ7`&"27H$5<];Z9U>AH$\_F\->^VA)P&Q^UV
M)_CV97AO[;RW;PC^6>O3I[&,605C6@I4-V!<:<I#J(!BQA\V8$SW&%VM#K0"
MRIWKG)R<!+8WM]=43D'?T`142D.H8*;ZB?&P%8H$A^ITVB?==F44T[\E`&)(
M@.LK(9,!3&@6ZY[W(Z,QFS"(/.*,J-:2C3,-%;.,+PWK8D;Z>?RR*N\#UUD0
M.P#.$[U(054A"L+65#P&1:_UW&]W_&ZG"N<X1[)D?28B+0.##M#(1RN0+*RA
M?P[-86:.4<Z%IAIGNWU+4\8GPCR:S)U*$<-7A!#S\.?HNBD'ICL8B#`STE_P
MZ!/73"^ND4HFEMPC+.IY&RW.31!NV`@FC#/K5+M-?%+@RH^41\21D!++65`G
M6+)F^)7=\G/[G$I0R&(Q0VS(<;G)>LR2=%M$2.,PBQL'R=\+D?=3_9+&YD.^
MGP%HY62N-C7HBHL,N4<!(!>V+W@$W"Q$.9PX_($K>D<E1C4#S7#H-?)6^YNT
MWE9L<E3A>W=XXC^KI&XGMZG95G&T?%XW]#6(?MRH^9*'B`E9,I&CC-,L8KB3
M'[CR?:IF5[&8KQ%^V=6@>W=+W0T1L4S_(]WW6W`RQ3@HA=LB'@49BGQ7BBY?
M=#;;-.3B0]NN\P.FPEBH3`*^%$QV![5<)AMEME\\!_O,_1DNN_88WA=)BK.U
MI'Q#7[/BQW7%+8/O3OEECL/3V4RW$*?P@,5X^(YN0`^%4M=XP4K@#J05JMAD
MM[!LSD%W9=8;/COE<T:"E.3(D+XCCI8@K\O5X24&IV4B^+T6X8/3O]S0+/,?
M=9D=C%C<(:H8QW0LW'$")^^0A6;GNYA*</M>H>W/S)H5?[^J>(G,3O"<CBSY
M?O%,%+DP_TP!8@038BL+I^8ZV_,42](8UPW7-I,PZ7DF-7Y1&OB.0[;P=ER8
M&.X-A0Z;RYJ7^;@%`Y7A"LE*X2-(I<##I69XUR]\+PCPXFK@_>4HQ`RC?B<T
M1C^#<_+RJ#&=NT9=GP&O%';YM/'/QXW?PZYQ(P3B5PQX:/C71!J4*BY!M1:#
M80JI"5];,&NHYA%7,AR*T-)L@)@WO\#YILGO'/O=3NM)1<:YW1Q81KV;`P7N
M)0ZLE+6V\J&.,AZ<&`\Z'PH/R!XNE(MRN[DA^,U^GDRH&ENNM77%!B>L`V7D
ME-+4`@.(M7KF\I=<.SOS3/ER7TS+KJY4:JX1L*U=J6/,0\/@IGJ?%YQ57K3/
M7ZU#FRN>%V.E)0VU.Q28)>S[=N9N';0E_E-L8WQZC?=JLUEB8!F:,9T9Q&<I
MLK0PQ-MU@HN2?<;%BHGHJZ6),IE?=F@^0,_3,D,JSLS)PJQ>[CUP6W$UP,KQ
M8P2/P#,H!;2^NQP`'A=!4[G8.H2Z6YM"<GUC5V/K>:&$B.E\=:G&4;MO_`7F
M=QN(+AY!TBG@ISD&>3NQMP-5BF\W6"5QMNU5HEX3WH!)"+60:@`3D'+=/==-
MP,UV_U;B(A@WY.V.+EQABO=IRC2-AX#["6;DBG&#C3[]R%AJ3&[',9N6RXDV
MX#WQ_XD9'+A5#!__!E!+`0(>`Q0````(`%MU9#_*-%\EBBX``)4V`0`1`!@`
M``````$```"D@0````!G='AI+3(P,3$P.3,P+GAM;%54!0`#+C*T3G5X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`%MU9#^DO3D;\0@``/]=```5`!@`````
M``$```"D@=4N``!G='AI+3(P,3$P.3,P7V-A;"YX;6Q55`4``RXRM$YU>`L`
M`00E#@``!#D!``!02P$"'@,4````"`!;=60_+7NL*0H9``!40`$`%0`8````
M```!````I($5.```9W1X:2TR,#$Q,#DS,%]L86(N>&UL550%``,N,K1.=7@+
M``$$)0X```0Y`0``4$L!`AX#%`````@`6W5D/Y;U0X9Q#@``A,H``!4`&```
M`````0```*2!;E$``&=T>&DM,C`Q,3`Y,S!?<')E+GAM;%54!0`#+C*T3G5X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`%MU9#_2>2M<+@4``+<<```1`!@`
M``````$```"D@2Y@``!G='AI+3(P,3$P.3,P+GAS9%54!0`#+C*T3G5X"P`!
@!"4.```$.0$``%!+!08`````!0`%`+\!``"G90``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E6AAG"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (USD $)<br />In Thousands</strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td><td class="nump">$ 73,296<span /></td><td class="nump">$ 58,181<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments</a></td><td class="nump">9,715<span /></td><td class="nump">450<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td><td class="nump">830<span /></td><td class="nump">683<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td><td class="nump">150<span /></td><td class="nump">171<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td><td class="nump">1,351<span /></td><td class="nump">875<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td><td class="nump">85,342<span /></td><td class="nump">60,360<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td><td class="nump">1,302<span /></td><td class="nump">2,040<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible and other assets, net</a></td><td class="nump">264<span /></td><td class="nump">1,850<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td><td class="nump">86,908<span /></td><td class="nump">64,250<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td><td class="nump">829<span /></td><td class="nump">848<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td><td class="nump">4,367<span /></td><td class="nump">3,112<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current portion</a></td><td class="nump">0<span /></td><td class="nump">1,345<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td><td class="nump">5,196<span /></td><td class="nump">5,305<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, less current portion</a></td><td class="nump">0<span /></td><td class="nump">6,721<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td><td class="nump">240<span /></td><td class="nump">497<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 120,000,000 and 60,000,000 shares authorized at September 30, 2011 and December 31, 2010, respectively; 62,790,223 and 51,719,187 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively</a></td><td class="nump">63<span /></td><td class="nump">52<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td><td class="nump">456,901<span /></td><td class="nump">404,555<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td><td class="num">(375,492)<span /></td><td class="num">(352,880)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td><td class="nump">81,472<span /></td><td class="nump">51,727<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td><td class="nump">$ 86,908<span /></td><td class="nump">$ 64,250<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19(a))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -Subparagraph a(1)<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.3-4)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.30(a)(1))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Concepts (CON)<br /><br /><br /><br /> -Number 6<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.18)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Assets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.9)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -Footnote 1<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 230<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7, 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash Equivalents<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 942<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.9-03.17)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -Article 9<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 944<br /><br /><br /><br /> -SubTopic 210<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.7-03.(a),19)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 450<br /><br /><br /><br /> -SubTopic 20<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 5<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.25)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 30<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 605<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 7, 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 13<br /><br /><br /><br /> -Section A<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 48<br /><br /><br /><br /> -Paragraph 6<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 142<br /><br /><br /><br /> -Paragraph 45<br /><br /><br /><br /> -Subparagraph a(1)<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 350<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (a)(1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents investments in debt securities which are categorized as held-to-maturity and that have scheduled maturities within one year of the balance sheet date or the normal operating cycle, whichever is longer; such investments are measured at amortized cost (carrying value). The held-to-maturity category is for those securities that the Entity has the positive intent and ability to hold until maturity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 11<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 17<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 320<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br /><br /><br /><br /><br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 115<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 320<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 25<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (c)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6379932&amp;loc=d3e22054-111558<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_HeldToMaturitySecuritiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.6(a))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 330<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 35<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InventoryNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 32<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.32)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 21<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.21)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 24<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.24)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.13)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 13<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -Subparagraph b, c<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 360<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.31(a)(3))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A3<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29, 30, 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 4<br /><br /><br /><br /> -Section E<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 310<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.15</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>10</ContextCount>
  <ElementCount>76</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>01 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>011 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>02 - Statement - Condensed Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>03 - Statement - Condensed Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>06001 - Disclosure - Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/BusinessAndBasisOfPresentation</Role>
      <ShortName>Business and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>06002 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>06003 - Disclosure - Basic and Diluted Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/BasicAndDilutedNetLossIncomePerShare</Role>
      <ShortName>Basic and Diluted Net (Loss) Income Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>06004 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>06005 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gtxinc.com/role/CollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 01 - Statement - Condensed Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 011 - Statement - Condensed Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 02 - Statement - Condensed Statements of Operations (unaudited)</Log>
    <Log type="Info">Process Flow-Through: 03 - Statement - Condensed Statements of Cash Flows (unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>gtxi-20110930.xml</File>
    <File>gtxi-20110930.xsd</File>
    <File>gtxi-20110930_cal.xml</File>
    <File>gtxi-20110930_lab.xml</File>
    <File>gtxi-20110930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>25
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]C-S(V-C`V8E\T-V(P7S1B,61?8C9B.5\R9#8R
M-C8R8S8R,F0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]C-S(V-C`V8E\T-V(P7S1B,61?8C9B.5\R
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T)A
M;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0V]N9&5N<V5D7T)A;&%N8V5?4VAE971S7U!A<F5N/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7U-T871E
M;65N='-?;V9?3W!E<F%T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N9&5N<V5D7U-T871E;65N='-?;V9?0V%S:%]&/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0G5S:6YE<W-?86YD
M7T)A<VES7V]F7U!R97-E;G1A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4VAA<F5"87-E9%]#;VUP96YS871I;VX\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"87-I8U]A;F1?1&EL=71E
M9%].971?3&]S<U]);F,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y#;VUM;VY?4W1O8VL\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y#;VQL86)O<F%T:6]N7V%N9%],:6-E;G-E7T%G<F4\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2
M968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H
M965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^
M1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O
M=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O
M;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F
M="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]C-S(V-C`V8E\T-V(P7S1B,61?8C9B.5\R
M9#8R-C8R8S8R,F0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S<R
M-C8P-F)?-#=B,%\T8C%D7V(V8CE?,F0V,C8V,F,V,C)D+U=O<FMS:&5E=',O
M4VAE970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14%7044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B`H55-$("9N
M8G-P.R0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`P,RP@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y'5%@@24Y#("]$12\\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X
M($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,3(V,#DY
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L#0H)"3(P,3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N
M="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E$S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT
M($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S;VYE9"!)
M<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R
M($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E
M;&5R871E9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y(%!U8FQI8R!&;&]A=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`U-BPX-#0L,38X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#<Y,"PR,C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,W,C8V,#9B7S0W8C!?-&(Q
M9%]B-F(Y7S)D-C(V-C)C-C(R9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]C-S(V-C`V8E\T-V(P7S1B,61?8C9B.5\R9#8R-C8R8S8R,F0O5V]R
M:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-D%!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0F%L86YC92!3:&5E=',@*%531"`F
M;F)S<#LD*3QB<CY);B!4:&]U<V%N9',\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E
M=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B9N8G-P.R0@-S,L,CDV/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`U."PQ.#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M;W)T+71E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDL-S$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE+"!N970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A
M:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,U,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E
M;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-2PS
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,"PS-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT86YG:6)L
M92!A;F0@;W1H97(@87-S971S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX-BPY,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PR-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R
M<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S(&%N
M9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E("T@
M8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PS-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$Y-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S`U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M979E;G5E+"!L97-S(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L-S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!L;VYG+71E<FT@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6ET;65N=',@86YD(&-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO
M;&1E<G,G(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`F;F)S<#LD,"XP,#$@<&%R('9A
M;'5E.B`Q,C`L,#`P+#`P,"!A;F0@-C`L,#`P+#`P,"!S:&%R97,@875T:&]R
M:7IE9"!A="!397!T96UB97(@,S`L(#(P,3$@86YD($1E8V5M8F5R(#,Q+"`R
M,#$P+"!R97-P96-T:79E;'D[(#8R+#<Y,"PR,C,@86YD(#4Q+#<Q.2PQ.#<@
M<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P
M+"`R,#$Q(&%N9"!$96-E;6)E<B`S,2P@,C`Q,"P@<F5S<&5C=&EV96QY/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L
M('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#4V+#DP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0P-"PU-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W-2PT.3(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4R+#@X,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#$L-#<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3$L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@
M86YD('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XF;F)S<#LD(#@V+#DP.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@-C0L,C4P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-S(V-C`V8E\T
M-V(P7S1B,61?8C9B.5\R9#8R-C8R8S8R,F0-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO8S<R-C8P-F)?-#=B,%\T8C%D7V(V8CE?,F0V,C8V,F,V
M,C)D+U=O<FMS:&5E=',O4VAE970P,RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139+04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D($)A;&%N8V4@4VAE971S
M("A087)E;G1H971I8V%L*2`H55-$("9N8G-P.R0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=&]C:VAO;&1E<G,G(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,"XP,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S
M<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L-SDP+#(R,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#<Q.2PQ.#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,BPW.3`L,C(S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L-S$Y+#$X-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S<R-C8P-F)?-#=B
M,%\T8C%D7V(V8CE?,F0V,C8V,F,V,C)D#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V,W,C8V,#9B7S0W8C!?-&(Q9%]B-F(Y7S)D-C(V-C)C-C(R
M9"]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q24%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!3=&%T96UE;G1S(&]F($]P
M97)A=&EO;G,@*'5N875D:71E9"D@*%531"`F;F)S<#LD*3QB<CY);B!4:&]U
M<V%N9',L(&5X8V5P="!3:&%R92!D871A/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3`\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$P/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N
M=65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]D=6-T('-A;&5S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B9N8G-P.R0@,BPP,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#DV,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@-"PY,#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF
M;F)S<#LD(#(L,S4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:6]N(')E=F5N=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,S-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#8V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L-#4P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#(Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPY-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU."PX,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]S=',@86YD(&5X<&5N<V5S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;W-T(&]F('!R;V1U8W0@<V%L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$X
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L-3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C,L,#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C(L-S(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV
M92!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY
M,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R+#`U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$R+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-O<W1S(&%N9"!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,SDV/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX-S4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-2PY,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-BPQ,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XH3&]S<RD@:6YC;VUE(&9R;VT@;W!E<F%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PS-C<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PU-SDI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L
M.30T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(R+#8X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(@:6YC;VUE+"!N970\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="`H;&]S<RD@:6YC;VUE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#DL,S0T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)FYB<W`[)"`H."PU-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XF;F)S<#LD("@R,BPV,3(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`R,BPX,C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3F5T("AL;W-S*2!I;F-O;64@<&5R('-H87)E.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@
M9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD
M("@P+C$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)FYB<W`[)"`H,"XR-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#`N-#$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`P+C8S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E=E:6=H=&5D(&%V97)A9V4@<VAA<F5S('5S960@:6X@8V]M
M<'5T:6YG(&YE="`H;&]S<RD@:6YC;VUE('!E<B!S:&%R93H\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I
M;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#<W."PU
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-BPT,C0L.3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-34L-3(Y+#,R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#0R,BPR-S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,W,C8V,#9B7S0W8C!?-&(Q
M9%]B-F(Y7S)D-C(V-C)C-C(R9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]C-S(V-C`V8E\T-V(P7S1B,61?8C9B.5\R9#8R-C8R8S8R,F0O5V]R
M:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1$I!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY#;VYD96YS960@4W1A=&5M96YT<R!O9B!#87-H($9L
M;W=S("AU;F%U9&ET960I("A54T0@)FYB<W`[)"D\8G(^26X@5&AO=7-A;F1S
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$P
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-A<V@@9FQO=W,@9G)O;2!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T("AL;W-S
M*2!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[
M)"`H,C(L-C$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B9N8G-P.R0@,C(L.#(S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S
M('1O(')E8V]N8VEL92!N970@*&QO<W,I(&EN8V]M92!T;R!N970@8V%S:"!U
M<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M
M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPQ-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<W,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ER96-T;W)S)R!D969E
M<G)E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92!A;6]R=&EZ871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,#8V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q+#0U,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM
M<&%I<FUE;G0@;V8@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV.#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I
M;B!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE+"!N
M970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,S`Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@
M<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H97(@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#8R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PW-#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C0L-30Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y+#$W-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O
M9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@X."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F('-H;W)T+71E<FT@:6YV
M97-T;65N=',L(&AE;&0@=&\@;6%T=7)I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$R+#0U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@X+#$Q.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@;6%T
M=7)I=&EE<R!O9B!S:&]R="UT97)M(&EN=F5S=&UE;G1S+"!H96QD('1O(&UA
M='5R:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$X-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M+#<W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H("AU<V5D(&EN*2!P<F]V:61E9"!B>2!I;G9E<W1I
M;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.2PS,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPU-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I;F%N8VEN
M9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@L.3@R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M87EM96YT<R!O;B!C87!I=&%L(&QE87-E(&%N9"!F:6YA;F-E9"!E<75I<&UE
M;G0@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!E;7!L;WEE92!S
M=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!F:6YA;F-I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@L
M.3<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&EN8W)E87-E("AD96-R96%S92D@:6X@8V%S:"!A;F0@
M8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34L,3$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C(L-C8Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@
M8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3@L,3@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#`L,C$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M+"!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XF;F)S<#LD(#<S+#(Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,3<L-34P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-S(V-C`V8E\T-V(P7S1B,61?
M8C9B.5\R9#8R-C8R8S8R,F0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO8S<R-C8P-F)?-#=B,%\T8C%D7V(V8CE?,F0V,C8V,F,V,C)D+U=O<FMS
M:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D)U<VEN97-S(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY"=7-I;F5S<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0G5S:6YE<W,@86YD($)A<VES(&]F(%!R97-E;G1A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E
M(#$@+2!U<RUG86%P.D]R9V%N:7IA=&EO;D-O;G-O;&ED871I;VY"87-I<T]F
M4')E<V5N=&%T:6]N0G5S:6YE<W-$97-C<FEP=&EO;D%N9$%C8V]U;G1I;F=0
M;VQI8VEE<U1E>'1";&]C:RTM/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E
M<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/"$M+2!X8G)L+&YS("TM
M/@T*("`@/"$M+2!X8G)L+&YX("TM/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0^
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P<'0G/CQB/CPO8CX-"B`@
M(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/CQB/CPO8CX\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SX\8CX\+V(^/"]D:78^
M#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P="<^/&(^/"]B/CPO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXQ
M+B!"=7-I;F5S<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]B/@T*("`@
M/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/D)U<VEN97-S/"]I
M/CPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@-"4G/D=4>"P@26YC+B`H)B,X,C(P.T=4>"8C.#(R,3L@;W(@=&AE
M("8C.#(R,#M#;VUP86YY)B,X,C(Q.RDL(&$@1&5L87=A<F4@8V]R<&]R871I
M;VX@:6YC;W)P;W)A=&5D(&]N(%-E<'1E;6)E<B8C,38P.S(T+"`Q.3DW#0H@
M("!A;F0@:&5A9'%U87)T97)E9"!I;B!-96UP:&ES+"!496YN97-S964L(&ES
M(&$@8FEO<&AA<FUA8V5U=&EC86P@8V]M<&%N>2!D961I8V%T960@=&\@=&AE
M(&1I<V-O=F5R>2P-"B`@(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA
M=&EO;B!O9B!S;6%L;"!M;VQE8W5L97,@=&AA="!S96QE8W1I=F5L>2!T87)G
M970@:&]R;6]N92!P871H=V%Y<R!F;W(-"B`@('1H92!T<F5A=&UE;G0@;V8@
M8V%N8V5R+"!C86YC97(@<W5P<&]R=&EV92!C87)E+"!A;F0@;W1H97(@<V5R
M:6]U<R!M961I8V%L(&-O;F1I=&EO;G,N#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@0V]M<&%N>2!I<R!D
M979E;&]P:6YG('-E;&5C=&EV92!A;F1R;V=E;B!R96-E<'1O<B!M;V1U;&%T
M;W)S("@F(S@R,C`[4T%237,F(S@R,C$[*2P@:6YC;'5D:6YG#0H@("!/<W1A
M<FEN93QS=7`@<W1Y;&4],T0G9F]N="US:7IE.B`X-24[('9E<G1I8V%L+6%L
M:6=N.B!T97AT+71O<"<^5$T@/"]S=7`^*$=4>"TP,C0I+B!305)-<R!A<F4@
M82!N97<@8VQA<W,@;V8@9')U9W,@=VET:"!T:&4@<&]T96YT:6%L('1O('!R
M979E;G0@86YD#0H@("!T<F5A="!M=7-C;&4@=V%S=&EN9R!I;B!P871I96YT
M<R!W:71H(&-A;F-E<B!A;F0@;W1H97(@;75S8W5L;W-K96QE=&%L('=A<W1I
M;F<@;W(@;75S8VQE(&QO<W,-"B`@(&-O;F1I=&EO;G,L(&EN8VQU9&EN9R!C
M:')O;FEC('-A<F-O<&5N:6$@*&%G92!R96QA=&5D(&UU<V-L92!L;W-S*2X@
M5&AE($-O;7!A;GD@:&%S(&-O;6UE;F-E9"!T=V\-"B`@('!I=F]T86P@4&AA
M<V4@24E)(&-L:6YI8V%L('1R:6%L<R!E=F%L=6%T:6YG($]S=&%R:6YE/'-U
M<"!S='EL93TS1"=F;VYT+7-I>F4Z(#@U)3L@=F5R=&EC86PM86QI9VXZ('1E
M>'0M=&]P)SY433PO<W5P/B!F;W(@=&AE('!R979E;G1I;VX@86YD('1R96%T
M;65N=`T*("`@;V8@;75S8VQE('=A<W1I;F<@:6X@<&%T:65N=',@=VET:"!N
M;VXM<VUA;&P@8V5L;"!L=6YG(&-A;F-E<BX-"B`@(#PO9&EV/@T*("`@/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D%D9&ET:6]N86QL>2P@
M=&AE($-O;7!A;GD@:7,@9&5V96QO<&EN9R!#87!E<V%R:7,\<W5P('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.#4E.R!V97)T:6-A;"UA;&EG;CH@=&5X="UT;W`G
M/E1-/"]S=7`^("A'5'@M-S4X*2P@86X@;W)A;"!N;VYS=&5R:6]D86P-"B`@
M('-E;&5C=&EV92!E<W1R;V=E;B!R96-E<'1O<B!A;'!H82!A9V]N:7-T+B!4
M:&4@0V]M<&%N>2!I<R!D979E;&]P:6YG($-A<&5S87)I<SQS=7`@<W1Y;&4]
M,T0G9F]N="US:7IE.B`X-24[('9E<G1I8V%L+6%L:6=N.B!T97AT+71O<"<^
M5$T\+W-U<#X@9F]R#0H@("!F:7)S="!L:6YE(&%N9"!S96-O;F0@;&EN92!H
M;W)M;VYA;"!T<F5A=&UE;G0@;V8@861V86YC960@<')O<W1A=&4@8V%N8V5R
M+B!7:71H(')E<W!E8W0@=&\@9FER<W0-"B`@(&QI;F4@:&]R;6]N86P@=&AE
M<F%P>2P@=&AE($-O;7!A;GD@:&%S(&-O;7!L971E9"!E;G)O;&QM96YT(&EN
M(&$@4&AA<V4@24D@;6%I;G1E;F%N8V4@9&]S92!F:6YD:6YG(&-L:6YI8V%L
M('1R:6%L(&%N9`T*("`@:&%S(&EN:71I871E9"!A(%!H87-E($E)(&QO861I
M;F<@9&]S92!F:6YD:6YG(&-L:6YI8V%L('1R:6%L(&5V86QU871I;F<@0V%P
M97-A<FES/'-U<"!S='EL93TS1"=F;VYT+7-I>F4Z(#@U)3L@=F5R=&EC86PM
M86QI9VXZ('1E>'0M=&]P)SY433PO<W5P/B!I;@T*("`@;65N('=I=&@@861V
M86YC960@<')O<W1A=&4@8V%N8V5R+B!4:&4@0V]M<&%N>2!W:6QL(&%L<V\@
M:6YI=&EA=&4@82!S96-O;F0@;&EN92!H;W)M;VYA;"!T:&5R87!Y#0H@("!0
M:&%S92!)22!C;&EN:6-A;"!T<FEA;"!E=F%L=6%T:6YG($-A<&5S87)I<SQS
M=7`@<W1Y;&4],T0G9F]N="US:7IE.B`X-24[('9E<G1I8V%L+6%L:6=N.B!T
M97AT+71O<"<^5$T\+W-U<#X@:6X@;65N('=I=&@@8V%S=')A=&EO;B!R97-I
M<W1A;G0@<')O<W1A=&4-"B`@(&-A;F-E<BX-"B`@(#PO9&EV/@T*("`@/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!#;VUP86YY(&UA
M<FME=',@1D%215-43TX\<W5P('-T>6QE/3-$)V9O;G0M<VEZ93H@.#4E.R!V
M97)T:6-A;"UA;&EG;CH@=&5X="UT;W`G/B8C,3<T.SPO<W5P/B`H=&]R96UI
M9F5N92!C:71R871E*2`V,"!M9R!T86)L971S+"!A<'!R;W9E9"!F;W(@=&AE
M#0H@("!T<F5A=&UE;G0@;V8@861V86YC960@;65T87-T871I8R!B<F5A<W0@
M8V%N8V5R(&EN('!O<W1M96YO<&%U<V%L('=O;65N+"!I;B!T:&4@56YI=&5D
M(%-T871E<RX@5&AE#0H@("!#;VUP86YY('!R979I;W5S;'D@9&5T97)M:6YE
M9"!T;R!D:7-C;VYT:6YU92!I=',@=&]R96UI9F5N92`X,"!M9R!A;F0@=&]R
M96UI9F5N92`R,"!M9R!D979E;&]P;65N=`T*("`@<')O9W)A;7,N#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^0F%S:7,@;V8@4')E
M<V5N=&%T:6]N/"]I/CPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q
M,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!A8V-O;7!A;GEI;F<@=6YA=61I
M=&5D(&-O;F1E;G-E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!R969L96-T+"!I
M;B!T:&4@;W!I;FEO;B!O9@T*("`@;6%N86=E;65N="P@86QL(&%D:G5S=&UE
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M:"!T:&4@:6YS=')U8W1I;VYS('1O($9O<FT@,3`M42!A;F0@07)T:6-L928C
M,38P.S$P(&]F(%)E9W5L871I;VX-"B`@(%,M6"X@06-C;W)D:6YG;'DL(&EN
M9F]R;6%T:6]N(&%N9"!F;V]T;F]T92!D:7-C;&]S=7)E<R!N;W)M86QL>2!I
M;F-L=61E9"!I;B!F:6YA;F-I86P@<W1A=&5M96YT<PT*("`@<')E<&%R960@
M:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE
M<F%L;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@:&%V92!B965N
M#0H@("!C;VYD96YS960@;W(@;VUI='1E9"!F<F]M('1H92!A8V-O;7!A;GEI
M;F<@8V]N9&5N<V5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!4:&5S92!I;G1E
M<FEM(&-O;F1E;G-E9`T*("`@9FEN86YC:6%L('-T871E;65N=',@<VAO=6QD
M(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@875D:71E9"!F:6YA
M;F-I86P@<W1A=&5M96YT<R!A;F0-"B`@(')E;&%T960@;F]T97,@=&AE<F5T
M;RP@=VAI8V@@87)E(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@
M06YN=6%L(%)E<&]R="!O;B!&;W)M(#$P+4L@9F]R('1H92!Y96%R#0H@("!E
M;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P+B!/<&5R871I;F<@<F5S=6QT
M<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!A;F0@;FEN92!M;VYT:',@96YD960@
M4V5P=&5M8F5R#0H@("`S,"P@,C`Q,2!A<F4@;F]T(&YE8V5S<V%R:6QY(&EN
M9&EC871I=F4@;V8@=&AE(')E<W5L=',@=&AA="!M87D@8F4@97AP96-T960@
M9F]R('1H92!E;G1I<F4@9FES8V%L#0H@("!Y96%R(&5N9&EN9R!$96-E;6)E
M<B8C,38P.S,Q+"`R,#$Q+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P
M<'0G/CQB/CQI/E5S92!O9B!%<W1I;6%T97,\+VD^/"]B/@T*("`@/"]D:78^
M#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^5&AE('!R
M97!A<F%T:6]N(&]F(&-O;F1E;G-E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I
M;B!C;VYF;W)M:71Y('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S#0H@("!G
M96YE<F%L;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@<F5Q=6ER
M97,@;6%N86=E;65N="!T;R!M86ME(&5S=&EM871E<R!A;F0@87-S=6UP=&EO
M;G,@=&AA=`T*("`@869F96-T('1H92!R97!O<G1E9"!A;6]U;G1S(&]F(&%S
M<V5T<R!A;F0@;&EA8FEL:71I97,L('1H92!D:7-C;&]S=7)E(&]F(&-O;G1I
M;F=E;G0@87-S971S(&%N9`T*("`@;&EA8FEL:71I97,@870@=&AE(&1A=&4@
M;V8@=&AE(&-O;F1E;G-E9"!F:6YA;F-I86P@<W1A=&5M96YT<RP@86YD('1H
M92!R97!O<G1E9"!A;6]U;G1S(&]F(')E=F5N=65S#0H@("!A;F0@97AP96YS
M97,@9'5R:6YG('1H92!R97!O<G1I;F<@<&5R:6]D+B!!8W1U86P@86UO=6YT
M<R!A;F0@<F5S=6QT<R!C;W5L9"!D:69F97(@9G)O;2!T:&]S90T*("`@97-T
M:6UA=&5S+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM/@T*("`@/"$M
M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'14)214%+("TM
M/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2
M;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,'!T)SX-"B`@(#QB/@T*("`@/"]B/@T*("`@/"]D:78^
M#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB/CQI/E)E=F5N=64@4F5C;V=N:71I
M;VX\+VD^/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E
M>'0M:6YD96YT.B`T)2<^5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E
M(&9R;VT@<')O9'5C="!S86QE<R!O9B!&05)%4U1/3CQS=7`@<W1Y;&4],T0G
M9F]N="US:7IE.B`X-24[('9E<G1I8V%L+6%L:6=N.B!T97AT+71O<"<^)B,Q
M-S0[/"]S=7`^(&QE<W,@9&5D=6-T:6]N<R!F;W(-"B`@(&5S=&EM871E9"!S
M86QE<R!D:7-C;W5N=',@86YD('-A;&5S(')E='5R;G,N(%)E=F5N=64@9G)O
M;2!P<F]D=6-T('-A;&5S(&ES(')E8V]G;FEZ960@=VAE;@T*("`@<&5R<W5A
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M"B`@('-A;&5S+"!B87-E9"!O;B!F86-T;W)S('=H:6-H(&EN8VQU9&4@:&ES
M=&]R:6-A;"!P<F]D=6-T(')E='5R;G,@86YD(&5S=&EM871E9"!P<F]D=6-T
M(&EN('1H90T*("`@9&ES=')I8G5T:6]N(&-H86YN96P@=VAI8V@@:7,@97AP
M96-T960@=&\@97AC965D(&ET<R!E>'!I<F%T:6]N(&1A=&4N($%T(%-E<'1E
M;6)E<B8C,38P.S,P+"`R,#$Q(&%N9`T*("`@1&5C96UB97(F(S$V,#LS,2P@
M,C`Q,"P@=&AE($-O;7!A;GDF(S@R,3<[<R!A8V-R=6%L(&9O<B!P<F]D=6-T
M(')E='5R;G,@=V%S("9N8G-P.R0Y-S@@86YD("9N8G-P.R0X,#(L(')E<W!E
M8W1I=F5L>2X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@-"4G/D-O;&QA8F]R871I;VX@<F5V96YU92!C;VYS:7-T960@
M;V8@;F]N+7)E9G5N9&%B;&4@=7!F<F]N="!P87EM96YT<RP@;&EC96YS92!F
M965S+`T*("`@<F5I;6)U<G-E;65N=',@9F]R(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!A8W1I=FET:65S+"!A;F0@;6EL97-T;VYE('!A>6UE;G1S(&%S
M<V]C:6%T960@=VET:"!T:&4-"B`@($-O;7!A;GDF(S@R,3<[<R!F;W)M97(@
M8V]L;&%B;W)A=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G1S+B!2979E;G5E
M<R!F<F]M('1H92!#;VUP86YY)B,X,C$W.W,@<')I;W(-"B`@(&-O;&QA8F]R
M871I;VX@86YD(&QI8V5N<V4@86=R965M96YT<R!W97)E(')E8V]G;FEZ960@
M8F%S960@;VX@=&AE('!E<F9O<FUA;F-E(')E<75I<F5M96YT<R!O9B!T:&4-
M"B`@('-P96-I9FEC(&%G<F5E;65N=',N(%1H92!#;VUP86YY(&%N86QY>F5D
M(&%G<F5E;65N=',@=VET:"!M=6QT:7!L92!E;&5M96YT(&%R<F%N9V5M96YT
M<R!T;PT*("`@9&5T97)M:6YE('=H971H97(@=&AE(&1E;&EV97)A8FQE<R!U
M;F1E<B!T:&4@86=R965M96YT+"!I;F-L=61I;F<@;&EC96YS92!A;F0@<&5R
M9F]R;6%N8V4-"B`@(&]B;&EG871I;VYS('-U8V@@87,@:F]I;G0@<W1E97)I
M;F<@8V]M;6ET=&5E('!A<G1I8VEP871I;VX@86YD(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!A8W1I=FET:65S+`T*("`@8V]U;&0@:&%V92!B965N('-E
M<&%R871E9"!O<B!W:&5T:&5R(&%L;"!O9B!T:&4@9&5L:79E<F%B;&5S(&UU
M<W0@:&%V92!B965N(&%C8V]U;G1E9"!F;W(@87,@80T*("`@<VEN9VQE('5N
M:70@;V8@86-C;W5N=&EN9RX@4F5V96YU97,@9G)O;2!M:6QE<W1O;F4@<&%Y
M;65N=',@9F]R('=H:6-H('1H92!#;VUP86YY(&AA9"!N;PT*("`@8V]N=&EN
M=6EN9R!P97)F;W)M86YC92!O8FQI9V%T:6]N<R!W97)E(')E8V]G;FEZ960@
M=7!O;B!A8VAI979E;65N="!O9B!T:&4@<&5R9F]R;6%N8V4@;6EL97-T;VYE
M+`T*("`@87,@9&5F:6YE9"!I;B!T:&4@<F5L871E9"!A9W)E96UE;G0L('!R
M;W9I9&5D('1H92!M:6QE<W1O;F4@=V%S('-U8G-T86YT:79E(&%N9"!A(&-U
M;&UI;F%T:6]N(&]F#0H@("!T:&4@96%R;FEN9W,@<')O8V5S<R!H860@;V-C
M=7)R960N($1U92!T;R!T:&4@=&5R;6EN871I;VX@;V8@=&AE($-O;7!A;GDF
M(S@R,3<[<R!L:6-E;G-E(&%N9`T*("`@8V]L;&%B;W)A=&EO;B!A9W)E96UE
M;G0@=VET:"!)<'-E;B!":6]P:&%R;2!,:6UI=&5D("@F(S@R,C`[27!S96XF
M(S@R,C$[*2!I;B!-87)C:"8C,38P.S(P,3$L('1H92!#;VUP86YY(')E8V]G
M;FEZ960-"B`@(&-O;&QA8F]R871I;VX@<F5V96YU92!O9B`F;F)S<#LD."PP
M-C8@:6X@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,2!A<R!T:&4@0V]M<&%N
M>2!H87,@;F\@9G5R=&AE<@T*("`@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,N
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^4F5S96%R
M8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V5S/"]I/CPO8CX-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E)E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!I;F-L=61E+"!B=70@87)E
M(&YO="!L:6UI=&5D('1O+"!T:&4@0V]M<&%N>28C.#(Q-SMS(&5X<&5N<V5S
M(&9O<@T*("`@<&5R<V]N;F5L+"!S=7!P;&EE<RP@86YD(&9A8VEL:71I97,@
M87-S;V-I871E9"!W:71H(')E<V5A<F-H(&%C=&EV:71I97,L('-C<F5E;FEN
M9R!A;F0-"B`@(&ED96YT:69I8V%T:6]N(&]F('!R;V1U8W0@8V%N9&ED871E
M<RP@9F]R;75L871I;VX@86YD('-Y;G1H97-I<R!A8W1I=FET:65S+"!M86YU
M9F%C='5R:6YG+`T*("`@<')E8VQI;FEC86P@<W1U9&EE<RP@=&]X:6-O;&]G
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M92!R96-E:79E9"X-"B`@($%S('-U8V@L(&%C8W)U960@;&EA8FEL:71I97,@
M<F5L871E9"!T;R!T:&ER9"!P87)T>2!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@86-T:79I=&EE<R!A<F4-"B`@(')E8V]G;FEZ960@8F%S960@=7!O;B!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&5S=&EM871E(&]F('-E<G9I8V5S(')E8V5I
M=F5D(&%N9"!D96=R964@;V8@8V]M<&QE=&EO;B!O9B!T:&4-"B`@('-E<G9I
M8V5S(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@<W!E8VEF:6,@=&AI<F0@<&%R
M='D@8V]N=')A8W0N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^
M/&(^/&D^0V%S:"P@0V%S:"!%<75I=F%L96YT<R!A;F0@4VAO<G0M=&5R;2!)
M;G9E<W1M96YT<SPO:3X\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@0V]M<&%N>2!C;VYS:61E<G,@
M:&EG:&QY(&QI<75I9"!I;G9E<W1M96YT<R!W:71H(&EN:71I86P@;6%T=7)I
M=&EE<R!O9B!T:')E92!M;VYT:',@;W(-"B`@(&QE<W,@=&\@8F4@8V%S:"!E
M<75I=F%L96YT<RX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T
M97AT+6EN9&5N=#H@-"4G/D%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q(&%N
M9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P+"!S:&]R="UT97)M(&EN=F5S=&UE
M;G1S(&-O;G-I<W1E9"!O9B!C97)T:69I8V%T97,-"B`@(&]F(&1E<&]S:70@
M=VET:"!O<FEG:6YA;"!M871U<FET:65S(&]F(&=R96%T97(@=&AA;B!T:')E
M92!M;VYT:',@86YD(&QE<W,@=&AA;B!O;F4@>65A<BX@07,@=&AE#0H@("!#
M;VUP86YY(&AA<R!T:&4@<&]S:71I=F4@:6YT96YT(&%N9"!A8FEL:71Y('1O
M(&AO;&0@=&AE(&-E<G1I9FEC871E<R!O9B!D97!O<VET('5N=&EL(&UA='5R
M:71Y+`T*("`@=&AE<V4@:6YV97-T;65N=',@:&%V92!B965N(&-L87-S:69I
M960@87,@:&5L9"!T;R!M871U<FET>2!I;G9E<W1M96YT<R!A;F0@87)E('-T
M871E9"!A="!C;W-T+`T*("`@=VAI8V@@87!P<F]X:6UA=&5S(&9A:7(@=F%L
M=64N#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L:6\@+2T^#0H@("`\(2TM("]&
M;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M+2!004=%0E)%04L@+2T^#0H@
M("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N
M)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD:78@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G
M:6XM=&]P.B`P<'0G/@T*("`@/&(^#0H@("`\+V(^#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^26UP86ER;65N="!O9B!,;VYG+4QI
M=F5D($%S<V5T<SPO:3X\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@0V]M<&%N>2!R979I97=S(&QO
M;F<M;&EV960@87-S971S(&9O<B!I;7!A:7)M96YT('=H96YE=F5R(&5V96YT
M<R!O<B!C:&%N9V5S(&EN(&9A8W1S(&%N9`T*("`@8VER8W5M<W1A;F-E<R!A
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M.W,@8F5S=`T*("`@97-T:6UA=&5S+"!U<VEN9R!A<'!R;W!R:6%T92!A;F0@
M8W5S=&]M87)Y(&%S<W5M<'1I;VYS(&%N9"!P<F]J96-T:6]N<R!A="!T:&4@
M=&EM92X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@-"4G/D)A<V5D('5P;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!D96-I
M<VEO;B!T;R!D:7-C;VYT:6YU92!T;W)E;6EF96YE(#@P(&UG(&1E=F5L;W!M
M96YT(&%N9"!A9G1E<@T*("`@86YA;'EZ:6YG(&9U='5R92!C87-H(&9L;W=S
M(&%N9"!E<W1I;6%T97,@;V8@9F%I<B!M87)K970@=F%L=64@9G)O;2!A(&UA
M<FME="!P87)T:6-I<&%N=`T*("`@<&5R<W!E8W1I=F4L('1H92!#;VUP86YY
M(&1E=&5R;6EN960@=&AA="!I=',@=&]R96UI9F5N92`X,"!M9R!I;G1A;F=I
M8FQE(&%S<V5T('=A<R!I;7!A:7)E9"!A;F0-"B`@(')E8V]R9&5D(&%N(&EM
M<&%I<FUE;G0@8VAA<F=E(&]F("9N8G-P.R0Q+#4Y."!D=7)I;F<@=&AE('1H
M<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q+"`R,#$Q+B!4:&4@:6UP
M86ER960-"B`@(&EN=&%N9VEB;&4@87-S970@8V]N<VES=&5D(&]F('1H92!U
M;F%M;W)T:7IE9"!P;W)T:6]N(&]F(&-A<&ET86QI>F5D(&QI8V5N<V4@9F5E
M<R!P86ED('1O($]R:6]N#0H@("!#;W)P;W)A=&EO;B`H)B,X,C(P.T]R:6]N
M)B,X,C(Q.RD@<F5L871E9"!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS('1O<F5M
M:69E;F4@.#`@;6<@<')O9W)A;2X@5&AI<R!L:6-E;G-E(&9E92!W87,@<&%I
M9`T*("`@=6YD97(@=&AE(&%M96YD960@86YD(')E<W1A=&5D(&QI8V5N<V4@
M86YD('-U<'!L>2!A9W)E96UE;G0@9F]R('1H92!#;VUP86YY)B,X,C$W.W,@
M97AC;'5S:79E(&QI8V5N<V4-"B`@(&9R;VT@3W)I;VX@=&\@9&5V96QO<"!A
M;F0@8V]M;65R8VEA;&EZ92!T;W)E;6EF96YE+6)A<V5D('!R;V1U8W1S+@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T
M)2<^5&AE(&EM<&%I<FUE;G0@8VAA<F=E('=A<R!I;F-L=61E9"!I;B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,@:6X@=&AE(&-O;F1E;G-E
M9`T*("`@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,@9F]R('1H92!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,2X-"B`@(#PO9&EV
M/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CX\:3Y);F-O;64@5&%X97,\+VD^
M/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R(&1E9F5R<F5D('1A
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M;F0@;&EA8FEL:71I97,@87)E(&1E=&5R;6EN960-"B`@(&)A<V5D(&]N('1H
M92!D:69F97)E;F-E(&)E='=E96X@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G0@
M86YD('1A>"!B87-I<R!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S#0H@("!U
M<VEN9R!E;F%C=&5D('1A>"!R871E<R!I;B!E9F9E8W0@9F]R('1H92!Y96%R
M(&EN('=H:6-H('1H92!D:69F97)E;F-E<R!A<F4@97AP96-T960@=&\@<F5V
M97)S92X@00T*("`@=F%L=6%T:6]N(&%L;&]W86YC92!I<R!P<F]V:61E9"!W
M:&5N(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H870@<V]M92!P;W)T
M:6]N(&]R(&%L;"!O9B!T:&4-"B`@(&1E9F5R<F5D('1A>"!A<W-E=',@=VEL
M;"!N;W0@8F4@<F5A;&EZ960N($%C8V]R9&EN9VQY+"!A="!397!T96UB97(F
M(S$V,#LS,"P@,C`Q,2!A;F0@1&5C96UB97(F(S$V,#LS,2P-"B`@(#(P,3`L
M(&YE="!O9B!T:&4@=F%L=6%T:6]N(&%L;&]W86YC92P@=&AE(&YE="!D969E
M<G)E9"!T87@@87-S971S('=E<F4@<F5D=6-E9"!T;R!Z97)O+B!);F-O;64-
M"B`@('1A>&5S(&%R92!D97-C<FEB960@;6]R92!F=6QL>2!I;B!.;W1E(#D@
M=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!F:6YA;F-I86P@<W1A=&5M96YT<R!I
M;F-L=61E9"!I;B!T:&4-"B`@($-O;7!A;GDF(S@R,3<[<R!!;FYU86P@4F5P
M;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F
M(S$V,#LS,2P@,C`Q,"X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M)SX\8CX\:3Y/=&AE<B!);F-O;64L(&YE=#PO:3X\+V(^#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY/=&AE<B!I
M;F-O;64L(&YE="!C;VYS:7-T<R!O9B!I;G1E<F5S="!E87)N960@;VX@=&AE
M($-O;7!A;GDF(S@R,3<[<R!C87-H+"!C87-H(&5Q=6EV86QE;G1S(&%N9`T*
M("`@<VAO<G0M=&5R;2!I;G9E<W1M96YT<RP@:6YT97)E<W0@97AP96YS92P@
M9F]R96EG;B!C=7)R96YC>2!T<F%N<V%C=&EO;B!G86EN<R!A;F0@;&]S<V5S
M+"!A;F0@;W1H97(-"B`@(&YO;BUO<&5R871I;F<@:6YC;VUE(&]R(&5X<&5N
M<V4N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^4W5B
M<V5Q=65N="!%=F5N=',\+VD^/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^5&AE($-O;7!A;GD@:&%S(&5V
M86QU871E9"!A;&P@979E;G1S(&]R('1R86YS86-T:6]N<R!T:&%T(&]C8W5R
M<F5D(&%F=&5R(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q('5P#0H@("!T:')O
M=6=H('1H92!D871E('1H92!C;VYD96YS960@9FEN86YC:6%L('-T871E;65N
M=',@=V5R92!I<W-U960N(%1H97)E('=E<F4@;F\@;6%T97)I86P-"B`@(')E
M8V]G;FEZ86)L92!O<B!N;VYR96-O9VYI>F%B;&4@<W5B<V5Q=65N="!E=F5N
M=',@9'5R:6YG('1H92!P97)I;V0@979A;'5A=&5D+@T*("`@/"]D:78^#0H@
M("`\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?8S<R-C8P-F)?-#=B,%\T8C%D7V(V8CE?,F0V,C8V,F,V,C)D#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,W,C8V,#9B7S0W8C!?-&(Q
M9%]B-F(Y7S)D-C(V-C)C-C(R9"]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R92U"87-E
M9"!#;VUP96YS871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92U"87-E9"!#;VUP96YS871I;VX@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R92U"87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7
M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W
M=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD
M=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`R("T@
M=7,M9V%A<#I$:7-C;&]S=7)E3V9#;VUP96YS871I;VY296QA=&5D0V]S='-3
M:&%R94)A<V5D4&%Y;65N='-497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF
M.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\
M8CXR+B!3:&%R92U"87-E9"!#;VUP96YS871I;VX\+V(^#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY3:&%R92UB
M87-E9"!P87EM96YT<R!I;F-L=61E('-T;V-K(&]P=&EO;B!G<F%N=',@=6YD
M97(@=&AE($-O;7!A;GDF(S@R,3<[<R!S=&]C:R!O<'1I;VX@86YD(&5Q=6ET
M>0T*("`@:6YC96YT:79E('!L86YS(&%N9"!D969E<G)E9"!C;VUP96YS871I
M;VX@87)R86YG96UE;G1S(&9O<B!T:&4@0V]M<&%N>28C.#(Q-SMS(&YO;BUE
M;7!L;WEE92!D:7)E8W1O<G,N#0H@("!4:&4@0V]M<&%N>2!R96-O9VYI>F5S
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O<B!I=',@<VAA<F4M8F%S960@<&%Y
M;65N=',@8F%S960@;VX@=&AE(&9A:7(@=F%L=64@;V8-"B`@('1H92!A=V%R
M9',@;W9E<B!T:&4@<&5R:6]D(&1U<FEN9R!W:&EC:"!A;B!E;7!L;WEE92!O
M<B!N;VXM96UP;&]Y964@9&ER96-T;W(@:7,@<F5Q=6ER960@=&\@<')O=FED
M90T*("`@<V5R=FEC92!I;B!E>&-H86YG92!F;W(@=&AE(&%W87)D+B!4:&4@
M0V]M<&%N>28C.#(Q-SMS('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!P;&%N
M<R!A<F4@9&5S8W)I8F5D(&UO<F4-"B`@(&9U;&QY(&EN($YO=&4@,R!T;R!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU
M9&5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E<&]R="!O;@T*
M("`@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P
M.S,Q+"`R,#$P+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM/@T*("`@
M/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'14)214%+
M("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE
M=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@
M("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,'!T)SX-"B`@(#QB/@T*("`@/"]B/@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^5&AE
M(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('-H87)E+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E(&EN8VQU9&5D('=I=&AI;B!T:&4@8V]N9&5N<V5D
M#0H@("!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!A
M;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$@
M86YD(#(P,3`Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(^
M#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L92!(
M96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0@
M=VED=&@],T0T-"4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q
M)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A
M;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V/CQB/E1H<F5E($UO;G1H<R!%
M;F1E9#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#8^/&(^3FEN92!-;VYT:',@16YD
M960\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B
M;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q
M<'@@<V]L:60@(S`P,#`P,"<^/&(^4V5P=&5M8F5R(#,P+#PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/E-E<'1E;6)E<B`S,"P\+V(^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^
M,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C
M,#`P,#`P)SX\8CXR,#$Q/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,#PO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE
M($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A
M8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E)E
M<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<PT*("`@/"]D:78^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C4P,SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT-#(\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^,2PT,3`\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,2PW-#(\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*
M("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N
M=#HM,35P>"<^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS97,-
M"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M-C(S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1R:6=H=#XV-S<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$L.3`Y/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XR+#$W,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@
M("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[
M('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R
M:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT
M<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F
M9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^5&]T86P@<VAA<F4M8F%S960@
M8V]M<&5N<V%T:6]N#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PQ,C8\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,2PQ,3D\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,RPS,3D\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB
M<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,RPY,3(\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X]
M,T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O
M=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P
M86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@
M<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^4VAA
M<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5C;W)D960@87,@9V5N
M97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS92!F;W(@8F]T:"!O9@T*
M("`@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@
M,C`Q,2!A;F0@,C`Q,"!I;F-L=61E9"!S:&%R92UB87-E9"!C;VUP96YS871I
M;VX@97AP96YS90T*("`@<F5L871E9"!T;R!D969E<G)E9"!C;VUP96YS871I
M;VX@87)R86YG96UE;G1S(&9O<B!T:&4@0V]M<&%N>28C.#(Q-SMS(&YO;BUE
M;7!L;WEE92!D:7)E8W1O<G,@;V8@)FYB<W`[)#0U+@T*("`@4VAA<F4M8F%S
M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!D969E<G)E9"!C
M;VUP96YS871I;VX@87)R86YG96UE;G1S(&9O<B!T:&4@0V]M<&%N>28C.#(Q
M-SMS#0H@("!N;VXM96UP;&]Y964@9&ER96-T;W)S(&]F("9N8G-P.R0Q-#$@
M=V%S(&EN8VQU9&5D(&EN('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E(')E8V]R9&5D(&%S(&=E;F5R86P-"B`@(&%N9"!A9&UI;FES=')A=&EV
M92!E>'!E;G-E<R!F;W(@8F]T:"!O9B!T:&4@;FEN92!M;VYT:',@96YD960@
M4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$@86YD(#(P,3`N#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@9F%I
M<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@=V%S(&5S=&EM871E9"!U<VEN
M9R!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS(&9O<B!T:&4-"B`@('!E<FEO
M9',@<')E<V5N=&5D.@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N
M=&5R/@T*("`@/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`@(#PA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@
M/'1D('=I9'1H/3-$-#0E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-CX\8CY4:')E92!-;VYT
M:',@16YD960\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V/CQB/DYI;F4@36]N=&AS
M($5N9&5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E-E<'1E;6)E<B`S,"P\+V(^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S
M;VQI9"`C,#`P,#`P)SX\8CY397!T96UB97(@,S`L/"]B/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G
M/CQB/C(P,3$\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$P/"]B/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E
M<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L
M:60@(S`P,#`P,"<^/&(^,C`Q,3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/C(P
M,3`\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!4
M86)L92!";V1Y("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X
M)SY%>'!E8W1E9"!P<FEC92!V;VQA=&EL:71Y#0H@("`\+V1I=CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0^-C4N,SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<#XE/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C8V+C(\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`^)3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XV-"XY/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^-C0N-CPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<#XE
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@
M=&5X="UI;F1E;G0Z+3$U<'@G/E)I<VLM9G)E92!I;G1E<F5S="!R871E#0H@
M("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BXS/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BXT/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,BXU/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P/B4\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^,RXT/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P/B4\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@
M/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT
M+6EN9&5N=#HM,35P>"<^5V5I9VAT960@879E<F%G92!E>'!E8W1E9"!L:69E
M(&EN('EE87)S#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!C;VQS
M<&%N/3-$,"!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#XV+C4@>65A
M<G,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!C;VQS<&%N/3-$,"!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#XV
M+C4@>65A<G,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!C;VQS<&%N/3-$,"!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#XV+C4@>65A<G,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!C;VQS<&%N/3-$,"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#XV+C4@>65A<G,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@
M("`\+W1A8FQE/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E
M>'0M:6YD96YT.B`T)2<^5&AE(&9O;&QO=VEN9R!I<R!A('-U;6UA<GD@;V8@
M<W1O8VL@;W!T:6]N('1R86YS86-T:6]N<R!F;W(@86QL(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@<W1O8VL-"B`@(&]P=&EO;B!A;F0@97%U:71Y(&EN8V5N
M=&EV92!P;&%N<R!S:6YC92!T:&4@0V]M<&%N>28C.#(Q-SMS(&UO<W0@<F5C
M96YT(&9I<V-A;"!Y96%R(&5N9#H-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG
M;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM($)E
M9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9"!W:61T:#TS1#<R)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V
M86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY796EG:'1E
M9#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-
M"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O
M='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D%V97)A9V4@17AE<F-I<V4\
M+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T
M;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@
M<V]L:60@(S`P,#`P,"<^/&(^3G5M8F5R(&]F(%-H87)E<SPO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/E!R:6-E(%!E<B!3:&%R93PO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\
M='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E
M9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D]P=&EO;G,@;W5T<W1A;F1I
M;F<@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,`T*("`@/"]D:78^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT+#0S,"PT.34\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^,3`N.3$\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HS
M,'!X.R!T97AT+6EN9&5N=#HM,35P>"<^3W!T:6]N<R!G<F%N=&5D#0H@("`\
M+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$L,SDS
M+#4P,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^,BXX,3PO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C,P<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SY/<'1I;VYS(&9O<F9E:71E9"!O<B!E>'!I<F5D#0H@("`\+V1I=CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^*#@T,RPV-C(\+W1D/@T*("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^."XR,3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C,P<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SY/<'1I;VYS(&5X97)C:7-E9`T*("`@/"]D:78^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B@Q,RPP,#`\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-"XR
M,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@
M("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT
M.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N
M/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S
M;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*
M("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N
M=#HM,35P>"<^3W!T:6]N<R!O=71S=&%N9&EN9R!A="!397!T96UB97(F(S$V
M,#LS,"P@,C`Q,0T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XT+#DV-RPS,S,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/CDN,3(\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A
M8FQE/@T*("`@/"]D:78^#0H@("`\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S<R-C8P-F)?-#=B,%\T8C%D7V(V
M8CE?,F0V,C8V,F,V,C)D#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V,W,C8V,#9B7S0W8C!?-&(Q9%]B-F(Y7S)D-C(V-C)C-C(R9"]7;W)K<VAE
M971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY"87-I8R!A;F0@1&EL=71E9"!.970@*$QO<W,I($EN8V]M92!0
M97(@4VAA<F4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY%87)N:6YG<R!097(@4VAA<F4@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A
M;F0@1&EL=71E9"!.970@*$QO<W,I($EN8V]M92!097(@4VAA<F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"
M3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@
M(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS
M:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@
M3F]T92`S("T@=7,M9V%A<#I%87)N:6YG<U!E<E-H87)E5&5X=$)L;V-K+2T^
M#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O
M;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P="<^/&(^,RX@0F%S:6,@86YD($1I;'5T960@3F5T("A,
M;W-S*2!);F-O;64@4&5R(%-H87)E/"]B/@T*("`@/"]D:78^#0H@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^0F%S:6,@86YD(&1I;'5T
M960@;F5T("AL;W-S*28C,38P.VEN8V]M92!P97(@<VAA<F4@871T<FEB=71A
M8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@:7,-"B`@(&-A;&-U;&%T960@
M8F%S960@;VX@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO
M;B!S:&%R97,@;W5T<W1A;F1I;F<@9'5R:6YG('1H92!P97)I;V0N#0H@("!$
M:6QU=&5D(&YE="`H;&]S<RDF(S$V,#MI;F-O;64@<&5R('-H87)E(&%L<V\@
M9VEV97,@969F96-T('1O('1H92!D:6QU=&EV92!P;W1E;G1I86P@;V8@8V]M
M;6]N('-T;V-K#0H@("!C;VYS:7-T:6YG(&]F('-T;V-K(&]P=&EO;G,N#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E
M)SY796EG:'1E9"!A=F5R86=E(&]P=&EO;G,@;W5T<W1A;F1I;F<@=&\@<'5R
M8VAA<V4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B`U+#$Q,RPY-#,@86YD
M#0H@("`T+#4Q-2PP,#8@9F]R('1H92!T:')E92!M;VYT:',@96YD960@4V5P
M=&5M8F5R)B,Q-C`[,S`L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I=F5L>2P@
M86YD(#4L-#4U+#<P,"!A;F0-"B`@(#0L-3`Q+#`P,B!F;W(@=&AE(&YI;F4@
M;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q(&%N9"`R,#$P
M+"!R97-P96-T:79E;'DL('=E<F4@97AC;'5D960@9G)O;0T*("`@=&AE(&-A
M;&-U;&%T:6]N<R!O9B!D:6QU=&5D(&YE="`H;&]S<RDF(S$V,#MI;F-O;64@
M<&5R('-H87)E(&%S(&EN8VQU<VEO;B!O9B!T:&4@;W!T:6]N<R!W;W5L9"!H
M879E(&AA9`T*("`@86X@86YT:2UD:6QU=&EV92!E9F9E8W0@;VX@=&AE(&YE
M="`H;&]S<RDF(S$V,#MI;F-O;64@<&5R('-H87)E(&9O<B!T:&4@<&5R:6]D
M<RX-"B`@(#PO9&EV/@T*("`@/"$M+2!&;VQI;R`M+3X-"B`@(#PA+2T@+T9O
M;&EO("TM/@T*("`@/"]D:78^#0H@("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@
M(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#!P="<^#0H@("`\8CX-"B`@(#PO8CX-"B`@(#PO9&EV/@T*("`@
M/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V,W,C8V,#9B7S0W8C!?-&(Q9%]B-F(Y7S)D-C(V-C)C-C(R9`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-S(V-C`V8E\T-V(P7S1B,61?
M8C9B.5\R9#8R-C8R8S8R,F0O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6]N(%-T;V-K
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M;6]N(%-T;V-K(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)
M0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H
M='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET
M:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO
M=&4@-"`M('5S+6=A87`Z4W1O8VMH;VQD97)S17%U:71Y3F]T941I<V-L;W-U
M<F5497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@
M,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXT+B!#;VUM;VX@4W1O
M8VL\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI
M;F1E;G0Z(#0E)SY/;B!-87DF(S$V,#LV+"`R,#$Q+"!T:&4@0V]M<&%N>2!F
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M;VX@<W1O8VLL('!A<B!V86QU92`F;F)S<#LD,"XP,#$@<&5R('-H87)E+"!F
M<F]M#0H@("`V,"PP,#`L,#`P('-H87)E<R!T;R`Q,C`L,#`P+#`P,"!S:&%R
M97,N(%1H92!F;W)E9V]I;F<@86UE;F1M96YT('=A<R!A<'!R;W9E9"!B>2!T
M:&4@0V]M<&%N>28C.#(Q-SMS#0H@("!S=&]C:VAO;&1E<G,@870@=&AE($-O
M;7!A;GDF(S@R,3<[<R`R,#$Q($%N;G5A;"!-965T:6YG(&]F(%-T;V-K:&]L
M9&5R<R!H96QD(&]N($UA>28C,38P.S4L(#(P,3$N#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY/;B!*=6YE)B,Q
M-C`[,C@L(#(P,3$L('1H92!#;VUP86YY(&-O;7!L971E9"!A;B!U;F1E<G=R
M:71T96X@<'5B;&EC(&]F9F5R:6YG(&]F(#$P+#`P,"PP,#`@<VAA<F5S#0H@
M("!O9B!I=',@8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@=&\@=&AE('!U8FQI
M8R!O9B`F;F)S<#LD-"XW-2!P97(@<VAA<F4N(%1H92!#;VUP86YY(&%L<V\@
M9W)A;G1E9"!T:&4-"B`@('5N9&5R=W)I=&5R<R!A(#,P+61A>2!O<'1I;VX@
M=&\@<'5R8VAA<V4@=7`@=&\@86X@861D:71I;VYA;"`Q+#4P,"PP,#`@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!T;PT*("`@8V]V97(@;W9E<BUA;&QO=&UE
M;G1S+"!I9B!A;GDN(%1H92!U;F1E<G=R:71E<G,@97AE<F-I<V5D('1H:7,@
M;W!T:6]N(&%N9"!P=7)C:&%S960@86X@861D:71I;VYA;`T*("`@,2PP,C,L
M,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C
M:R!O;B!*=6YE)B,Q-C`[,C@L(#(P,3$@870@82!P<FEC92!O9B`F;F)S<#LD
M-"XW-2!P97(@<VAA<F4N($YE=`T*("`@8V%S:"!P<F]C965D<R!F<F]M('1H
M92!P=6)L:6,@;V9F97)I;F<@=V5R92!A<'!R;WAI;6%T96QY("9N8G-P.R0T
M.2PP,#`@869T97(@9&5D=6-T:6YG('1H92!U;F1E<G=R:71I;F<-"B`@(&1I
M<V-O=6YT(&%N9"!O9F9E<FEN9R!E>'!E;G-E<RX-"B`@(#PO9&EV/@T*("`@
M/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V,W,C8V,#9B7S0W8C!?-&(Q9%]B-F(Y7S)D-C(V-C)C-C(R9`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-S(V-C`V8E\T-V(P7S1B,61?
M8C9B.5\R9#8R-C8R8S8R,F0O5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]L;&%B;W)A=&EO
M;B!A;F0@3&EC96YS92!!9W)E96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]L;&%B;W)A=&EO;B!A;F0@
M3&EC96YS92!!9W)E96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A;F0@
M3&EC96YS92!!9W)E96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A4
M34P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]4
M4B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@
M(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@-2`M('5S+6=A87`Z0V]L
M;&%B;W)A=&EV94%R<F%N9V5M96YT1&ES8VQO<W5R951E>'1";&]C:RTM/@T*
M("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA
M;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$P<'0G/CQB/C4N($-O;&QA8F]R871I;VX@86YD($QI8V5N<V4@
M06=R965M96YT<SPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M)SX\8CX\:3Y5;FEV97)S:71Y(&]F(%1E;FYE<W-E92!297-E87)C:"!&;W5N
M9&%T:6]N($QI8V5N<V4@06=R965M96YT<SPO:3X\+V(^#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@0V]M
M<&%N>2!A;F0@=&AE(%5N:79E<G-I='D@;V8@5&5N;F5S<V5E(%)E<V5A<F-H
M($9O=6YD871I;VX@*"8C.#(R,#M55%)&)B,X,C(Q.RD@87)E('!A<G1I97,@
M=&\@80T*("`@8V]N<V]L:61A=&5D+"!A;65N9&5D(&%N9"!R97-T871E9"!L
M:6-E;G-E(&%G<F5E;65N="`H=&AE("8C.#(R,#M305)-($QI8V5N<V4@06=R
M965M96YT)B,X,C(Q.RD@<'5R<W5A;G0@=&\-"B`@('=H:6-H('1H92!#;VUP
M86YY('=A<R!G<F%N=&5D(&5X8VQU<VEV92!W;W)L9'=I9&4@<FEG:'1S(&EN
M(&%L;"!E>&ES=&EN9R!305)-('1E8VAN;VQO9VEE<R!O=VYE9"!O<@T*("`@
M8V]N=')O;&QE9"!B>2!55%)&+"!A;F0@8V5R=&%I;B!I;7!R;W9E;65N=',@
M=&AE<F5T;RP@86YD(&5X8VQU<VEV92!R:6=H=',@=&\@8V5R=&%I;B!F=71U
M<F4@4T%230T*("`@=&5C:&YO;&]G>2!T:&%T(&UA>2!B92!D979E;&]P960@
M8GD@8V5R=&%I;B!S8VEE;G1I<W1S(&%T('1H92!5;FEV97)S:71Y(&]F(%1E
M;FYE<W-E92!O<@T*("`@<W5B<V5Q=65N=&QY(&QI8V5N<V5D('1O(%544D8@
M=6YD97(@8V5R=&%I;B!E>&ES=&EN9R!I;G1E<BUI;G-T:71U=&EO;F%L(&%G
M<F5E;65N=',@=VET:"!4:&4@3VAI;PT*("`@4W1A=&4@56YI=F5R<VET>2X@
M56YD97(@=&AE(%-!4DT@3&EC96YS92!!9W)E96UE;G0L('1H92!#;VUP86YY
M(&ES(&]B;&EG871E9"!T;R!P87D@55121B!A;FYU86P-"B`@(&QI8V5N<V4@
M;6%I;G1E;F%N8V4@9F5E<RP@;&]W('-I;F=L92UD:6=I="!R;WEA;'1I97,@
M;VX@;F5T('-A;&5S(&]F('!R;V1U8W1S(&%N9"!M:60@<VEN9VQE+61I9VET
M#0H@("!R;WEA;'1I97,@;VX@<W5B;&EC96YS92!R979E;G5E<RX-"B`@(#PO
M9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D%D
M9&ET:6]N86QL>2P@=&AE($-O;7!A;GD@86YD(%544D8@<')E=FEO=7-L>2!E
M;G1E<F5D(&EN=&\@86X@86UE;F1E9"!A;F0@<F5S=&%T960@;&EC96YS90T*
M("`@86=R965M96YT("AT:&4@)B,X,C(P.U-%4DT@3&EC96YS92!!9W)E96UE
M;G0F(S@R,C$[*2!P=7)S=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!W87,@
M9W)A;G1E9"!E>&-L=7-I=F4-"B`@('=O<FQD=VED92!R:6=H=',@=&\@5512
M1B8C.#(Q-SMS(&UE=&AO9"!O9B!U<V4@<&%T96YT<R!R96QA=&EN9R!T;R!3
M15)-<RP@:6YC;'5D:6YG('1O<F5M:69E;F4@9F]R#0H@("!C:&5M;W!R979E
M;G1I;VX@;V8@<')O<W1A=&4@8V%N8V5R+B!);B!L:6=H="!O9B!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&1E8VES:6]N('1O(&1I<V-O;G1I;G5E(&9U<G1H97(-
M"B`@(&-L:6YI8V%L(&1E=F5L;W!M96YT(&]F('1O<F5M:69E;F4@,C`@;6<L
M('1H92!#;VUP86YY(&5X97)C:7-E9"!I=',@<FEG:'0@=&\@=&5R;6EN871E
M('1H92!315)-#0H@("!,:6-E;G-E($%G<F5E;65N="!W:71H(%544D8@9'5R
M:6YG('1H92!F:7)S="!Q=6%R=&5R(&]F(#(P,3$N#0H@("`\+V1I=CX-"B`@
M(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M;6%R9VEN+71O<#H@,3!P="<^/&(^/&D^27!S96X@0V]L;&%B;W)A=&EO;B!A
M;F0@3&EC96YS92!!9W)E96UE;G0\+VD^/"]B/@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^26X@4V5P=&5M8F5R
M)B,Q-C`[,C`P-BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8V]L;&%B
M;W)A=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G0@=VET:"!)<'-E;@T*("`@
M*'1H92`F(S@R,C`[27!S96X@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0F(S@R
M,C$[*2!P=7)S=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!G<F%N=&5D($EP
M<V5N(&5X8VQU<VEV92!R:6=H=',-"B`@(&EN('1H92!%=7)O<&5A;B!5;FEO
M;BP@4W=I='IE<FQA;F0L($YO<G=A>2P@26-E;&%N9"P@3&EC:'1E;G-T96EN
M+"!A;F0@=&AE($-O;6UO;G=E86QT:"!O9@T*("`@26YD97!E;F1E;G0@4W1A
M=&5S("AT:&4@)B,X,C(P.T5U<F]P96%N(%1E<G)I=&]R>28C.#(R,3LI('1O
M(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@=&]R96UI9F5N92!I;B!A;&P-
M"B`@(&EN9&EC871I;VYS('=H:6-H('1H92!#;VUP86YY(&AA<R!L:6-E;G-E
M9"!F<F]M($]R:6]N+"!W:&EC:"!I;F-L=61E(&%L;"!I;F1I8V%T:6]N<R!I
M;B!H=6UA;G,-"B`@(&5X8V5P="!T:&4@=')E871M96YT(&%N9"!P<F5V96YT
M:6]N(&]F(&)R96%S="!C86YC97(@;W5T<VED92!O9B!T:&4@56YI=&5D(%-T
M871E<RX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@-"4G/DEN(&%C8V]R9&%N8V4@=VET:"!T:&4@=&5R;7,@;V8@=&AE
M($EP<V5N($-O;&QA8F]R871I;VX@06=R965M96YT+"!)<'-E;B!P86ED('1H
M92!#;VUP86YY#0H@("`F(S@S-C0[,C,L,#`P(&%S(&$@;&EC96YS92!F964@
M86YD(&5X<&5N<V4@<F5I;6)U<G-E;65N="X@26X@1F5B<G5A<GDF(S$V,#LR
M,#`X+"!T:&4@0V]M<&%N>2!E87)N960@80T*("`@;6EL97-T;VYE(&]F("8C
M.#,V-#LQ+#`P,"`H87!P<F]X:6UA=&5L>2`F;F)S<#LD,2PT.#(I('=I=&@@
M=&AE(&%C:&EE=F5M96YT(&]F('1H92!P<FEM87)Y(&5N9'!O:6YT(&EN('1H
M90T*("`@0V]M<&%N>28C.#(Q-SMS(&-O;7!L971E9"!P:79O=&%L(%!H87-E
M($E)22!C;&EN:6-A;"!T<FEA;"!E=F%L=6%T:6YG('1O<F5M:69E;F4@.#`@
M;6<@=&\@<F5D=6-E#0H@("!F<F%C='5R97,@:6X@;65N('=I=&@@<')O<W1A
M=&4@8V%N8V5R(&]N($%$5"X@5&AI<R!A;6]U;G0@=V%S(')E8V]G;FEZ960@
M87,@8V]L;&%B;W)A=&EO;B!R979E;G5E#0H@("!I;B!T:&4@9FER<W0@<75A
M<G1E<B!O9B`R,#`X+B!5;F1E<B!T:&4@27!S96X@0V]L;&%B;W)A=&EO;B!!
M9W)E96UE;G0L('1H92!#;VUP86YY(')E8V]R9&5D#0H@("!D969E<G)E9"!R
M979E;G5E(&]F("9N8G-P.R0R.2PS,S`@<F5L871E9"!T;R!T:&4@27!S96X@
M=7!F<F]N="!L:6-E;G-E(&9E92!A;F0@97AP96YS92!R96EM8G5R<V5M96YT
M#0H@("!W:&EC:"!W87,@8F5I;F<@86UO<G1I>F5D(&EN=&\@<F5V96YU92!O
M;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E<B!T:&4@97-T:6UA=&5D('1E
M;B!Y96%R#0H@("!D979E;&]P;65N="!P97)I;V0@9F]R('1O<F5M:69E;F4@
M:6X@=&AE($5U<F]P96%N(%1E<G)I=&]R>2X-"B`@(#PO9&EV/@T*("`@/"$M
M+2!&;VQI;R`M+3X-"B`@(#PA+2T@+T9O;&EO("TM/@T*("`@/"]D:78^#0H@
M("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM
M;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#!P="<^#0H@("`\8CX-
M"B`@(#PO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@-"4G/DEN($UA<F-H)B,Q-C`[,C`Q,2P@=&AE($-O;7!A;GD@
M<F5A8W%U:7)E9"!F=6QL(')I9VAT<R!T;R!I=',@=&]R96UI9F5N92!P<F]G
M<F%M(&9O;&QO=VEN9R!T:&4-"B`@('1E<FUI;F%T:6]N(&)Y('1H92!#;VUP
M86YY(&%N9"!)<'-E;B!O9B!T:&4@8V]L;&%B;W)A=&EO;B!A;F0@;&EC96YS
M92!A9W)E96UE;G0L(&%S(&%M96YD960@*'1H90T*("`@)B,X,C(P.T%M96YD
M960@27!S96X@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0F(S@R,C$[*2X@1'5R
M:6YG('1H92!F:7)S="!Q=6%R=&5R(&]F(#(P,3$L('1H92!#;VUP86YY(')E
M8V]G;FEZ960-"B`@(&%S(&-O;&QA8F]R871I;VX@<F5V96YU92!A;&P@;V8@
M=&AE(')E;6%I;FEN9R`F;F)S<#LD."PP-C8@=6YA;6]R=&EZ960@<F5V96YU
M92!T:&%T('=A<R!D969E<G)E9"!A<R!O9@T*("`@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,"X@5&AI<R!A;6]U;G0@:7,@:6YC;'5D960@:6X@8V]L;&%B;W)A
M=&EO;B!R979E;G5E(&EN('1H92!C;VYD96YS960@<W1A=&5M96YT(&]F#0H@
M("!O<&5R871I;VYS(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R)B,Q-C`[,S`L(#(P,3$N(%1H92!#;VUP86YY(')E8V]G;FEZ960@87,@
M8V]L;&%B;W)A=&EO;@T*("`@<F5V96YU92`F;F)S<#LD,S,V(&%N9"`F;F)S
M<#LD,2PU.34@9F]R('1H92!T:')E92!M;VYT:',@86YD(&YI;F4@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$P+`T*("`@<F5S<&5C=&EV
M96QY+"!F<F]M('1H92!A;6]R=&EZ871I;VX@;V8@=&AE($EP<V5N(&1E9F5R
M<F5D(')E=F5N=64N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^
M/&(^/&D^365R8VL@)B,P,S@[($-O+BP@26YC+B!#;VQL86)O<F%T:6]N(&%N
M9"!,:6-E;G-E($%G<F5E;65N=#PO:3X\+V(^#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY);B!$96-E;6)E<B8C
M,38P.S(P,#<L($=4>"!A;F0@365R8VL@)B,P,S@[($-O+BP@26YC+B`H)B,X
M,C(P.TUE<F-K)B,X,C(Q.RD@96YT97)E9"!I;G1O(&$@9VQO8F%L(&5X8VQU
M<VEV92!L:6-E;G-E#0H@("!A;F0@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@
M*'1H92`F(S@R,C`[365R8VL@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0F(S@R
M,C$[*2!G;W9E<FYI;F<@=&AE($-O;7!A;GDF(S@R,3<[<R!A;F0-"B`@($UE
M<F-K)B,X,C$W.W,@:F]I;G0@<F5S96%R8V@L(&1E=F5L;W!M96YT(&%N9"!C
M;VUM97)C:6%L:7IA=&EO;B!O9B!305)-(&-O;7!O=6YD<R!A;F0@<F5L871E
M9"!305)-#0H@("!P<F]D=6-T<R!F;W(@86QL('!O=&5N=&EA;"!I;F1I8V%T
M:6]N<R!O9B!I;G1E<F5S="X@26X@36%R8V@F(S$V,#LR,#$P+"!T:&4@0V]M
M<&%N>2!R96%C<75I<F5D(&9U;&P-"B`@(')I9VAT<R!T;R!I=',@4T%232!P
M<F]G<F%M+"!I;F-L=61I;F<@3W-T87)I;F4\<W5P('-T>6QE/3-$)V9O;G0M
M<VEZ93H@.#4E.R!V97)T:6-A;"UA;&EG;CH@=&5X="UT;W`G/E1-/"]S=7`^
M+"!F;VQL;W=I;F<@=&AE('1E<FUI;F%T:6]N(&)Y('1H90T*("`@0V]M<&%N
M>2!A;F0@365R8VL@;V8@=&AE($UE<F-K($-O;&QA8F]R871I;VX@06=R965M
M96YT+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^56YD97(@=&AE($UE<F-K($-O;&QA8F]R871I;VX@06=R965M
M96YT+"!T:&4@0V]M<&%N>2!G<F%N=&5D($UE<F-K(&%N(&5X8VQU<VEV92!W
M;W)L9'=I9&4-"B`@(&QI8V5N<V4@=6YD97(@:71S(%-!4DTM<F5L871E9"!P
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M:PT*("`@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0N($UE<F-K('!A:60@=&AE
M($-O;7!A;GD@86X@=7!F<F]N="!L:6-E;G-I;F<@9F5E(&]F("9N8G-P.R0T
M,"PP,#`@86YD('!U<F-H87-E9`T*("`@87!P<F]X:6UA=&5L>2`F;F)S<#LD
M,S`L,#`P(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K+B!)
M;B!A9&1I=&EO;BP@365R8VL@<&%I9"!T:&4@0V]M<&%N>2`F;F)S<#LD,34L
M,#`P#0H@("!I;B!C;W-T(')E:6UB=7)S96UE;G1S(&9O<B!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@86-T:79I=&EE<R!I;B!E<75A;"!A;FYU86P@:6YS
M=&%L;&UE;G1S(&]V97(@80T*("`@=&AR964@>65A<B!P97)I;V0N#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4
M:&4@0V]M<&%N>2!D969E<G)E9"!T:&4@<F5C;V=N:71I;VX@;V8@=&AE('5P
M9G)O;G0@;&EC96YS:6YG(&9E92!O9B`F;F)S<#LD-#`L,#`P(&%N9"!T:&4@
M)FYB<W`[)#$P+#@P,`T*("`@:6X@97%U:71Y('!R96UI=6T@<F5C96EV960@
M=&AA="!R97!R97-E;G1E9"!T:&4@9&EF9F5R96YC92!B971W965N('1H92!P
M=7)C:&%S92!P<FEC92!A;F0@=&AE#0H@("!C;&]S:6YG('!R:6-E(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&]N('1H92!D871E('1H
M92!S=&]C:R!W87,@<'5R8VAA<V5D(&)Y($UE<F-K+B!4:&5S90T*("`@<&%Y
M;65N=',@=V5R92!B96EN9R!R96-O9VYI>F5D(&%S(&-O;&QA8F]R871I;VX@
M<F5V96YU92!O=F5R('1H92!P97)I;V0@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<PT*("`@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;BP@=VAI8V@@=&AE($-O;7!A
M;GD@97-T:6UA=&5D('1O(&)E('1E;B!Y96%R<RX@5&AE("9N8G-P.R0U+#`P
M,"!O9B!C;W-T#0H@("!R96EM8G5R<V5M96YT<R!R96-E:79E9"!I;B!B;W1H
M($1E8V5M8F5R)B,Q-C`[,C`P."!A;F0@1&5C96UB97(F(S$V,#LR,#`Y('=E
M<F4@8F5I;F<@<F5C;V=N:7IE9"!A<PT*("`@8V]L;&%B;W)A=&EO;B!R979E
M;G5E(&]V97(@=&AE(')E;6%I;FEN9R!P97)I;V0@;V8@=&AE($-O;7!A;GDF
M(S@R,3<[<R!P97)F;W)M86YC92!O8FQI9V%T:6]N+B!);B!-87)C:`T*("`@
M,C`Q,"P@=&AE($-O;7!A;GD@<F5A8W%U:7)E9"!F=6QL(')I9VAT<R!T;R!T
M:&4@0V]M<&%N>28C.#(Q-SMS(%-!4DT@<')O9W)A;2!F;VQL;W=I;F<@=&AE
M('1E<FUI;F%T:6]N(&)Y#0H@("!T:&4@0V]M<&%N>2!A;F0@365R8VL@;V8@
M=&AE($UE<F-K($-O;&QA8F]R871I;VX@06=R965M96YT+B!);B!T:&4@9FER
M<W0@<75A<G1E<B!O9B`R,#$P+"!T:&4-"B`@($-O;7!A;GD@<F5C;V=N:7IE
M9"!A<R!C;VQL86)O<F%T:6]N(')E=F5N=64@86QL(&]F('1H92!R96UA:6YI
M;F<@)FYB<W`[)#0Y+#@U-B!U;F%M;W)T:7IE9"!R979E;G5E('1H870-"B`@
M('=A<R!D969E<G)E9"!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#`Y+"!A
M<R!W96QL(&%S('1H92!F:6YA;"`F;F)S<#LD-2PP,#`@<F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT#0H@("!A8W1I=FET:65S(&-O<W0@<F5I;6)U<G-E;65N
M="!D=64@=6YD97(@=&AE('1E<FUS(&]F('1H92!-97)C:R!#;VQL86)O<F%T
M:6]N($%G<F5E;65N="!I;B!$96-E;6)E<@T*("`@,C`Q,"!F;W(@=VAI8V@@
M=&AE($-O;7!A;GD@:&%D(&YO(&9U<G1H97(@<&5R9F]R;6%N8V4@;V)L:6=A
M=&EO;BX@5&AE<V4@86UO=6YT<R!A<F4@:6YC;'5D960@:6X-"B`@(&-O;&QA
M8F]R871I;VX@<F5V96YU92!I;B!T:&4@8V]N9&5N<V5D('-T871E;65N="!O
M9B!O<&5R871I;VYS(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R#0H@("`S,"P@,C`Q,"X-"B`@(#PO9&EV/@T*("`@/"]D:78^#0H\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,W,C8V,#9B
M7S0W8C!?-&(Q9%]B-F(Y7S)D-C(V-C)C-C(R9`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]C-S(V-C`V8E\T-V(P7S1B,61?8C9B.5\R9#8R-C8R
M8S8R,F0O5V]R:W-H965T<R]F:6QE;&ES="YX;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/'AM;"!X;6QN<SIO
M/3-$(G5R;CIS8VAE;6%S+6UI8W)O<V]F="UC;VTZ;V9F:6-E.F]F9FEC92(^
M#0H@/&\Z36%I;D9I;&4@2%)E9CTS1"(N+B]7;W)K8F]O:RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'10
L87)T7V,W,C8V,#9B7S0W8C!?-&(Q9%]B-F(Y7S)D-C(V-C)C-C(R9"TM#0H`
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
